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1. Abstract 
A Study of the Aetiology and Epidemiology of Cancers in Teenagers And Young Adults 
Dr Ramandeep Singh Arora, MD, University of Manchester, 2010 
 
Introduction 
 Little is known about the aetiology of cancer in teenagers and young adults (TYA) aged 
15-24 years, although in England, cancer is the most common cause of disease-related mortality 
in this age group. The most common cancers at this age are lymphomas, central nervous system 
(CNS) tumours and germ cell tumours (GCT). The commonest carcinomas seen at older ages 
including lung, breast, large bowel and prostate account for only 3-4% of TYA cancers. In this 
thesis I describe the incidence patterns of selected cancers in TYA and the variation seen with 
geography, time and in population subgroups. The focus is on CNS tumours, GCT and bone 
tumours as they either peak in incidence in TYA and/or contribute disproportionately to cancer-
related mortality in TYA. This will allow formulation of hypotheses regarding aetiology of 
cancer in this age group which can then be tested by further research.  
Methods 
 For the majority of the analysis, anonymised national cancer registration data from 
England on individual patients of all ages with newly diagnosed cancer between 1979 and 2003 
were used. To contrast the incidence patterns in England with that of India, data from five Indian 
urban population based cancer registries were used for part of the analysis. Age, sex, site and 
histology specific incidence rates were calculated and expressed per million person years. All 
rates, where appropriate, were adjusted to the world standard population using direct methods. 
 To explore the link of growth with development of osteosarcoma and Ewing sarcoma, a 
random-effects meta-analysis was undertaken on studies which investigated an association of 
these tumours with height at diagnosis. 
Results 
 The incidence of cancer in TYA overall in England exceeded that of India. This was also 
true for most individual sites including epithelial cancers of lung, colon/rectum, breast, ovary and 
cervix, and non-epithelial cancers including melanoma, Hodgkin lymphoma and testicular 
cancer. Notable exceptions to this pattern were cancers of the mouth, gall bladder and stomach 
(females only) where incidence was higher in India.  
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 In England, CNS tumours in TYA were a composite of pilocytic astrocytomas and 
embryonal tumours (representing tail end of childhood CNS tumours), pituitary tumours, nerve 
sheath tumours, high grade astrocytomas and meningiomas (representing early-onset of CNS 
tumours that peak in incidence in the 6th and 7th decade of life), and of CNS GCTs, pleomorphic 
xanthoastrocytomas and neurocytomas which show a peak incidence in TYA.   
 Irrespective of site or histology, GCT in England showed a peak in incidence between 
ages of 10 to 39 years which was more marked in males. This however varied by site and the 
peak incidence was seen at 10 to 14 years in the CNS, 15 to 19 years in ovary, 25 to 29 in 
mediastinum & thorax and abdomen & pelvis, and 30 to 34 years in testicular tumours.  
 Osteosarcoma and Ewing sarcoma were the predominant bone tumours in TYA in 
England and showed a distinct peak of incidence at 10 to 14 years age in females and a larger 
peak at 15 to 19 years age in males. The peak incidence of osteosarcoma of long bones of the 
lower limb was six times more than that at any other site while the peak incidence of Ewing 
sarcomas located in the bones of the central axis exceeded those in long bones of the lower limb. 
The average height of patients with osteosarcoma at diagnosis was found to be significantly 
above the average height of the reference population, at the 95% level. The association of greater 
height at diagnosis with Ewing sarcoma was also significant at the 95% level but much weaker. 
Conclusion 
 In this thesis I have explored the epidemiology of cancer in TYA using some of the 
established methodologies which have previously been used in advancing our knowledge of 
childhood and older adult cancers. These studies provide some clues to aetiology. Variation in 
environmental exposures and lifestyle factors between England and India can explain the 
majority of the differences in incidence patterns observed. Genetic predisposition to cancer along 
with carcinogen exposure could lead to early onset of some cancers generally seen in older 
adults. Regardless of site, the similarity in age-incidence patterns of GCT, suggests a common 
initiation of these tumours in embryonic/foetal life with variable rates of tumour progression as a 
result of local factors or events during postnatal and pubertal period. The incidence patterns of 
osteosarcoma along with the strong and consistent association with a greater height at diagnosis 
indicate that bone growth is important in the development of this tumour while different 
biological pathways which may be unrelated to growth could also be relevant for Ewing 
sarcoma. 
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5. Introduction 
 
5.1  Background 
 Cancer is one of the leading causes of death worldwide and in 2004 accounted for 7.4 
million deaths (around 13% of all deaths) [1]. In England, each year nearly 250,000 people are 
newly diagnosed with cancer and 65% of these are in people aged 65 years and over [2]. Cancer 
in teenagers and young adults (TYA) aged 15 to 24 years constitutes a small fraction (<1%) of 
this overall cancer burden [3]. But, it is a major cause of mortality and morbidity in TYA. In 
England, cancer is the most common cause of disease-related death in TYA and second only to 
accidents as the overall cause of death [4]. The impact of late effects of treatment in this age 
group can be considerable, including loss of fertility, secondary malignancies and organ failure. 
In addition, at this critical period of life, disruption of educational, vocational and professional 
training can potentially have profound and long lasting effects on the future quality of life of 
patients [5]. 
 
What are Teenage and Young Adult (TYA) Cancers? 
 Biologically, adolescence begins with onset of puberty, at about 10 years in girls and 12 
years in boys [6]. Adolescence ends and early adulthood begins with attainment of adult height 
and full reproductive maturity. However if physiological and psychobehavioural attributes are 
taken into account, attainment of early adulthood equates to about age 19 years in women and 
21-25 years in men [7]. In practice, adolescence is a flexible concept that encompasses most 
young people. For the specific purpose of this report, TYA refers to individuals aged 15 to 24 
years. However, where appropriate for specific tumours, variations to this definition will be used 
and clearly specified.     
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 In 2002 Birch et al proposed a cancer classification scheme [8] which is largely 
morphology-based and has now become the accepted vehicle for cancer incidence studies in 
TYA [9]. The main groups of cancer types in TYA (Table I) are lymphomas, carcinomas, central 
nervous system (CNS) tumours, germ cell tumours (GCT), leukaemias, melanomas, bone 
tumours and soft tissue sarcomas [10]. In contrast to older age groups, carcinomas in TYA arise 
mainly in the thyroid and female genitourinary tract. Carcinomas of lung, breast, large bowel and 
prostate, which represent half of all cancers overall, account for only 3-4% of TYA cancers.  
 
Table I - Incidence of cancers (rate per million person years at risk) in those aged 13 to 24 years 
in England, 1979–2001, by cancer group and sex from Alston et al 2007 [10] 
  Male Female All  
  N Rate N Rate N Rate 
Leukaemia 2375 25.2 1560 17.1 3935 21.2 
Lymphoma 4794 50.5 3704 40.0 8498 45.3 
CNS tumours 2671 28.2 2373 25.9 5044 27.1 
Bone tumours 1308 13.9 884 9.8 2192 11.9 
Soft tissue sarcoma 930 9.8 774 8.4 1704 9.1 
Germ cell tumour 4152 43.3 544 6.0 4696 24.8 
Melanoma 967 10.1 1813 19.4 2780 14.7 
Carcinoma 1658 17.4 4126 44.0 5784 30.6 
Other Specified 200 2.1 235 2.6 435 2.3 
Unspecified 95 1.0 128 1.4 223 1.2 
Total 19150 201.5 16141 174.5 35291 188 
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Cancers in TYA with the highest mortality differ from those with the highest incidence. 
CNS tumours, lymphoid leukaemias and bone tumours are TYA cancers with the highest 
mortality rates. [4]. In England, the 5-year overall survival of cancers in TYA for the period 
1996 to 2001 was 77% [11]. However the relative overrepresentation in TYA of cancers with 
higher survival (Hodgkin lymphoma, testicular GCT, melanoma and thyroid carcinoma) 
obscures a more grim reality. Detailed analysis reveals that current survival of leukaemias, CNS 
tumours, and bone and soft tissue sarcomas in TYA is worse than that of children with these 
groups of diseases [11,12] and worryingly there have been no sustained improvements in 
survival over time among TYA with high-grade brain tumours and bone and soft tissue sarcomas 
[11]. 
 
Aetiology of Cancers in TYAs 
 Much of our understanding of cancer causation has come from epidemiological 
approaches describing the patterns of cancer in human populations and identifying risk factors 
through case-control and cohort studies. Using these approaches, we now know much more 
about the exogenous and endogenous factors associated with causation of common cancers in 
adults [13,14]. 20% of cancers are associated with chronic infections (e.g. chronic hepatitis 
viruses, human papilloma viruses, human immunodeficiency virus and helicobacter pylori). 
Lung carcinoma is strongly associated with tobacco smoke. Breast carcinoma is linked to 
hormonal and reproductive factors but is also influenced by diet and lifestyle. Colorectal 
carcinoma is associated with a diet rich in fat, refined carbohydrates and animal protein and a 
lifestyle involving low physical activity. For most of these cancers, clinical onset follows a 
prolonged period of exposure.  
  
11
  
 As TYA with these cancers will not have had the same duration of diet and lifestyle-
related exposures, other factors including genetic susceptibility may play a greater role in this 
age range than in older people [5]. There is some evidence that there may be a relatively greater 
proportion of high-penetrance mutations in some cases of early-onset carcinomas, although few 
systematic studies have addressed this issue [15,16]. Nevertheless, we know that the contribution 
of high-penetrance mutations in the causation of childhood cancer is 5-10% [17] and it is 
unlikely that their role would be greater in the causation of cancer in TYA. Low-penetrance 
cancer susceptibility cancer genes could also be relevant and this needs to be explored in the 
future. Polymorphisms in drug metabolism pathways like that involving the cytochrome p450 
system have an established role in the causation of several adult-onset cancers [18]. 
 An association of birth weight and childhood growth has been reported with several 
adult-onset cancers like breast [19,20] and prostate [21] as well as with childhood cancers [22-
25]. The possible explanation for these associations are that growth is a biomarker for biological 
mediators of risk (like cellularity or growth promoting hormones) or alternatively is a biomarker 
for other exposures that influence cancer risk (like foetal nutrition, chronic infection, calorie 
intake or exposure to high levels of sex hormones) [26]. Growth spurt linked to puberty is a key 
physiological event in adolescence and this makes it a candidate for further investigation in the 
evolution of cancers in TYA, particularly those which peak in incidence in this age group like 
bone tumours and GCT.  
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5.2  Rationale and format of this thesis 
There is clearly a need for better understanding of the occurrence and causation of 
tumours in TYA. This can be achieved in a variety of ways. In this thesis I explore the 
descriptive epidemiology and what that may imply for aetiology of cancer in TYA applying 
some of the established methodologies which have previously been used in advancing our 
knowledge of childhood and older adult cancers. My work focuses on selected cancers and uses 
data obtained from a variety of sources. The common theme running through the research is the 
relevance of these cancers in TYA. Because of this, my thesis lends well to being presented in 
the alternative format where the results are presented as a collection of papers. Each of these 
papers is of a journal manuscript length and is suitable for submission for publication. 
My first paper looks at the variation in the incidence of cancer at all sites in those aged 15 
to 29 years in England and contrasts this with the incidence patterns in India. Data for this study 
were obtained from five urban population-based cancer registries (PBCR) of India and from the 
eight regional PBCR in England. Geographic and ethnic variations in the incidence of adult 
cancer have enhanced our understanding of their causation [13,27]. For example, elucidation of 
the high incidence of liver cancer in Africa and Asia secondary to food contamination by 
aflatoxins, of bladder cancer in Egypt as a result of chronic cystitis from Schistosoma 
haematobium, and of oral cancer in South Asia from highly prevalent use of oral tobacco all 
stem from epidemiological observations. Similar examination of geographical variation in cancer 
incidence in TYA may provide important aetiological clues and stimulate further investigations. 
Such studies can give an indication of the extent to which environmental factors are implicated 
in the causation of each cancer type although part of the international difference in cancer risks 
may be genetic rather than environmental.  
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 The next four papers in this thesis deal with detailed age-incidence patterns and 
longitudinal trends with a focus on three individual cancer groups: CNS tumours, GCT and bone 
tumours. These cancers have been selected based on their distinct incidence patterns and/or 
disproportionate contribution to cancer-related mortality in TYA. The variation of incidence 
patterns over time and in population subgroups will allow formulation of hypotheses that might 
explain the observed differences and which can then be tested by further research 
 The final paper in this thesis is a meta-analysis of the possible link of osteosarcoma and 
Ewing sarcoma risk with height at diagnosis. Some evidence exists that patients with 
osteosarcoma and Ewing sarcoma are taller than the general population [28-31]. However, these 
studies are under-powered and/or lack comprehensive data and there are inconsistencies. Meta-
analysis is a commonly used statistical tool where the results from two or more separate studies 
are combined. This increases the chance of detecting a real effect as being statistically significant 
if it exists, as well as improving the estimation of an intervention effect. My objective was to do 
a comprehensive literature search to identify relevant studies in order to meta-analyse the 
strength of association between height at diagnosis and risk of developing the above tumours. 
This can then assist with developing areas for future research. 
 In addition to the work done above, I have also been actively involved in  developing the 
protocol and associated study materials for a grant-funded project on bone tumours in children 
and young people. Prof Jillian Birch successfully secured funding to conduct a pilot study of 
osteosarcoma and Ewing sarcoma as the forerunner of a multi-centre international case-control 
study. The main objectives of the pilot study are to ascertain and recruit a population-based 
sample of patients diagnosed up to 24 years of age with osteosarcoma and Ewing sarcoma; 
interview families, collect DNA samples and abstract relevant medical records.  The results of 
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the pilot will enable us to determine the feasibility of setting up the full international study of 
bone tumour aetiology. Cases of histologically confirmed osteosarcoma and Ewing sarcoma in 
persons aged 0-24 years diagnosed during a 2 year period, July 2009 to June 2011, resident in the 
North West and Yorkshire and the Humber Strategic Health Authority areas are currently being 
recruited. By the end of 2010, 12 patients had been recruited and another six have been 
approached.   
 My contribution to this has been in writing the initial draft of the ethics application using 
the online Integrated Research Application System (IRAS) forms. As part of this application, I 
was also involved in designing the protocol and drafting the patient and parent interview 
proformas, age-appropriate information leaflets and consent forms (see appendix) for use in this 
pilot interview-based study. In order to investigate the association between growth from birth to 
adulthood and development of these tumours, specific questions with regards to physical growth 
in childhood and adolescence, onset of puberty, and related sports and exercise activities were 
added to the proforma. I sought the advice of experts in paediatric and adolescent endocrinology 
to aid the construction of the proforma in addition to searching the literature. The questionnaires 
and other study materials will be evaluated when data collection is complete and I hope to 
contribute to data analysis, interpretation and development of the protocol for the future full 
study. 
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5.3. Cancer registration and population estimates 
 The core of the work carried out for this thesis is based on cancer registration data for 
England and India. In this section, I will describe the cancer registration systems in England and 
India. Calculation of incidence rates needs population denominators and I will also discuss how 
these are derived for each of the countries. Specific details about coding and classification of 
cancer, and statistical analysis are given in the methods sections of the individual papers. 
 
Cancer Registration in England 
 The beginning of cancer registration in several parts of UK was in the 1920s with the 
main purpose of finding the outcome of patients treated with radium at that time. Gradually the 
objectives became broader, the coverage expanded and by 1962 there was complete geographic 
national coverage via a series of regional population-based cancer registries [32,33]. The coding 
and classification of individual cancer cases has followed international standards: International 
Classification of Diseases [34,35] and International Classification of Diseases for Oncology [36-
38]. At the present time, there are 11 cancer registries in the UK. Cancer registration in England 
is conducted by eight regional registries (Figure 1), which submit a standard dataset of 
information to the Office for National Statistics (ONS), for the collation of national cancer 
incidence data. Northern Ireland, Scotland and Wales have national cancer registries.  
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Figure 1 Areas covered by the regional cancer registries, England 2007 
 
 The information for cancer registration is acquired from a variety of sources including 
hospitals, cancer centres, treatment centres, hospices, private hospitals, cancer screening 
programmes, other cancer registers, general practices, nursing homes, death certificates and 
Hospital Episode Statistics. There is a high degree of case ascertainment, and registry records are 
largely complete, accurate, and reliable with less than 0.1% of serious errors detected on regular 
completeness and validity checks [32]. The quality of registration is reflected by the high 
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percentages of histological verification of cancers (84.9% in England for the year 2009) and low 
proportion of registrations by death certificate alone (2.8% in England for the year 2009) [39].  
 A particular aspect of importance of cancer registration is the link with the National 
Health Service Central Register (NHSCR). Since 1971, as far as possible all registrations in 
England and Wales have been recorded ('flagged') on the NHSCR, a register of almost all of the 
population of England and Wales. This allows completeness of registration and eliminates 
duplication. The proportion of cancer registrations received by ONS that were successfully 
linked to an NHSCR record was on average about 96 per cent from 1971 up to 1989 and has 
been over 99 per cent for data for 1993 and subsequent years [40].  
  
Population Estimates for England  
 National population estimates by single year of age, sex and calendar year are supplied 
by the Population Estimates Unit, ONS. They are produced based on decennial census 
(conducted in England and Wales every ten years) data together with information on births, 
deaths and migration using a well established demographic approach called the cohort 
component method [41]. The compulsory registration of births and deaths with the General 
Register Office ensures that administrative records for these life events are accurate. 
International migration is estimated using survey data and internal migration is estimated using 
changes in administrative data as a proxy measure of movements of individuals between areas 
within the UK. Adjustments are made for changes to special population subgroups, including 
prisoners, school boarders, and the armed forces and their dependents. Extensive analysis is 
carried out to validate and quality assure the data and estimates at every stage of the process.  
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Cancer Registration in India 
 Information on cancer occurrence in India was available only from cross-sectional 
surveys until 1964, when the first PBCR was set up in Bombay (now Mumbai) [42]. The next 
major milestone was the initiation of the National Cancer Registry Programme by Indian Council 
of Medical Research in 1982 which included the existing Bombay PBCR and establishment of 
two new PBCR at Bangalore and Madras (now Chennai). Over the years several other urban 
PBCR (Bhopal & Delhi in 1987, and Kolkata in 2005) and two rural PBCR (Barshi in 1987 and 
Ahmedabad district in 2003) have been set up [43]. Additionally, a North Eastern Regional 
Cancer Registry has been initiated from 1 January 2003 in six areas at Guwahati, Dibrugarh and 
Silchar in Assam, Aizawl in Mizoram, Imphal in Manipur and Gangtok in Sikkim with a 
Monitoring Unit at Regional Medical Research Centre, Dibrugarh [44]. Together all these urban, 
rural and regional registries cover around 5% of the Indian population (with a predominantly 
urban skew) and less than 1% of the total geographical area [43,44]. A map of India depicting 
the locations of the various cancer registries in the National Cancer Registry Programme is 
shown in figure 2.  
 Cancer is not a notifiable disease in India and registration is active but voluntary. Staff of 
registries visit hospitals on a routine basis and scrutinise the records in various departments that 
include pathology, radiology, radiotherapy, in-patient wards and out-patient clinics to elicit the 
desired information on reported cancer cases using a common core proforma that has been 
standardised for all cancer registries in India [42,43]. Death certificates are also scrutinised from 
the municipal corporation units. Every attempt is made by registries to register all cancer patients 
in the registration area who are resident (at least for one year) in the area in all hospitals and 
copy all death certificates in which cancer is mentioned. 
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Figure 2 Location of Cancer registries in India which are part of the National Cancer 
Registry Programme 
 
Coding of the disease is done according to International Classification of Diseases 
[34,35] and according to International Classification of Disease for Oncology [36-38]. Certain 
basic checks of data, especially those related to duplicate registrations verification and matching 
with mortality records, are carried out by the individual registries. After this, the data are sent to 
the Coordinating Unit in Bangalore for checks on variable specific value ranges, consistency and 
unlikely combinations together with a further round of possible duplicates. The Coordinating 
Unit collates the data and performs tabulations to prepare the consolidated report for that year. 
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The completeness and quality of registration is variable. Several of the above mentioned 
registries have been listed in the Cancer Incidence in Five Continents published by the 
International Agency for Research in Cancer [45]. An earlier survey had estimated completeness 
of population coverage previously to be 72% in Bangalore, 100% in Chennai and 78% in 
Mumbai [46]. In the Mumbai PBCR there has been progressive increase in percentages of 
histological verification for cancers, decrease in the proportion of registrations by death 
certificate alone as well as the proportion of cases registered to other and unspecified sites [47]. 
Similar data for other PBCR in India at present are not available. 
  
Population Denominators in India 
 In India, population figures are based on census conducted every 10 years starting from 
the year 1951. The latest Census was conducted in the year 2001. The exponential growth rate 
method is in use to estimate the total population for the given year. The total population 
denominators for calculating the incidence rates are calculated in this way. The same method is 
used to estimate population by five-year age groups according to sex. Recently, this approach has 
been shown to suffer from bias and often corrections become necessary in five yearly age group 
populations [48]. 
 
5.4. Summary of studies included in this thesis 
 A summary of the individual studies which form part of this thesis is displayed in Table 
II. In all these studies I have been the lead investigator with support from various colleagues. My 
role and their contributions are detailed in Table III. 
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Table II – Summary of individual studies presented in this thesis 
Title of Paper Type of Study Cancer Source of Data Time Period 
Cancer at ages 15–29 years: The contrasting incidence in 
India and England 
Geographical comparison of 
incidence patterns 
All Cancers Cancer registration data from 
England and India 
2001 to 2003 
Age-incidence patterns of primary CNS tumours in children, 
adolescents, and adults in England 
Analyses of incidence by age 
groups 0-14, 15-24 & 25-84 years  
CNS Tumours Individual patient level cancer 
registration data from England 
1995 to 2003 
Are reported increases in incidence of primary CNS tumours 
real? An analysis of longitudinal trends in England, 1979-
2003 
Longitudinal trends by age groups 
0-14, 15-24, 25-64 & 65-84 years 
CNS Tumours Individual patient level cancer 
registration data from England 
1979 to 2003 
Comparative incidence patterns and trends of gonadal and 
extragonadal germ cell tumours in England, 1979 to 2003 
Analysis of incidence and 
longitudinal trends by age groups 0-
9, 10-49 & 50-84 years 
Germ Cell Tumours Individual patient level cancer 
registration data from England 
1979 to 2003 
The contrasting age-incidence patterns of bone tumours in 
teenagers and young adults: Implications for aetiology 
Age-specific incidence patterns and 
longitudinal trends 
Osteosarcoma, Ewing 
sarcoma, Chondrosarcoma 
Individual patient level cancer 
registration data from England 
1979 to 2003 
Relationship between height at diagnosis and bone tumours 
in young people: A meta-analysis 
Meta-analysis of results from 
previously published reports 
Osteosarcoma, Ewing 
sarcoma 
Pubmed 1950 to 2010 
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Table III – Details of my contribution and that of my co-authors in the individual studies presented in this thesis 
 
Title of Paper My Role Assistance of Others 
Cancer at ages 15–29 years: The contrasting incidence in India 
and England 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
Advice on data analysis – JMB, RDA 
Comments on draft of manuscript – JMB, MG, RDA, TOE 
Age-incidence patterns of primary CNS tumours in children, 
adolescents, and adults in England 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
Advice on data analysis – JMB, RDA 
Comments on draft of manuscript – AM, EJE, JMB, MG, RDA, TOE 
Are reported increases in incidence of primary CNS tumours 
real? An analysis of longitudinal trends in England, 1979-2003 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
Advice on data analysis – JMB, RDA 
Comments on draft of manuscript – AM, EJE, JMB, MG, RDA, TOE 
Comparative incidence patterns and trends of gonadal and 
extragonadal germ cell tumours in England, 1979 to 2003 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
Advice on data analysis – JMB, RDA 
Comments on draft of manuscript – JMB, MG, RDA, TOE 
The contrasting age-incidence patterns of bone tumours in 
teenagers and young adults: Implications for aetiology 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
Advice on data analysis – JMB, RDA 
Comments on draft of manuscript – JMB, RDA, TOE 
Relationship between height at diagnosis and bone tumours in 
young people: A meta-analysis 
Conceived and designed the study 
Data analysis 
Data interpretation & writing of manuscript 
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Cancer at Ages 15–29 Years: The Contrasting Incidence in India and England
Ramandeep S. Arora, MRCPCH,1* Robert D. Alston, PhD,1 Tim O.B. Eden, FRCP,2 Anthony Moran, FFPH,3
Marco Geraci, PhD,1 Catherine O’Hara, PhD,3 and Jillian M. Birch, PhD1
Background. There has been a steady increase in published
research from Europe and North America on the epidemiology of
cancers in young people. There are limited data from the devel-
oping world. We contrast the incidence of cancer at ages 15–29
years in India and England. Procedure. Malignant neoplasms in
those aged 15–29 years registered during 2001–2003 in ﬁve urban
population-based cancer registries (PBCRs) of India and in eight
PBCRs in England were included. Site-based classiﬁcation was used.
Age-standardized incidence rates were expressed per 100,000 per-
son years. Results. In India, 4,864 (5.8%) of 84,450 cases and in
England, 8,137 (1.2%) of 65,6752 cancer cases occurred in those
aged 15–29 years. For this age group, the incidence rate for males
and females in India were 12.91 and 14.19, and in England were
27.75 and 28.88, respectively. In males aged 15–29 years, the three
most common cancers in India were leukemia, lymphoma, and cen-
tral nervous system tumors and in England were cancers of male
genital organs, lymphoma, and leukemia. Cancers of female genital
organs, breast, and leukemia were most common in females in India
and cancers of female genital organs, lymphoma, and melanoma in
England. For cancers of mouth, stomach, and gall bladder, the inci-
dence was higher in India. Conclusion. Incidence of cancer at ages
15–29 years in England is higher at most sites than in India. Variation
in environmental exposures between the two countries might be an
explanation. Under-ascertainment of cases and gender bias in seek-
ing healthcare may also inﬂuence reported incidence rates in India.
Pediatr Blood Cancer. © 2010 Wiley-Liss, Inc.
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INTRODUCTION
In 2002, Birch et al. [1], defined the incidence of cancers in
people 15–24 years of age in England using a morphology-based
classification scheme. Subsequently, other countries in Europe have
done similar analyses for their local populations using the same
classification scheme [2,3]. Incidence data in this age group have
also been published from USA although a site-based classification
was used [4]. As a result of these studies from Europe and North
America, our understanding of the cancers which occur in teenagers
and young adults (TYA) has improved. However, there are little or
no data on cancers in this age group from the developing world.
Based on a single recent review with a more limited age range, the
incidence of cancer in adolescents aged 15–19 years was reported
to range from 9.5 to 25.5 per 100,000 person years across the world
[5]. The highest incidence rates were reported from Australia and
among Jews in Israel with the lowest in India and Japan.
We present here incidence rates of cancer among males and
females aged 15–29 years (henceforth, referred as TYA) in India
and contrast this with the rates for the same age range in England.
Studying variations in cancer incidence in these age groups in dif-
ferent populations and geographical areas is likely to be informative
as the relative exposures to potential environmental risk factors will
be different.
METHODS
Data were obtained for the period 2001 to 2003 in the five
urban population-based cancer registries (PBCR) of India (Ban-
galore, Bhopal, Chennai, Delhi, and Mumbai, shown in Figure 1,
which cover 3.7% of the population of India and equate to 36 mil-
lion person years) and eight regional registries in England (which
cover the entire population and equate to 28 million person years)
[6,7]. All primary neoplasms of malignant behavior, except non-
melanoma skin cancer, registered for individuals 15–29 years of
age were included. Cancer registration in India is active and data
are collected from relevant hospital departments, pathology labora-
tories, and death certificates from the municipal corporation units.
Reliability of data and quality of registration are constantly mon-
itored by re-abstraction and coding on a random sample of cases.
Checks related to duplicate verification and matching with mortality
records are also carried out by the individual registries. After this,
data are sent to the Coordinating Unit at Bangalore where various
range, consistency, and unlikely combination checks are carried out
[6]. Completeness of population coverage by the registries does vary
and has been estimated to be 72% in Bangalore, 100% in Chennai,
and 78% in Mumbai [8].
Cancer registration in England is carried out by a network of eight
population-based regional registries. Registration is coordinated by
the Office for National Statistics in London, which maintains the
national cancer registry covering all age groups. There is a high
degree of case ascertainment and reviews have shown that registry
records are largely complete, accurate, and reliable [9]. National
population estimates by single year of age, gender, and calendar year
are supplied by the Population Estimates Unit, Office for National
Statistics. Annual mid-year estimates of population in England,
based on census data together with information on births, deaths,
and migration are very accurate on a national basis [9].
As available data in India were coded by site and not morphology,
tumors in both countries were categorized based on International
Classification of Diseases site codes [7]. Incidence rates were
expressed per 100,000 person years and where appropriate, rates
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Fig. 1. Location of urban population-based cancer registries in India.
were adjusted to the world standard population using direct methods.
P-values for variability in cancer-specific incidence rates by country
for both males and females were calculated. R and Microsoft Excel
were used for analyzing the data and producing tables and graphs.
RESULTS
During the period 2001–2003, 4,864 of the 84,450 overall can-
cer cases (5.8%) registered in the five urban cancer registries in
India occurred in those aged 15–29 years (TYA). Two thousand five
hundred fifty-nine were male (52.6%) and 2305 were female and
the overall age-standardized incidence rates were 12.91 and 14.19
per 100,000 person years, respectively. Correspondingly, 8,137 of
the 656,752 cases (1.2%) registered in England occurred in TYA.
There were 3,992 males (49.1%) and 4,145 females and the overall
age-standardized incidence rates were 27.75 and 28.88 per 100,000
person years, respectively. Further analysis by 5-year age groups
showed that incidence rates in both sexes in both countries increased
with age with the incline of slope steeper in females (Fig. 2). The
result was that while for ages 15–19 years the incidence was higher
in males, this pattern reversed and the incidence for those aged 25–29
years was higher in females.
Age-adjusted cancer incidence rates for all major sites and
selected sub-sites are shown in Tables I and II. The three most com-
mon cancers in India in TYA males were leukemia, lymphoma, and
central nervous system (CNS) tumors and in females cancers of the
female genital organs, breast, and leukemia. In contrast, the three
most common cancers in England in TYA males were those of the
male genital organs, lymphoma, and leukemia and in females were
cancers of the female genital organs, lymphoma, and melanoma. The
incidence of melanoma in males in England was 61 times higher than
the incidence in India and in females was 188 times higher. Sim-
Fig. 2. Age- and sex-specific cancer incidence rates in those aged
15–29 years in England and India, 2001–2003.
ilarly, the incidence of testicular cancer was 14 times higher and
of cancer of the cervix uteri 6 times higher in England. Cancer at
all sites generally, had a significantly higher incidence in England.
Notable exceptions to this pattern were cancer of the mouth (in
males), stomach (in females), gall bladder (in males and females)
and bone (in males) which had higher rates in India.
DISCUSSION
In this paper, we have contrasted the incidence of cancers in
India and England in TYA. Our analysis shows that the incidence of
cancer at these ages in England is around double that in India and
the gap between the reported incidence rates in the two countries
appears to increase with age. Similar patterns are observed when
we contrast the incidence rates from India to published data from
USA and other European countries [2–4]. The observed difference
in incidence may be real but when interpreting these observations,
one needs to consider a number of factors including under ascer-
tainment of cases and gender bias in seeking health care which
may influence reported incidence rates in India [8,10]. In addition,
while data from England are national with high levels of ascertain-
ment and completeness [9], the data from the Indian registries cover
only 3.7% of the total Indian population. However, these registries
are distributed across India and cover 42 million persons, 12.5%
of the urban population. In this latter respect the population cov-
ered is more comparable to the English population since England
is a densely populated industrialized nation. In terms of ethnic and
religious sub-groups the populations covered can be considered as
representative of India as a whole [6]. It is noteworthy that cancer
in TYA as a proportion of cancer at all ages is five times higher
in India than England despite the actual incidence being lower in
India. This possibly reflects the higher percentage of young people
in the population pyramid (31% of the population in India are TYA
compared to only 19% in England).
Certain epithelial cancers which typically occur in older adults
(lung, colorectal, breast, and ovarian cancer) have a higher incidence
in the developed world which is well-recognized. This is explained
by the prevalence of tobacco smoking and other western lifestyle-
related exposures (high-caloric diet, low physical activity), together
with differences in reproductive history (early menarche, late or no
pregnancy) [11,12]. Our analysis shows that the incidence of lung,
breast, colorectal, and ovarian cancer in TYA is higher in England
than in India. TYA with these cancers will not have had the decades
Pediatr Blood Cancer DOI 10.1002/pbc
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TABLE I. Site-Speciﬁc Cancer Incidence Rates (Expressed Per 100,000 Person Years) and Male to Female Incidence Ratio in Those Aged
15–29 Years in England and India, 2001–2003
India England
Number Incidence Male:female Number Incidence Male:female
All sites 4,864 13.51 0.9 8,137 28.33 1.0
Lip, oral cavity, pharynx 309 0.85 1.7 146 0.51 1.0
Tongue 51 0.14 2.0 37 0.13 1.1
Mouth 74 0.20 1.9 23 0.08 0.7
Salivary gland 71 0.20 1.1 41 0.14 0.8
Nasopharynx 58 0.17 2.6 38 0.14 1.7
Other 55 0.15 1.5 7 0.02 1.3
Digestive organs 490 1.33 1.0 352 1.22 1.0
Stomach 78 0.21 0.9 36 0.12 1.4
Colorectum 225 0.61 1.0 224 0.78 1.0
Liver 54 0.15 1.8 44 0.16 0.9
Gall bladder 44 0.12 0.7 6 0.02 3.0
Other 89 0.24 0.8 42 0.16 0.9
Respiratory and intrathoracic Organs 107 0.29 1.7 117 0.41 1.3
Lung 51 0.14 2.0 70 0.24 0.8
Other 56 0.15 1.5 47 0.16 2.3
Bone and articular cartilage 382 1.10 1.7 245 0.89 1.5
Melanoma 11 0.03 2.0 1003 3.44 0.5
Mesothelial and soft tissue 225 0.63 1.3 229 0.81 1.2
Mesothelioma 2 0.01 2 0.01
Kaposi’s sarcoma 0 0.00 21 0.07 1.3
Connective and soft tissue 223 0.62 1.3 206 0.73 1.1
Breast 347 0.02 0.0 398 1.34 0.0
Female genital organs 422 2.59 991 6.81 0.0
Cervix uteri 108 0.64 0.0 604 4.09 0.0
Ovary 257 1.60 0.0 328 2.32 0.0
Other 57 0.34 0.0 59 0.40 0.0
Male genital organs 142 0.70 1271 8.74
Testis 126 0.63 1262 8.67
Other 16 0.08 9 0.07
Urinary tract 76 0.21 1.0 93 0.32 1.3
Eye 15 0.04 3.0 28 0.10 1.4
Central nervous system 491 1.53 1.3 562 1.98 1.3
Thyroid and other endocrine 292 0.80 0.2 403 1.39 0.3
Thyroid 279 0.76 0.2 391 1.35 0.3
Other 13 0.04 0.8 12 0.04 0.3
Lymphoma 633 1.77 1.8 1562 5.52 1.3
Hodgkin’s lymphoma 255 0.72 1.7 982 3.48 1.2
Non-Hodgkin’s Lymphoma 378 1.05 1.9 580 2.03 1.6
Leukemia 777 2.19 1.6 585 2.09 1.4
Lymphoid leukemia 250 0.72 1.7 232 0.85 1.7
Myeloid leukemia 421 1.18 1.3 338 1.19 1.2
Other 106 0.29 2.7 15 0.05 2.7
Other and unspecified 145 0.41 1.0 152 0.53 1.7
of tobacco, diet, reproductive, and other lifestyle exposures expe-
rienced by older adults. Genetic susceptibility may play a greater
role in this age range [13]. In Britain, a relatively high proportion of
predisposing mutations in BRCA1, BRCA2, and TP53 have been
found in a series of breast cancer patients diagnosed at age 30 years
or under [14], and of mismatch repair genes MSH2 and MLH1 in
colorectal cancer patients aged less than 30 years [15]. The relative
frequency of these high-penetrance mutations reported in Indian
patients with these cancers is similar [16,17].
Although variation in low-penetrance cancer susceptibility genes
could also play a role and needs to be explored in future studies,
our observations imply that the differences seen in the incidence
of these cancers in TYA in India and England are more likely to
be the result of differences in lifestyle-related factors. This is sup-
ported by studies of cancer incidence among populations of South
Asian extract in England. Less than 4% of the UK population is of
Asian extraction (1.8% Indian, 1.3% Pakistani, 0.5% Bangladeshi,
and 0.4% other Asian). Analyses of cancer incidence among South
Asians resident in England have shown that whereas overall rates for
all cancers among all ages combined were lower in South Asians
than non-South Asians these rates were higher than in the Indian
sub-continents [18]. Furthermore, English South Asian rates for 0-
to 29-year olds were similar or higher than non-South Asian rates
[19]. A more recent study analyzed cancer incidence trends in the
Pediatr Blood Cancer DOI 10.1002/pbc
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TABLE II. Site- and Sex-Speciﬁc Cancer Incidence Rates (Expressed Per 100,000 Person Years) in Those Aged 15–29 Years in England
and India, 2001–2003
Male Female
India England P-value India England P-value
All sites 12.91 27.75 <0.0001 14.19 28.88 <0.0001
Lip, oral cavity, pharynx 1.04 0.52 <0.0001 0.62 0.50 0.15
Tongue 0.18 0.13 0.22 0.09 0.12 0.28
Mouth 0.26 0.06 <0.0001 0.14 0.09 0.27
Salivary gland 0.20 0.12 0.1 0.19 0.16 0.54
Nasopharynx 0.23 0.17 0.28 0.09 0.10 0.73
Other 0.18 0.03 <0.0001 0.12 0.02 0.0002
Digestive organs 1.31 1.22 0.45 1.34 1.22 0.25
Stomach 0.20 0.14 0.19 0.22 0.10 0.01
Colorectum 0.61 0.77 0.07 0.61 0.79 0.07
Liver 0.18 0.15 0.44 0.10 0.16 0.22
Gall bladder 0.10 0.03 0.005 0.14 0.01 <0.0001
Other 0.21 0.16 0.07 0.28 0.17 0.06
Respiratory and intrathoracic organs 0.36 0.46 0.25 0.21 0.36 0.02
Lung 0.18 0.21 0.45 0.09 0.27 0.0001
Other 0.18 0.25 0.21 0.12 0.11 0.31
Bone and articular cartilage 1.35 1.07 0.02 0.78 0.70 0.44
Melanoma 0.04 2.22 <0.0001 0.02 4.67 <0.0001
Mesothelial and soft tissue 0.71 0.87 0.09 0.53 0.75 0.02
Mesothelioma 0.01 0.01 0.75 0.00 0.00 —
Kaposi’s sarcoma 0.00 0.08 <0.0001 0.00 0.06 0.0002
Connective and soft tissue 0.70 0.77 0.43 0.53 0.69 0.09
Breast 0.03 0.02 0.62 2.04 2.66 0.0003
Female genital organs 2.59 6.81 <0.0001
Cervix uteri 0.64 4.09 <0.0001
Ovary 1.60 2.32 <0.0001
Other 0.34 0.40 0.37
Male genital organs 0.70 8.74 <0.0001
Testis 0.63 8.67 <0.0001
Other 0.08 0.07 0.54
Urinary tract 0.20 0.35 0.01 0.21 0.28 0.21
Eye 0.06 0.11 0.07 0.02 0.08 0.02
Central nervous system 1.53 2.25 <0.0001 1.17 1.71 <0.0001
Thyroid and other endocrine 0.33 0.63 <0.0001 1.38 2.17 <0.0001
Thyroid 0.29 0.61 <0.0001 1.34 2.11 <0.0001
Other 0.03 0.02 0.72 0.04 0.06 0.45
Lymphoma 2.22 6.21 <0.0001 1.21 4.81 <0.0001
Hodgkin’s lymphoma 0.89 3.72 <0.0001 0.51 3.23 <0.0001
Non-Hodgkin’s lymphoma 1.33 2.49 <0.0001 0.69 1.58 <0.0001
Leukemia 2.62 2.42 0.22 1.65 1.76 0.44
Lymphoid leukemia 0.88 1.06 0.12 0.52 0.62 0.19
Myeloid leukemia 1.33 1.28 0.72 0.99 1.11 0.29
Other 0.41 0.08 <0.0001 0.15 0.03 0.0002
Other and unspecified 0.40 0.66 0.001 0.41 0.40 0.93
city of Leicester, in the East Midlands region of England, where 22%
of residents are of South Asian extract [20]. Overall cancer rates
were lower in South Asians than in non-South Asians but younger
South Asians were at somewhat increased risk compared with non-
South Asians. Furthermore, across all ages incidence increased over
time in South Asians but decreased in non-South Asians. This was
accounted for by increases in lung and prostate cancer in men and
colorectal and breast cancer in women. The pattern of cancers in
South Asians was therefore becoming more like that in non-South
Asians. These changes are consistent with the adoption of Western
life-style among the South Asian community in England.
Differences in lifestyle can also explain the variation seen in the
incidence of oral cancer in TYA in India and England. Chewing
tobacco is a major causative factor responsible for Indians having
among the highest rates of oral cancer in the world [11]. Tobacco
consumption (predominantly in the oral form) begins in childhood
in India and is more prevalent in males [21]. It is mistakenly believed
to be good for the teeth and indeed to have medicinal properties [21].
Despite legislation prohibiting the use of tobacco as an ingredient
in dental products, the practice continues [22].
In contrast to the above cancers, where the incidence is either
higher in both younger and older adults in England (colorectal,
Pediatr Blood Cancer DOI 10.1002/pbc
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lung, breast, and ovarian cancer) or in younger and older adults
in India (oral cancer), the incidence of cervical cancer is higher in
TYA females in England (Table I), while it is much higher in older
females in India [11]. This paradox probably reflects differences
in sexual behavior and screening practices in the two countries.
Since the introduction of national cervical screening programme in
England the overall incidence of cervical cancer has halved [23].
The incidence is much higher in developing countries like India
where no national screening programmes exist. As cervical screen-
ing in England starts at 25 years of age, there may be an artefactual
higher incidence of cervical cancers in those aged 25–29 years of
age compared with India, where cancers are only diagnosed when
symptomatic. Although cervical cancer screening in India is not
national policy and no organized screening programmes exist, trials
of simple, and inexpensive screening methodologies have been con-
ducted to assess their suitability and effectiveness in a low-resource
setting. Two such trials were carried out in Kerala, in Southern India,
and Osmanabad in Central India, respectively [24,25]. These trial
areas do not overlap with those covered by the five urban cancer
registries and will therefore have had no impact on cervical cancer
incidence rates presented here. A third trial was conducted in Mum-
bai but included only women aged 35–64 years [26]. The interim
results of these trials are promising and it is to be hoped that future
introduction of more widespread screening programmes will have
an impact on incidence and mortality.
The other cancers with significantly higher incidence in TYA in
India are stomach cancer (females only) and gall bladder cancer.
The higher incidence of stomach cancer in TYA females in India is
unexpected. Despite a high prevalence of helicobacter pylori infec-
tion, reported stomach cancer rates in India are among the lowest
in the world [27]. Within India, the overall incidence of gastric can-
cer is reported to be four times higher in Southern India compared
with Northern India [28]. In our analysis, stomach cancer incidence
in TYA in Bangalore (0.36 per 100,000 person years) and Chennai
(0.32 per 100,000 person years) is twice that of other parts of India
(Bhopal 0.15, Delhi 0.18, and Mumbai 0.13 per 100,000 person
years). Higher intake of spicy food in Southern India is hypothesized
to be associated [29,30], although there have been no epidemiolog-
ical studies to verify this. Gall bladder cancer rates in North and
Central India are among the highest in the world and long-standing
cholelithiasis is a reported major risk factor [31]. Compared to Eng-
land, gall stone disease in India starts at a younger age, has a higher
prevalence and patients have a much longer median duration of
symptoms at presentation [31].
Several non-epithelial cancers (melanoma, Hodgkin lymphoma,
and CNS tumors) have higher incidence in England in TYA, and
while in some cases a biological/behavioral explanation exists or is
plausible, for others there is no clear explanation at present. The inci-
dence of melanoma worldwide is related to sun exposure, although
this association is complex. Chronic, continuous sun exposure seen
in tropical countries like India is inversely associated with risk of
melanoma [32] and increased melanin in dark-skinned individuals
acts as a natural sun-protection factor [33]. On the other hand, inter-
mittent sun exposure, which is seen at higher latitudes like England,
and where frequency of fair-skinned people is greater, is positively
associated with the risk of melanoma. In addition, sharp increases in
the incidence of melanoma have been seen in TYA in England [34]
which may be attributed to changing behaviors (increased travel and
sunbathing, and use of sunbeds) which are more prevalent in young
people [35–37].
Hodgkin lymphoma has a classical bimodal age distribution in
developed countries [38]. The first incidence peak of Hodgkin lym-
phoma (mainly nodular sclerosis type) is seen in TYA and then
again in the 8th decade of life. In contrast, in the developing world
the first peak of Hodgkin lymphoma, mainly mixed cellularity type
associated with Epstein–Barr virus, is more common in childhood.
Delayed exposure to childhood infections and maturation of cell
immunity as a result of less overcrowding in the developed world
are the proposed explanations behind these observations [39].
An increase in the incidence of CNS tumors seen mainly in
young people and the elderly has been observed all over the West-
ern world in the 1970s–1990s. Much of the increase in incidence in
the USA has been attributed to advances in neuroimaging, neuro-
surgery, and neuropathology, and to changes in registration practice
[40–42]. Availability and use of similar resources are likely to be
less widespread in India due to the cost and expertise needed and this
may account for lower CNS cancer incidence rates. Additional evi-
dence comes from the observation that the incidence of CNS tumors
in England among children, TYA and older adults of South Asian
and non-South Asian origin is not significantly different [18,19].
In conclusion, the incidence of cancer in TYA in England is gen-
erally higher at most sites compared with India. Notable exceptions
to this pattern are cancer of the mouth, stomach, and gall bladder.
Variation in environmental exposures between the two countries
might explain the majority of the observations. Under ascertainment
of cases and gender bias in seeking health care might also influence
reported incidence rates in India. These patterns help us to iden-
tify cancers with a known etiology which are potentially avoidable.
Societal initiatives including education and legislation leading to
modification of behavior at the individual level should be able to
help reduce the incidence of cancers of the oral cavity in India and
cervical carcinoma and melanoma in England in TYA.
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Around 25% of all tumors in those 0–14 years of age and 
9% in those 15–24 years of age involve the CNS. They 
are the most common cause of cancer-related deaths in 
both age groups. In adults 25–84 years of age, the pro-
portion of CNS tumors is 2%; 5-year overall survival is 
10%–15%; and survivors have considerable morbidity. 
Comprehensive up-to-date population-based incidence 
data on these tumors are lacking. We present incidence 
rates for primary CNS tumors based on data derived from 
the high-quality national cancer registration system in 
England. A total of 54,336 CNS tumors of malignant, 
benign, and uncertain behavior were registered across 
the whole of England from 1995 through 2003. The 
age-standardized rates for all ages (0–84 years) was 9.21 
per 100,000 person-years. This is higher than previously 
reported for England because it includes nonmalignant 
CNS tumors and hence gives a more accurate picture of 
burden of disease. The age-standardized rates for those 
0–14 years of age, 15–24 years of age, and 25–84 years of 
age were 3.56, 3.26, and 14.57 per 100,000 person-years, 
respectively. In this article, we describe the changing 
patterns in the epidemiology of primary CNS tumors in 
these three age groups with respect to sex, tumor behav-
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ior, and histology using the current WHO classification. 
This information will provide a reference for future stud-
ies nationally and internationally and make comparisons 
relevant and meaningful. Neuro-Oncology 11, 403–413, 
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Previous data from regional registries show that, overall, 1.5%–1.9% of all cancers registered in England are tumors of the CNS, including brain 
and spinal cord tumors.1 Although CNS tumors are pre-
dominantly a disease of old age, the proportion of CNS 
tumors among all cancers falls significantly with increas-
ing age. CNS tumors represent 24.5% of all tumors in 
those 0–14 years of age2 and 8.9% in those 15–24 years 
of age.3 Their importance as a health problem in young 
people is further highlighted by the fact that CNS tumors 
are the most common cause of cancer-related deaths in 
both the 0- to 14-year age group2 and the 15- to 24-year 
age group.4 Even histologically benign tumors can be 
life-threatening because of their space-occupying effects 
within the cranium, local infiltration, and for some, a 
tendency to undergo malignant transformation over 
time.5 There is also significant morbidity both from the 
disease and from the treatment required, with varying 
degrees of physical, cognitive, neurological, endocrino-
Copyright 2009 by the Society for Neuro-Oncology
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logical, and other deficits in survivors resulting in sig-
nificant handicap and diminished quality of life.6
Establishing accurate incidence rates for these tumors 
is a challenge not only because they are a very hetero-
geneous group with more than 100 distinct pathologi-
cal entities, but also because of variations in registration 
practice, changes in classification, and improvements 
in neurodiagnostic techniques over time. Previously, in 
Britain, studies by morphological type have been based 
on regional registry data only or cases ascertained from 
hospitals.7 There have been no national studies describing 
the epidemiology of CNS tumors in detail in adolescents 
and adults. Studies from Norway8 and Japan9 analyzed 
national data sets across all ages, but the diagnostic clas-
sifications used were historical and differed (1979 and 
1993 WHO CNS tumor classification10,11 in the study 
from Norway and the 1945 International Union against 
Cancer classification12 in the study from Japan), which 
does not permit easy comparison. Similarly, the Auto-
mated Childhood Cancer Information System (ACCIS) 
has reported Europe-wide CNS tumor incidence data in 
children and has used the International Classification of 
Childhood Cancer (ICCC),13 which is morphology based 
but is not suited to older ages. The Central Brain Tumor 
Registry of the United States (CBTRUS) has published 
incidence rates from 1998–200214 based on the 2000 
WHO CNS tumor classification,15 but these are from 
18 state cancer registries and cover only 32% of the U.S. 
population. There is also huge variability in the report-
ing of tumors among U.S. states, with the percentage 
of nonmalignant tumors varying from 27% to 60% of 
overall CNS tumors. Also, because data are collected 
from each registry without a unique identifier, there is 
the possibility of duplicate registration.
Cancer registration is conducted by eight regional 
cancer registries in England, and the essential features 
of the system of registration have remained unchanged 
for more than 30 years.16 England has a high degree of 
case ascertainment, and reviews have shown that regis-
try records are largely complete, accurate, and reliable.16 
Notification of cancer registrations to the National 
Health Service Information Centre allows complete-
ness of registration and eliminates duplication. Data on 
CNS tumors obtained from these registries have been 
grouped using the current WHO15 classification. We 
present here incidence rates of CNS tumors for ages 
0–14 years, 15–24 years, and 25–84 years for the whole 
of England during the period 1995–2003. We describe 
the differences in the site and pathology distributions 
of CNS tumors in these age ranges. This will allow us 
to better understand the changes with age in this large, 
heterogeneous collection of tumors. Use of the current 
WHO classification will make comparisons across geo-
graphical areas as well as over time more meaningful in 
the future.
Materials and Methods
Source of Data
Cancer registration in England is carried out by a net-
work of eight population-based regional registries. 
Registration is coordinated by the Office for National 
Statistics in London, which maintains the national 
cancer registry covering all age groups. Anonymized 
individual-level national cancer registration data were 
obtained from the Office for National Statistics for all 
CNS tumors (tumor at any of the following sites: brain, 
meninges, spinal cord, cranial nerves, other parts of the 
CNS, pituitary, and pineal glands) of malignant, benign, 
and uncertain behavior newly diagnosed between 1995 
and 2003. Information was available on the year of diag-
nosis, age at diagnosis, sex of patient, primary site code, 
morphology code, and behavior code. Individual-level 
data on ethnicity was not available. National population 
estimates by single year of age, gender, and calendar year 
were supplied by the Population Estimates Unit, Office 
for National Statistics.
Classification
The data obtained were classified into diagnostic groups 
to match the WHO 2000 classification on the basis of 
International Classification of Diseases for Oncology 
(ICD-O) M and T codes.15 Modifications had to be 
made to make the classification more comprehensive 
by including pituitary tumors, not otherwise specified 
(NOS), and unspecified CNS tumors. This is consistent 
with the modified version of the new WHO 2000 clas-
sification used by CBTRUS.14 We excluded metastatic 
tumors and tumors that were of uncertain primary/
metastatic status. Also excluded were CNS lymphomas, 
hemopoietic neoplasms, mesenchymal nonmeningothe-
lial tumors, and olfactory tumors. The final version of 
our classification is given in appendix A, where any 
departure from the current WHO classification are in 
bold and italicized.
Statistical Methods
Age- and sex-specific incidence rates were calculated and 
expressed per 100,000 person-years. Histology and site-
specific incidence rates were also calculated for three dif-
ferent age groups: 0–14 years, 15–24 years, and 25–84 
years. Those older than 85 years of age were excluded 
because of possible underascertainment and lower speci-
ficity in diagnosis. All rates were adjusted to the world 
standard population1 using direct methods, except where 
specifically stated. SPSS version 15.0 (SPSS Science, Inc., 
Chicago, IL, USA) and Excel version 2003 (Microsoft 
Corp., Redmond, WA, USA) were used to analyze the 
data and produce tables and graphs.
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group were 15.86 and 13.40 per 100,000 person-years, 
respectively.
Distribution by Tumor Behavior
Most primary CNS tumors in the 0- to 84-year age 
group were malignant (60%), and the overall incidence 
rate for malignant tumors for all ages was 5.64 per 
100,000 person-years. The incidence rates for tumors of 
benign and uncertain behavior were 2.78 and 0.79 per 
100,000 person-years, respectively. Tumors of malignant 
behavior decreased in proportion with increasing age, 
while tumors of benign behavior increased in proportion 
(Fig. 2). Within the malignant group, the astrocytomas 
in those 0–14 years of age were mainly low grade (WHO 
grade I and II), and those in the 25- to 84-year age group 
were high grade (WHO grade III and IV), while in those 
15–24 years of age there was an equal proportion of 
low- and high-grade astrocytomas.
Distribution by Site
The distribution of tumors by primary site within the 
CNS for age groups 0–14 years, 15–24 years, and 25–84 
years is shown in Fig. 3. Tumors located in infratento-
rial brain decreased in proportion with increasing age, 
while tumors located in supratentorial brain and menin-
ges increased in proportion. Tumors of the pituitary and 
pineal glands and of the craniopharyngeal duct were 
relatively higher in proportion in the 15- to 24-year age 
group than at other ages.
Distribution by Histology
The distribution of tumors by main histology groups 
within the CNS for age groups 0–14 years, 15–24 years, 
and 25–84 years is shown in Fig. 4. Tumors of neuro-
epithelial tissue decreased in proportion with increasing 
age, while meningeal and unspecified tumors increased 
in proportion.
Results
Overall Incidence
During the period 1995–2003, 54,336 primary CNS 
tumors of malignant, benign, and uncertain behav-
ior located in the brain, meninges, spinal cord, cra-
nial nerves, other parts of the CNS, and pituitary and 
pineal glands were registered in England in persons 
0–84 years of age, which gives an annual average of 
just more than 6,000 new cases. The population cov-
ered was all individuals between 0 and 84 years of age 
in England from 1995 through 2003, which equates to 
432 million person-years. There were 28,069 male cases 
(51.7%) and 26,267 female. The overall incidence rate 
was 9.21 per 100,000 person-years, and the male and 
female incidence rates were 9.96 and 8.52 per 100,000 
person-years, respectively, giving a male-to-female ratio 
of 1.17:1.
Age-Specific Incidence
The age-specific incidence rates for primary CNS 
tumors are shown in Fig. 1. Peak incidence was seen in 
the 75- to 79-year age group for males and females. The 
number of 0- to 14-year-olds with primary CNS tumors 
was 2,959, with an annual average of approximately 330 
new cases and an incidence rate of 3.56 per 100,000 
person-years. The male and female incidence rates for 
the 0- to 14-year age group were 3.72 and 3.39 per 
100,000 person-years, respectively. There were 1,764 
cases among persons 15–24 years of age, with an annual 
average just below 200 new cases and an incidence rate 
of 3.26 per 100,000 person-years. The male and female 
incidence rates for the 15- to 24-year age group were 
3.47 and 3.04 per 100,000 person-years, respectively. 
There were 49,612 cases, with an annual average of 
about 5,500 new cases, in the 25- to 84-year age group; 
the incidence rate was 14.57 per 100,000 person-years, 
and the male and female incidence rates for the same age 
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The data on median age at diagnosis, incidence 
rates, and male-to-female ratio are shown in Tables 1 
and 2. There was an overall male preponderance, but 
meningiomas showed a strong female preponderance 
(p , 0.0001), and they were twice as common in adult 
females compared with adult males. The most common 
specified tumors registered in the 0- to 14-year age group 
were pilocytic astrocytomas, medulloblastomas, and 
ependymal tumors. Craniopharyngioma was the most 
common nonneuroepithelial primary CNS tumor in 
children. Tumors with their peak incidence rates in those 
younger than 1 year of age were choroid plexus tumors, 
gangliogliomas, supratentorial primitive neuroectoder-
mal tumors, and teratomas (data not shown). Tumors 
with their peak incidence rates in those 1–14 years of age 
were pilocytic astrocytomas, subependymal giant cell 
astrocytomas, anaplastic ependymomas (some of them 
may actually be ependymoblastomas, because they have 
the same morphological code, 9,392/317), medulloblasto-
mas, and craniopharyngiomas. The most common spec-
ified tumors registered in the 15- to 24-year age group 
were pituitary tumors, pilocytic astrocytomas, and nerve 
sheath tumors, while tumors with their peak incidence 
rates in that age group were pleomorphic xanthoastro-
cytomas, neurocytomas, and germinomas. Overall, the 
most common specified tumors registered in the 25- to 
84-year age group were glioblastoma multiforme, men-
ingiomas (94.5% nonmalignant), and pituitary tumors. 
Neuroepithelial tumors peaking in this age group were 
specified diffuse astrocytomas (peak incidence rate at 
50–54 years of age), anaplastic astrocytomas, glioblas-
toma multiforme (peak incidence rate at 65–69 years of 
age), oligodendrogliomas (peak incidence rate at 50–54 
years of age), anaplastic oligodendrogliomas (peak inci-
dence rate at 55–59 years of age), mixed gliomas (peak 
incidence rate at 50–54 years of age), myxopapillary 
ependymomas, and subependymomas. Nonneuroepi-
thelial tumors peaking in this age group included nerve 
sheath tumors (peak incidence rate at 60–64 years of 
age), meningiomas (peak incidence rate at 80–84 years 
of age), pituitary tumors (peak incidence rate at 65–69 
years of age), and hemangioblastomas.
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Discussion
We believe that this large, comprehensive, and up-to-
date analysis of incidence data accurately reflects the 
incidence of primary CNS tumors in England. A total of 
54,336 CNS tumors of benign, uncertain, and definite 
malignant behavior were registered across the whole of 
England from 1995 through 2003. The incidence rate 
for all ages (0–84 years) was 9.21 per 100,000 person-
years.
Traditionally, the epidemiology of CNS tumors has 
been characterized for children and adults of all ages 
separately in recognition of the differences in pathology 
and etiology. It is now recognized that the epidemiol-
ogy of tumors in adolescents is quite distinct from that 
of older adults,3,4,18 and hitherto, the incidence of CNS 
tumors by morphological type has not been described 
in this age group. The age structure of a population can 
affect the crude incidence rates. Adjusting to world stan-
dard population (as has been done here) allows compari-
Table 1. Median age at diagnosis (years), incidence rates (age-standardized rate [ASR] in 100,000 person-years), and percentage of all 
CNS tumors by histology and sex: England, 1995–2003
 Total     Male    Female 
Histology No. Median Age ASR Percent ASR Percent ASRa Percent
Tumors of neuroepithelial tissue 28,814 57 5.24 53.0 6.26 59.8 4.29** 45.7
 Astrocytic tumors 19,139 58 3.42 35.2 4.14 40.6 2.74** 29.5
  Specified diffuse astrocytoma  399 41 0.08 0.7 0.10 0.9 0.07** 0.6
  Anaplastic astrocytoma 970 50 0.18 1.8 0.21 2.0 0.16** 1.6
  Glioblastoma 11,829 62 1.89 21.8 2.40 25.8 1.41** 17.5
  Pilocytic astrocytoma  915 10 0.31 1.7 0.31 1.6 0.32 1.7
  Other specified astrocytoma variants 65 15 0.02 0.1 0.02 0.1 0.02 0.1
  Astrocytoma not otherwise specified 4,961 52 0.94 9.1 1.11 10.3 0.78** 7.9
 Oligodendroglial tumors 6,632 64 1.03 12.2 1.22 13.1 0.86** 11.2
  Oligodendroglioma 1,103 46 0.21 2.0 0.24 2.2 0.18** 1.8
  Anaplastic oligodendroglioma 395 52 0.07 0.7 0.09 0.8 0.06** 0.6
  Glioma not otherwise specified 5,134 68 0.75 9.4 0.89 10.1 0.63** 8.8
 Mixed gliomas 425 46 0.08 0.8 0.09 0.8 0.08 0.8
 Ependymal tumors 1,070 40 0.25 2.0 0.29 2.2 0.21** 1.7
 Choroid plexus tumors 100 9 0.03 0.2 0.03 0.2 0.03 0.2
 Glial tumors of uncertain origin 53 42 0.01 0.1 0.01 0.1 0.01 0.1
 Neuronal and mixed neuronal-glial tumors 344 27 0.09 0.6 0.10 0.7 0.08* 0.6
 Pineal parenchymal tumors 208 40 0.05 0.4 0.05 0.4 0.04 0.4
 Embryonal tumors 843 10 0.28 1.6 0.33 1.8 0.23 1.3
  Medulloblastoma 583 9 0.20 1.1 0.24 1.3 0.15** 0.8
  Supratentorial primitive neuroectodermal tumors 259 14 0.08 0.5 0.08 0.5 0.08** 0.5
  Other embryonal tumors 1 2 ,0.01 ,0.1 0.00 0.0 ,0.01 ,0.1
Tumors of cranial and spinal nerves 3,716 53 0.66 6.8 0.67 6.5 0.66 7.2
 Nerve sheath tumors 3,716 53 0.66 6.8 0.67 6.5 0.66 7.2
Tumors of the meninges 9,134 62 1.38 16.8 0.96 10.7 1.78** 23.4
 Meningioma 8,619 63 1.28 15.9 0.84 9.6 1.69** 22.5
 Primary melanocytic lesions 12 51 ,0.01 ,0.1 ,0.01 ,0.1 ,0.01 ,0.1
 Hemangioblastoma 503 46 0.10 0.9 0.11 1.0 0.08** 0.8
Germ cell tumors 203 17 0.06 0.4 0.09 0.5 0.03** 0.2
Tumors of the sellar region 5,310 54 0.94 9.8 0.98 9.9 0.91** 9.7
 Craniopharyngioma 515 41 0.12 0.9 0.12 1.0 0.11 0.9
 Pituitary tumors 4,795 55 0.82 8.8 0.86 8.9 0.80** 8.7
Miscellaneous tumors 117 55 0.02 0.2 0.02 0.2 0.02 0.2
 Blood and lymphatic vessel tumors 69 51 0.01 0.1 0.01 0.1 0.01 0.1
 Chordoma 48 61 0.01 0.1 0.01 0.1 0.01 0.1
Unspecified tumors 7,042 72 0.90 13.0 0.99 12.4 0.82** 13.6
Total 54,336 59 9.21 100.0 9.96 100.0 8.52** 100.0
ap-Values for variability in incidence by sex: *p , 0.05, **p , 0.0001
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son between registries in different countries because it 
is independent of the effects of age. The major category 
of CNS tumors excluded from this analysis is primary 
CNS lymphoma, which is usually defined as extra-
nodal lymphoma confined to the CNS without evidence 
of systematic disease.15 The reliability of this diagno-
sis depends on the comprehensiveness of staging, and 
in several studies the diagnosis of primary CNS lym-
phoma has been revised to systemic non-Hodgkin’s lym-
phoma with possible secondary CNS disease on further 
investigation.19–22
Previously published age-standardized incidence rates 
of primary CNS tumors (based on ICD-O site and not 
morphological type) in England are 6.5–7.7 per 100,000 
person-years in males and 4.5–4.9 per 100,000 person-
years in females1,23 and are lower than incidence rates 
from this study. These figures significantly underes-
timated the true burden of CNS tumors because they 
included only malignant tumors located in the brain23 
or in the brain and spinal cord.1 They excluded tumors 
located in the pituitary gland, craniopharyngeal duct, 
and pineal gland, as well as all nonmalignant tumors. 
Table 2. Average annual number of cases (AAN), incidence rates standardized for world population (age-standardized rate [ASR], in 
100,000 person-years), and male to female ratio (M:F) for each histology group for age groups 0–14 years, 15–24 years, and 25–84 years: 
England, 1995–2003
  0–14 Years   15–24 Years   25–84 Years 
Histology AAN ASR M:F AAN ASR M:F AAN ASR M:F
Tumors of neuroepithelial tissue 276 3.01 1.10 116 1.94 1.32 2,809 7.68 1.57
 Astrocytic tumors 132 1.42 0.93 64 1.07 1.37 1,930 5.40 1.64
  Specified diffuse astrocytoma  4 0.04 1.76 4 0.06 0.98 37 0.12 1.61
  Anaplastic astrocytoma 5 0.05 1.10 5 0.08 1.21 98 0.29 1.38
  Glioblastoma 11 0.12 0.65 12 0.20 1.46 1,291 3.51 1.75
  Pilocytic astrocytoma  69 0.75 0.85 16 0.27 1.75 17 0.06 1.08
  Other specified astrocytoma variants 4 0.03 2.12 2 0.03 0.79 2 0.01 0.40
  Astrocytoma not otherwise specified 40 0.42 1.06 26 0.43 1.30 485 1.42 1.51
 Oligodendroglial tumors 38 0.41 1.07 16 0.26 1.57 683 1.66 1.46
  Oligodendroglioma 2 0.02 3.21 5 0.09 1.64 115 0.36 1.30
  Anaplastic oligodendroglioma 1 0.01 1.04 1 0.02 1.32 41 0.13 1.59
  Glioma not otherwise specified 35 0.38 1.02 9 0.15 1.57 527 1.17 1.51
 Mixed gliomas 2 0.02 0.48 2 0.04 1.07 43 0.14 1.13
 Ependymal tumors 23 0.26 1.34 10 0.16 1.03 86 0.27 1.48
 Choroid plexus tumors 6 0.08 1.29 1 0.01 0.70 4 0.01 0.63
 Glial tumors of uncertain origin 1 0.01 2.49 1 0.02 0.64 4 0.01 0.98
 Neuronal and mixed neuronal-glial tumors 9 0.10 1.13 8 0.14 1.35 21 0.07 1.28
 Pineal parenchymal tumors 5 0.06 1.26 3 0.05 1.80 15 0.04 1.07
 Embryonal tumors 59 0.66 1.48 12 0.19 1.13 23 0.08 1.44
  Medulloblastoma 44 0.49 1.73 7 0.11 1.04 14 0.05 1.70
  Supratentorial primitive neuroectodermal tumors 15 0.17 0.99 5 0.08 1.27 9 0.03 1.11
  Other embryonal tumors ,1 ,0.01 0.00 0 0.00  0 0.00  
Tumors of cranial and spinal nerves                  
 Nerve sheath tumors 5 0.05 0.64 15 0.25 1.06 393 1.17 1.03
Tumors of the meninges 5 0.05 0.94 13 0.22 0.78 996 2.56 0.53
 Meningioma 4 0.04 1.19 9 0.15 0.80 944 2.40 0.49
 Primary melanocytic lesions ,1 0.01 1.09 ,1 ,0.01 0.00 1 ,0.01 2.04
 Hemangioblastoma 1 0.01 0.16 4 0.06 0.75 51 0.16 1.50
Germ cell tumors 9 0.09 2.15 7 0.13 8.41 6 0.02 1.86
Tumors of the sellar region 15 0.15 1.08 31 0.51 0.59 544 1.56 1.14
 Craniopharyngioma 13 0.13 1.14 6 0.11 0.94 38 0.12 1.17
 Pituitary tumors 3 0.02 0.84 24 0.40 0.52 506 1.45 1.14
Miscellaneous tumors 1 ,0.01 0.17 1 0.01 2.61 12 0.03 1.06
 Blood and lymphatic vessel tumors ,1 ,0.01 0.67 1 0.01 4.25 7 0.02 0.90
 Chordoma ,1 ,0.01 0.00 ,1 ,0.01 1.01 5 0.01 1.45
Unspecified tumors 18 0.2 0.94 12 0.20 0.94 752 1.55 1.24
Total 329 3.56 1.10 196 3.26 1.14 5,512 14.57 1.18
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The reported incidence of CNS tumors in the United 
States of 14.8 per 100,000 person-years14 is higher 
than that given here, while that from Norway, 9.53 per 
100,000 person-years,8 is similar to ours. The reasons for 
the higher incidence rate in the United States are three-
fold. First, U.S. age-adjusted rates are standardized to the 
U.S. 2000 population where children younger than 15 
years comprised 21.5%, and adults older than 70 years, 
9.2% of the total age distribution.14 These contrast to 
the world standard population where children younger 
than 15 years comprise 31%, and adults older than 70 
years, 4% of the total age distribution.1 Standardizing 
with a population that has relatively older individuals 
will increase the overall incidence rates because CNS 
tumors are far more common in these age groups. After 
adjusting to the world standard population, the overall 
incidence rate for the United States is 11.61 per 100,000 
person-years. Second, there is considerable variation 
in reporting of nonmalignant (benign and uncertain) 
tumors in the United States, and the percentage varies 
from 27% to 60% between different U.S. states.14 In our 
data, 31% of CNS tumors were nonmalignant, and if 
we consider U.S. states with similar percentages of non-
malignant tumors (Connecticut, 40% nonmalignant; 
North Carolina, 38%), their incidence rates (Connecti-
cut, 13.61; North Carolina, 11.43) are well below the 
overall figure of 14.8 per 100,000 person-years reported 
by CBTRUS. Finally, we have excluded CNS lympho-
mas from our analysis, which account for 3% of the 
incidence in the United States. Thus, one can conclude 
that the incidence of CNS tumors in the United States is 
actually not very different from that in the United King-
dom and Europe. These caveats also explain the higher 
incidence of CNS tumors in females in the United States 
compared to England and elsewhere,8,24 which is caused 
by increased registration of nonmalignant tumors, espe-
cially meningiomas (57%), which are more common in 
females (74%).
The incidence rate of 3.56 per 100,000 person-years 
seen in children in our study is similar to the incidence 
rate of 3.3 per 100,000 person-years reported by ACCIS 
for England and Wales for 1993–1996.25 Correspond-
ing rates for the rest of Europe vary from 4.0 to 5.0 per 
100,000 person-years for Iceland, Norway, Finland, 
and Denmark and between 2.0 and 3.0 per 100,000 
person-years for Germany and the Netherlands.25 Data 
on the incidence of primary CNS tumors for adolescents 
is scanty. Our previous report showed that the overall 
incidence rate for malignant CNS tumors in those 15–24 
years of age registered in England from 1979 through 
1997 is 1.65 per 100,000 person-years.3 The U.S. Sur-
veillance, Epidemiology, and End Results (SEER) pro-
gram data, which also report only malignant tumors, 
give an incidence rate of 2.26 per 100,000 person-years 
for the 15- to 29-year age group.18 After accounting for 
the slightly higher rates contributed by the 25- to 29-year 
age group in those data, this is closer to our rate of 1.94 
per 100,000 person-years for malignant CNS tumors in 
those 15–24 years of age in a more recent time period. 
Further comparisons by histological group are not pos-
sible because the SEER report uses the ICCC rather than 
WHO 2000 classification. The 2008 CBTRUS report, 
which uses the WHO 2000 classification, is also unsuit-
able for comparison because the age groups are different 
(0–19 years, 20–34 years, and so on).26
With increasing age, not only does the proportion of 
benign CNS tumors increase but there is also a shift in 
the spectrum of malignant primary CNS tumors. Pilo-
cytic astrocytoma and embryonal tumors form the bulk 
of malignant tumors in children. Pilocytic astrocytoma 
is a WHO grade I astrocytoma, and although regarded 
as a benign tumor by many,27 it is classified as malignant 
in the ICD-O first and second editions28,17 (ICD-O1 and 
ICD-O2, respectively). However, in the recent ICD-O 
third edition29 (ICD-O3), pilocytic astrocytoma is clas-
sified as uncertain (morphological code 9421/1) rather 
than malignant in behavior. Future analysis of epidemi-
ology of childhood CNS tumors may show an artificial 
rise in the proportion of nonmalignant CNS tumors 
because of this. Embryonal tumors are the second largest 
group, with 74% medulloblastomas and 26% supraten-
torial primitive neuroectodermal tumors. Absent among 
this group are ependymoblastomas (because they share 
the same morphological code, 9392/3,17 with anaplastic 
ependymomas and will have been included there) and 
atypical teratoid/rhabdoid tumors, which have been rec-
ognized as a distinct entity only in ICD-O3.29 Based on 
a series of cases from single institutions, the incidence 
of atypical teratoid/rhabdoid tumors is thought to be 
around 1%–2% of pediatric CNS tumors and at least 
10% of all CNS tumors in infants. With increasing use 
of ICD-O3, incidence data for this group of tumors 
should be available in the future.30 The incidence of 
medulloblastoma in childhood from this study is 0.49 
per 100,000 person-years and is similar to that reported 
elsewhere.15,31 But there is much more variability in the 
proportion of supratentorial primitive neuroectodermal 
tumors.15,32 McNeil et al.32 found that supratentorial 
primitive neuroectodermal tumors, which had not been 
described until the 1980s, accounted for up to one-third 
of all embryonal CNS tumors from 1993 through 1998 
in the SEER database. Also seen in infancy are benign 
tumors of mixed cellular-lineage, such as desmoplastic 
infantile astrocytoma/ganglioglioma and dysembryo-
plastic neuroepithelial tumors, which have been tradi-
tionally difficult to categorize and are now included in 
neuronal and mixed neuronal-glial tumors.30 Because 
these pathological entities have been defined only in 
ICD-O3, it is not possible to comment on their occur-
rence in our study.
In adolescents, not only is there a transition from the 
typical childhood tumor pattern to a distribution more 
typical of older adults, but there are certain features 
unique to this age group. First, tumors from the sellar 
region form a significant proportion (16%) and while 
in those 0–14 years of age 87% of these tumors are cra-
niopharyngiomas, in those 15–24 years of age 78% are 
pituitary tumors. Also, this age group has a female pre-
ponderance for pituitary tumors, which has been pre-
viously reported.33,34 This is due to prolactinomas and 
clinically nonfunctioning pituitary adenomas, which 
are more frequent in females.35 The explanation for this 
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gender-related difference is not clear, but the role of 
estrogen in tumor promotion and a greater inclination 
in females to seek medical attention for hypogonadal 
symptoms has been suggested.35 Second, germ cell 
tumors peak in incidence in this age group, and germi-
nomas account for the majority of these. They have pre-
viously been noted to show a strong male preponderance 
at the pineal site,36 and this is also seen in our study, 
where germ cell tumors were eight times more common 
in males than in females (p , 0.0001).
The data reported here on primary CNS tumors 
in older adults, including specified diffuse astrocy-
tomas,14 anaplastic astrocytomas,14 glioblastoma mul-
tiforme,14,15 oligodendrogliomas,12,37 anaplastic oligo-
dendrogliomas,14 mixed gliomas,14,38 certain ependymal 
tumors14,15,39 (myxopapillary ependymomas1 and sub-
ependymomas15,40), nerve sheath tumors,14,15,41–43 men-
ingiomas,14,15,44 hemangioblastomas,14 and pituitary 
tumors,14,45 are generally similar to data from other 
studies. There are, however, a few obvious differences, 
particularly compared with the data from CBTRUS,14 
for reasons discussed above. A final point of note is that 
astrocytomas NOS and gliomas NOS constituted 18.5% 
of all primary CNS tumors in our series, and another 
13% are of unspecified histology. This is because only 
71%–73% of CNS tumors in all ages are microscopi-
cally verified.1 The proportion of tumors with unspeci-
fied histology in our series increased with increasing 
age (Fig. 4), with a median age at diagnosis of 72 years, 
which suggests that younger individuals are more likely 
to undergo extensive investigation to achieve specific 
diagnoses, although this attitude toward the elderly may 
be changing.46 Moreover, it has been shown that, over 
time, the advances made in neuroimaging, neurosur-
gery, and neuropathology and improvements in quality 
of registrations are reducing the incidence of NOS and 
unspecified tumors.47
Little is known about the etiology of primary CNS 
tumors, and the only proven causes (hereditary syn-
dromes and radiation) account for a small proportion of 
cases.48 The heterogeneous pathologies grouped under 
CNS tumors further limit our ability to study the etiol-
ogy of the disease. Analyzing the pattern of these pathol-
ogies with age and sex (as has been done here) allows us 
to speculate about the etiopathogenesis. A nadir in the 
incidence of CNS tumors at ages 15–19 years and a peak 
at 75–79 years suggest that both genetic and environ-
mental factors have a role, with the environment being 
the larger contributor. An increasing incidence of high-
grade astrocytoma with increasing age along with a 
decreasing incidence of low-grade astrocytoma supports 
the suggestion that malignant transformation of astro-
cytic cells is a multistep process with sequential acquisi-
tion of genetic alterations with age.15 The peak of CNS 
embryonal tumors in early childhood and of CNS germ 
cell tumors in those 15–24 years of age is similar to the 
incidence pattern seen in non-CNS embryonal tumors 
(nephroblastoma, neuroblastoma) and gonadal germ 
cell tumors. This implies that the etiologies for CNS or 
non-CNS tumors that share the same tissue of origin are 
likely to be related.
It would also be of interest to analyze the variation in 
epidemiology by race and ethnicity, as has been done by 
CBTRUS.26 Currently, the individual-level cancer regis-
tration data obtained from the Office of National Sta-
tistics is anonymized and does not include information 
on ancestry/ethnicity. In the future, it may be possible 
to get such data, and then such an analysis can be done. 
Moreover, the minority ethnic population in England 
comprises 7.9%49 (4% Asian or Asian British, 2% black 
or black British, 1.2% mixed, and 0.8% others), which 
is much less than the 26% in the United States (13.4% 
black or African-American, 4.4% Asian, 2% mixed, and 
6.2% others).50 Thus, the incidence rates for England are 
relatively less likely to be affected by ethnic variation.
Conclusion
In summary, we present a large, comprehensive, and 
up-to-date analysis of incidence data of primary CNS 
tumors in the world England that has been obtained 
from a high-quality national cancer registration system. 
We have described the epidemiology across the whole 
of England from 1995 through 2003 for all ages and 
focused on the changing patterns in children, adoles-
cents, and older adults. The overall incidence is similar 
to that reported elsewhere in the world but higher than 
that reported in Britain before. We have also described 
sex-specific, age-specific, and tumor-behavior–specific 
standardized incidence rates for all histology groups 
according to the WHO 2000 classification. We hope this 
allows other studies to make relevant and meaningful 
comparisons with our data and that it provides a base-
line for secular trend analysis.
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Appendix A. CNS tumor classification based on histology adapted from the WHO 2000 classification.15 Any departures from the WHO 
2000 classification are in bold and italicized.
Histology Histology Code
Tumors of Neuroepithelial Tissue 
 Astrocytic Tumors 
  Specified diffuse astrocytoma  9410, 9411, 9420 
  Anaplastic astrocytoma 9401
  Glioblastoma 9440, 9441, 9442 
  Pilocytic astrocytoma   9380 (Site code restrictions 192.0, 225.1 – ICD9; C72.3, D33.3,  
D43.3 – ICD10), 9421 
  Other specified astrocytoma variants 9384, 9422, 9423, 9424, 9443 
  Astrocytoma NOS 9400
 Oligodendroglial tumors
  Oligodendroglioma 9450
  Anaplastic oligodendroglioma 9451, 9460
  Glioma NOS  9380 (Site code restrictions except 192.0, 225.1 – ICD9; C72.3, D33.3,  
D43.3 – ICD10)
 Mixed gliomas 9382
 Ependymal tumors 9383, 9391–9394
 Choroid plexus tumors 9390
 Glial tumors of uncertain origin 9381, 9430 
 Neuronal and mixed neuronal-glial tumors 8680, 8681, 8690, 8693, 8700, 8711, 9492, 9505, 9506
 Neuroblastic tumors Not included
 Pineal parenchymal tumors  9360, 9361, 9362 (Site code restrictions 194.4, 227.4, 237.1 – ICD9; C75.3, 
D35.4, D44.5 – ICD10 Except 9350, 9060–9102) 
 Embryonal tumors
  Ependymoblastoma Included in ependymal tumors
  Medulloblastoma  9363, 9364, 9473, 9490, 9503 (T-Code restrictions 191.6 ICD9; C71.6 ICD10), 
9470, 9471, 9472
  Supratentorial primitive neuroectodermal tumor  9363, 9364, 9473, 9490, 9503 (T-Code restrictions 191.0–191.5,  
191.7–192.9 – ICD9; C70.0-C72.9 except C71.6 – ICD10) 
  Other embryonal tumors 9501, 9508 
Tumors of Cranial and Spinal Nerves 
 Nerve Sheath Tumors 9540, 9541, 9550, 9560, 9561, 9562, 9570 
Tumors of the Meninges 
 Meningioma 9530, 9531, 9532, 9533, 9534, 9536, 9537, 9538, 9539
 Mesenchymal, non-meningothelial tumors Not included
 Primary melanocytic lesions 8720, 8726, 8740
 Hemangioblastoma 9161, 9535
 Lymphomas and Haemopoietic Neoplasms Not included
Germ Cell Tumors 
 Germ Cell Tumors  9060, 9061, 9064, 9070, 9071, 9072, 9073, 9080, 9081, 9082, 9083, 9084, 
9085, 9090, 9091, 9093, 9100
Tumors of the Sellar Region 
 Craniopharyngioma 9350
 Pituitary tumors  Site Code restrictions 194.3, 227.3, 237.0 – ICD9; C75.1, C75.2, D35.2, D35.3, 
D44.3, D44.4 – ICD10 except 9350, 9060-9102
Metastatic Tumors Not included
Other Specified Tumors 
 Blood and Lymphatic Vessel Tumors 9120, 9121, 9122, 9123, 9130, 9131, 9150, 9160, 9170, 9173
 Chordoma 9370
Miscellaneous Tumors 
 Unspecified  intracranial and intraspinal neoplasms 8000-8004, 8010, 9990
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A B S T R A C T
Reported increases in the incidence of CNS tumours in the developed world in the 1970s to
1990s have been a cause for concern and debate. It still remains to be adequately answered
whether these increases are true or an artefact of changes in diagnostic and registration
practices. Using high-quality national cancer registration data, we have analysed incidence
trends for each major histological subgroup of CNS tumour (2000 World Health Organisa-
tion (WHO) classification) registered in those aged 0–84 years for the whole of England dur-
ing the period 1979 through 2003. 134,509 primary CNS tumours of malignant, benign and
uncertain behaviour located in the brain, meninges, spinal cord, cranial nerves, other parts
of the central nervous system and in the pituitary and pineal glands were registered. In
summary, we present the single largest nationwide study on the longitudinal incidence
trends of CNS tumours. The increase in incidence observed in the 1970s and 1980s was
mainly in the young and the elderly and has now plateaued and may even be decreasing.
There is however variation in trends by histology. The incidence of some histological sub-
groups has continued to increase until the most recent period of analysis. Much of the ini-
tial increase can be attributed to the emergence of much more widely available neuroimag-
ing, while the most recent incidence changes for specific sub-groups of CNS tumours
appear to be due to greater diagnostic specificity leading to a shift in registered categories.
However, the trends for high-grade astrocytomas and other gliomas need further observa-
tion and investigation.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
According to global estimates, central nervous system (CNS)
tumours account for 1.7% of all new cancers and 2.1% of all
cancer deaths worldwide.1 The highest incidence rates are
in the developed world (Australia/New Zealand, Europe and
North America) and lowest in Africa which suggests that
availability of diagnostic facilities may influence recorded
incidence rates in developing countries.2 There are more than
100 distinct pathological entities reported for the CNS
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tumours. Around 60% of them are malignant in behaviour3
although even this proportion depends on registration prac-
tices which vary in the extent to which registration of non-
malignant tumours occurs in each country.4,5 Even histologi-
cally non-malignant tumours can be life-threatening as a re-
sult of their space-occupying effects, degree of local
infiltration and, the tendency for some low-grade astrocyto-
mas to undergo malignant transformation, particularly those
which have received irradiation.6
In late 1980s and early 1990s there were several reports of
increasing incidence of CNS tumours, mainly in the elderly,
from Europe,7,8 North America9,10 and Oceania.11 By the mid
to late 1990s there were similar reports of increasing inci-
dence of CNS tumours in children, initially from Britain12,13
followed by other parts of Europe14,15 and North America.16,17
Recently studies from Asia,18 Europe19,20 and North Amer-
ica21,22 have shown that the increasing incidence of CNS tu-
mours overall (including children and the elderly) may be
levelling off and may actually be falling.
It is generally accepted that some of the increase in inci-
dence was not real but a result of advances in neuroimag-
ing23–26 and better registration of non-malignant CNS
tumours.27,28 However, there is a debate as to whether in all
cases, the increases can be attributed to such an artefact of
changes in diagnostic and registration practices.29,30 This is
because the incidence increases started prior to the introduc-
tion of computerised tomography (CT) scanning.7 In addition
there was not only an increase in the incidence of radiologi-
cally diagnosed CNS tumours, but also of those, albeit
smaller, diagnosed clinically.10,31 Alternate explanations pro-
posed for the increases include greater availability of neurol-
ogists,23 attitudinal change in the delivery of healthcare to the
elderly23,25 and increased availability of alternative imaging
procedures like arteriography prior to the advent of CT.11
The case for an artefactual increase seen elsewhere is sup-
ported by the observation of no such change in the incidence
of CNS tumours in the population of Rochester, Minnesota in
United States of America (USA) for the era 1935–1997 although
the number of CNS tumours diagnosed over this period was
relatively small (373).32,33 Rochester, which has one of the
highest reported incidence rates of CNS tumours in USA,
has historically had near-complete case ascertainment, regis-
tration of benign tumours, a high autopsy rate to confirm
diagnosis, greater than 95% histological confirmation of tu-
mour type, and easy access to neurological and neurosurgical
expertise. In such a setting, the effect of any artefact on inci-
dence patterns is likely to be minimal.
Furthermore, no new environmental risk factors have
been identified nor has there been an increase in any existing
environmental risk factor whose presence could explain the
rise in the observed incidence. So far, no consistent evidence
linking exposure to mobile phones, extremely low frequency
electromagnetic fields, infections and pesticides to CNS tu-
mour development has been identified.34,35 The heteroge-
neous pathologies grouped under the term CNS tumours
further limit our ability to study the aetiology of individual tu-
mour types. The recent levelling off would suggest that either
the exposure to the, as yet unidentified risk factor(s), has
reached its peak or that the rise in incidence was indeed
artefactual.
Using high quality national cancer registration data, we
present here incidence trends of primary CNS tumours in
children (0–14 years), adolescents and young adults (15–
24 years), older adults (25–64 years) and for the elderly (65–
84 years) covering the whole of England during the period
1979 through 2003 with the aim to explore the incidence trend
patterns in comparison with those seen elsewhere. Impor-
tantly, we analyse the trend for each major histological sub-
group of CNS tumours (malignant and non-malignant) using
the 2000 WHO classification6 for each of the four age groups.
Much of the published literature lacks such detailed informa-
tion on specific histologies. The only other study which has
applied the detailed 2000 WHO classification in the analysis
of trends, looked at 25,258 primary CNS tumours over a short-
er time period (1985–1999).26
2. Materials and methods
2.1. Source of data
Cancer registration in England is carried out by a network of
eight population-based regional registries and the national
data are collated by the Office for National Statistics in Lon-
don.36 Anonymised individual patient level national cancer
registration data were obtained from the Office for National
Statistics on all CNS tumours (tumour at any of the following
sites: brain, meninges, spinal cord, cranial nerves, other parts
of the central nervous system and pituitary and pineal
glands) of malignant, benign and uncertain behaviour, newly
diagnosed between 1979 and 2003. National population esti-
mates by single year of age, gender and calendar year were
supplied by the Population Estimates Unit, Office for National
Statistics.
2.2. Classification
The data obtained were classified into diagnostic groups
according to the WHO 2000 classification on the basis of
ICD-oncology second edition (ICD-O2) morphology codes37
and International Classification of Diseases 10th revision
(ICD-10) topography codes.38 In addition pituitary tumours
and not otherwise specified/unspecified CNS tumours were
also included. Metastatic tumours and those where it was
uncertain if they were primary or metastatic were excluded.
Also excluded were CNS lymphomas, haemopoietic neo-
plasms, mesenchymal non-meningothelial tumours and
olfactory tumours. Details of our classification including mor-
phology and site code allocations have been published
elsewhere.3
2.3. Statistical methods
Age and sex specific incidence rates were calculated and ex-
pressed per 100,000 person years. All rates were adjusted to
the world standard population2 using direct methods except
where specifically stated. To assess the variation in the longi-
tudinal trends with age, the total time period was divided into
five quinquennia 1979–1983, 1984–1988, 1989–1993, 1994–1998
and 1999–2003. Average annual percentage change (AAPC)
along with the 95% confidence intervals (CIs) was calculated
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for the entire period from 1979 to 2003 for four different age
groups (0–14, 15–24, 25–64 and 65–84 years) and for each of
the histological sub-groups. Those above the age of 85 were
excluded because of possible under-ascertainment and often
lower specificity in diagnosis. p-Values for variability in inci-
dence trends by sex within each age group as well as variabil-
ity among the four age groups were also calculated. SPSS, R39
and Microsoft Excel were used for analysing the data and pro-
ducing tables and graphs.
3. Results
During the period 1979 through 2003, 134,509 primary CNS tu-
mours of malignant, benign and uncertain behaviour located
in the brain, meninges, spinal cord, cranial nerves, other
parts of the central nervous system, and in the pituitary
and pineal glands were diagnosed and registered in England
in those aged 0–84 years. The population covered, equated
to 1.18 billion person years. About 69,408 of the tumours were
in males (51.6%) and 65,101 in females. The overall age-stand-
ardised incidence rate steadily increased from 7.41 per
100,000 person years in 1979 to 9.73 in 1992 but has not sub-
sequently increased (Fig. 1). Indeed, there seems to be some
decrease in overall incidence since 2001. Both benign and
malignant tumours show an increase in incidence while
those of uncertain/borderline behaviour have decreased
(Fig. 2).
Table 1 shows the incidence rates (adjusted to the stan-
dard world population) in each quinquennium for all the his-
tological sub-groups in the WHO 2000 classification. Four
main patterns have been identified:
(i) No change in incidence throughout the period – speci-
fied diffuse astrocytomas (WHO grade II – fibrillary, pro-
toplasmic and gemistocytic), pineal parenchymal
tumours, medulloblastomas, hemangioblastomas, cra-
niopharyngiomas and chordomas.
(ii) Increasing incidence throughout each of the quinquen-
nia – anaplastic astrocytomas (WHO grade III), glioblas-
tomas (WHO grade IV), pilocytic astrocytomas (WHO
Fig. 1 – Trends in age-standardised incidence rates of primary CNS tumours in England, 1979–2003.
Fig. 2 – Trends in age-standardised incidence rates of primary CNS tumours in England, 1979–2003 by behaviour.
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Table 1 – Incidence of primary CNS tumours in those aged 0–84 years in England from for the five quinquennia from 1979 to 2003.
Number of cases Age-standardised incidence ratesa in 100,000 person years p-Value
1979–1983 1984–1988 1989–1993 1994–1998 1999–2003
Total CNS tumours 134,509 7.61 8.27 8.99 9.24 9.13 0.00001
Tumours of neuroepithelial tissue (total) 70,048 4.16 4.55 4.68 5.26 5.22 0.00001
Astrocytic tumours 40,327 2.04 2.21 2.65 3.33 3.48 0.00001
Specified diffuse astrocytoma 1036 0.08 0.07 0.09 0.08 0.09 0.3
Anaplastic astrocytoma 1689 0.02 0.07 0.14 0.17 0.19 0.00001
Glioblastoma 18,309 0.47 0.53 0.82 1.60 2.05 0.00001
Pilocytic astrocytoma 1553 0.08 0.12 0.13 0.27 0.33 0.00001
Other specified astrocytoma variants 91 0.00 0.00 0.00 0.01 0.02 0.00001
Astrocytoma NOS 17,649 1.38 1.42 1.48 1.20 0.80 0.00001
Oligodendroglial tumours 3082 0.17 0.19 0.19 0.26 0.30 0.00001
Oligodendroglioma 2557 0.16 0.18 0.17 0.21 0.21 0.00001
Anaplastic oligodendroglioma 525 0.01 0.01 0.02 0.05 0.09 0.00001
Glioma NOS 20,041 1.45 1.61 1.25 0.92 0.64 0.00001
Mixed gliomas 765 0.03 0.04 0.05 0.06 0.10 0.00001
Ependymal tumours 2380 0.17 0.19 0.20 0.23 0.25 0.00001
Choroid plexus tumours 215 0.02 0.02 0.02 0.03 0.03 0.0001
Glial tumours of uncertain origin 198 0.03 0.02 0.01 0.01 0.01 0.00001
Neuronal and mixed neuronal-glial tumours 475 0.01 0.01 0.02 0.08 0.09 0.00001
Pineal parenchymal tumours 543 0.05 0.04 0.04 0.06 0.04 0.67
Embryonal tumours 2022 0.21 0.22 0.23 0.28 0.28 0.00001
Medulloblastoma 1707 0.21 0.21 0.22 0.20 0.20 0.65
Supratentorial primitive neuroectodermal tumour 314 0.00 0.01 0.01 0.08 0.08 0.00001
Tumours of cranial and spinal nerves
Nerve sheath tumours 8709 0.49 0.55 0.61 0.70 0.63 0.00001
Tumours of the meninges (total) 21,062 1.03 1.13 1.17 1.33 1.39 0.00001
Meningioma 19,721 0.94 1.04 1.07 1.24 1.29 0.00001
Primary melanocytic lesions 28 0.001 0.003 0.002 0.004 0.003 0.27
Hemangioblastoma 1313 0.08 0.09 0.09 0.09 0.10 0.15
Germ cell tumours
Germ cell tumours 488 0.04 0.04 0.06 0.06 0.06 0.00001
Tumours of the sellar region (total) 13,497 0.78 0.86 1.04 1.04 0.85 0.00001
Craniopharyngioma 1484 0.13 0.14 0.12 0.14 0.10 0.07
Pituitary tumours 12,013 0.65 0.72 0.91 0.90 0.75 0.00001
Miscellaneous tumours (total) 485 0.05 0.04 0.03 0.02 0.02 0.00001
Blood and lymphatic vessel tumours 346 0.04 0.03 0.02 0.01 0.01 0.00001
Chordoma 139 0.01 0.01 0.01 0.01 0.01 0.25
Unspecified tumours
Unspecified tumours 20,220 1.06 1.09 1.41 0.83 0.95 0.00001
a Adjusted to world standard population.
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grade I), anaplastic oligodendrogliomas (WHO grade III),
mixed gliomas, neuronal and mixed neuronal-glial
tumours and meningiomas.
(iii) Initial increase in incidence followed by stabilisation –
oligodendrogliomas (WHO grade II), ependymal
tumours, choroid plexus tumours, supratentorial prim-
itive neuroectodermal tumours (PNETs), nerve sheath
tumours, germ cell tumours and pituitary tumours.
(iv) Initial increase in incidence followed by decrease –
astrocytomas not otherwise specified, gliomas not
otherwise specified and unspecified tumours.
Age specific incidence rates for ages 0–4 years, and five-
year age groups up to 80–84 years for each quinquennium
are shown in Fig. 3. The increase in the incidence of primary
CNS tumours was seen mainly in the young and the elderly
and had been relatively stable for those aged 25–64 years.
Within the young, the increase in incidence was the highest
in the youngest (38%, 31%, 27%, 26% and 11% for 0–4, 5–9,
10–14, 15–19 and 20–24 year age groups, respectively, between
the period 1979–1983 and the period 1999–2003). Among the
elderly, the incidence change increased with age (15%, 24%,
54%, 115% and 176% for 60–64, 65–69, 70–74, 75–79 and 80–
84 year age groups, respectively). Because of this, the age of
peak incidence rate for CNS tumours shifted from 65–69 years
in 1979–1983 to 75–79 years in 1999–2003.
Table 2 shows the AAPC for four different age groups (0–14,
15–24, 25–64 and 65–84 years) and for each of the histological
sub-groups of the WHO 2000 classification. Overall the inci-
dence significantly increased in all age groups with the high-
est increases in those aged 0–14 years and 65–84 years.
Analysis by histology, however, revealed different patterns.
Firstly, for those CNS tumours where incidence had not chan-
ged over 25 years (see above), there was also little or no
change in each of those four age groups. Secondly, for those
CNS tumours where incidence had steadily increased in
25 years or had increased and stabilised, the change was
either seen in all age groups (anaplastic astrocytomas, glio-
blastomas, anaplastic oligodendrogliomas, mixed gliomas,
neuronal and mixed neuronal-glial tumours and supratento-
rial PNETs) or mainly in the elderly (oligodendrogliomas,
ependymal tumours, nerve sheath tumours, meningiomas
and pituitary tumours) or mainly in the young (pilocytic astro-
cytomas, other specified astrocytoma variants including pleo-
morphic xanthoastrocytomas, choroid plexus tumours and
germ cell tumours).
4. Discussion
This analysis of 134,509 primary CNS tumours across the
whole of England from 1979 through 2003 is the single largest
reported study of longitudinal trends in CNS tumour inci-
dence. Availability of such large numbers of cases derived
from a high quality national cancer registration system al-
lows us to study in detail the variation in incidence trends
by sex, age, tumour behaviour and histology. Overall, the inci-
dence of CNS tumours in England gradually increased from
1979 until 1992 and then levelled-off. Indeed since 2001, there
seems to be a slight downturn in incidence and future studies
will have to establish whether this decline continues.
This increase in overall incidence was mainly due to in-
creases in the incidence in the young (0–24 years) and the el-
derly (65–84 years), but in both these age groups the incidence
has been stable over the last ten years of the analysis period.
Looking beyond the overall trend, there are still some CNS tu-
mours which show an increase in incidence in all age groups
(anaplastic astrocytomas, glioblastomas, anaplastic oligoden-
drogliomas, mixed gliomas and neuronal and mixed neuro-
nal-glial tumours); in those 0–24 years of age (pilocytic
astrocytomas); and in those 25–84 years of age (meningiomas)
up to and including the most recent time period.
The variation in temporal trends by age and by histology
suggests that no single carcinogen (or lack of protective fac-
tor) can explain the rise and the subsequent stabilisation in
Fig. 3 – Age-specific logarithmic incidence curves of primary CNS tumours in England from 1979 to 2003.
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Table 2 – Average annual percentage change (AAPC) of primary CNS tumours in England from 1979 to 2003 across four different age groups.a, b.
Number of cases Average annual percentage change
0–14 years 15–24 years 25–64 years 65–84 years
Total CNS tumours 134,509 1.3 (1.0, 1.6) 0.9 (0.6, 1.3) 0.4 (0.3, 0.5) 2.5 (2.3, 2.6) c
Tumours of neuroepithelial tissue 70,048 2.2 (1.8, 2.6) 1.6 (1.1, 2.1) 0.4 (0.3, 0.5) 2.9 (2.7, 3.1) c
Astrocytic tumours 40,327 3.0 (2.4, 3.6) 2.2 (1.5, 3.0) 2.3 (2.1, 2.5) 6.2 (5.9, 6.5) c
Specified diffuse astrocytomas 1036 1.2 ()1.5, 4.1) 4.3 (1.0, 7.7) 0.2 ()0.8, 1.2) )1.0 ()3.6, 1.7)
Anaplastic astrocytoma 1689 8.9 (5.3, 12.7) 12.2 (8.0, 16.5) 7.7 (6.8, 8.7) 8.7 (6.9, 10.4)
Glioblastoma 18,309 6.5 (4.2, 8.8) 5.6 (3.6, 7.6) 7.8 (7.5, 8.1) 11.8 (11.4, 12.3) c
Pilocytic astrocytoma 1553 8.4 (7.4, 9.5) 8.4 (6.4, 10.5) 4.5 (2.6, 6.3) )0.4 ()4.4, 3.9) c
Other specified astrocytoma variants 91 19.5 (11.5, 28.0) 22.0 (11.3, 33.6) 2.8 ()2.5, 8.5) 16.7 ()3.7, 41.4) c
Astrocytoma NOS 17,649 )1.7 ()2.5, )1.0) )1.2 ()2.1, )0.3) )2.7 ()3.0, )2.5) )1.0 ()1.4, )0.6) c
Oligodendroglial tumours 3082 )1.6 ()4.3, 1.2) 1.6 ()0.6, 3.8) 3.4 (2.8, 4.0) 5.6 (4.0, 7.2) c
Oligodendroglioma 2557 )3.5 ()6.5, )0.5) 0.2 ()2.1, 2.5) 1.6 (1.0, 2.3) 3.3 (1.7, 5.0)
Anaplastic oligodendroglioma 525 10.8 (1.9, 20.5) 16.3 (6.8, 26.6) 14.8 (12.7, 16.9) 18.8 (13.3, 24.5)
Glioma NOS 20,041 1.2 (0.2, 2.2) )4.0 ()5.4, )2.6) )6.1 ()6.4, )5.8) )1.1 ()1.3, )0.8) c
Mixed gliomas 765 3.4 ()1.2, 8.3) 8.3 (3.7, 13.1) 6.3 (5.0, 7.7) 8.3 (4.9, 11.8)
Ependymal tumours 2380 0.8 ()0.4, 2.0) 1.56 ()0.2, 3.4) 2.8 (2.1, 3.6) 5.7 (3.8, 7.6) c
Choroid plexus tumours 215 6.7 (3.6, 9.8) 2.5 ()4.2, 9.7) 0.2 ()2.9, 3.3) )0.3 ()7.7, 7.7) c
Glial tumours of uncertain origin 198 )3.5 ()8.0, 1.1) 7.2 (0.5, 14.5) )9.5 ()12.2, )6.9) )1.1 ()6.7, 4.8) c
Neuronal and mixed neuronal-glial tumours 475 14.6 (10.8, 18.6) 14.2 (10.4, 18.2) 11.3 (8.9, 13.8) 9.1 (3.3, 15.2)
Pineal parenchymal tumours 543 0.1 ()2.4, 2.6) )2.2 ()5.1, 0.7) 0.0 ()1.7, 1.7) 4.4 (1.1, 7.8)
Embryonal tumours 2022 1.4 (0.6, 2.1) 2.1 (0.4, 3.8) 2.8 (1.3, 4.3) 8.2 (1.5, 15.3)
Medulloblastoma 1707 )0.2 ()1.0, 0.6) )0.9 ()2.7, 0.9) 0.5 ()1.1, 2.1) 2.5 ()5.4, 11.2)
Supratentorial primitive neuroectodermal tumour 314 16.6 (13.1, 20.2) 20.4 (14.0, 27.2) 13.5 (9.3, 18.0) 17.3 (4.3, 32.0)
Other embryonal tumours 1
Tumours of cranial and spinal nerves
Nerve sheath tumours 8709 )4.6 ()6.2, )3.0) 0.4 ()0.9, 1.8) 2.2 (1.8, 2.6) 1.5 (0.9, 2.2) c
Tumours of the meninges 21,062 1.8 ()0.8, 4.5) )0.6 ()0.9, 2.1) 1.2 (1.0, 1.5) 2.9 (2.6, 3.3) c
Meningioma 19,721 1.0 ()1.8, 3.9) 0.9 ()0.9, 2.8) 1.3 (1.0, 1.5) 3.0 (2.7, 3.3) c
Primary melanocytic lesions 28 8.4 ()2.8, 20.8) )3.9 ()10.6, 3.3) 24.3 ()2.1, 57.9)
Hemangioblastoma 1313 4.2 ()3.6, 12.6) )0.3 ()3.0, 2.5) 0.6 ()0.2, 1.5) 0.4 ()1.4, 2.3)
Germ cell tumours
Germ cell tumours 488 3.0 (1.0, 5.1) 6.0 (3.5, 8.6) 0.3 ()2.2, 2.9) )1.4 ()7.5, 5.1) c
Tumours of the sellar region 13,497 )0.2 ()1.5, 1.2) )0.2 ()1.2, 0.7) 0.5 (0.2, 0.8) 3.1 (2.6, 3.6) c
Craniopharyngioma 1484 )0.4 ()1.8, 1.1) )2.1 ()4.0, 0.0) )0.8 ()1.8, 0.2) 0.9 ()1.0, 2.9)
Pituitary tumours 12,013 0.7 ()2.6, 4.2) 0.3 ()0.8, 1.4) 0.6 (0.3, 0.9) 3.3 (2.8, 3.8) c
Miscellaneous tumours 485 )6.39 ()11.3, )1.2) )10.3 ()14.8, )5.6) )4.3 ()5.8, )2.7) )1.9 ()4.6, 0.8)
Blood and lymphatic vessel tumours 346 )11.9 ()18.0, )5.4) )12.2 ()17.4, )6.6) )4.8 ()6.6, )3.0) )3.3 ()6.8, 0.2)
Chordoma 139 14.8 ()0.8, 33.0) )5.0 ()13.5, 4.4) )2.7 ()5.7, 0.3) 0.1 ()4.0, 4.5)
Unspecified tumours
Unspecified tumours 20,220 )2.5 ()3.6, )1.5) )0.7 ()2.0, 0.6) )1.9 ()2.2, )1.6) 1.4 (1.1, 1.6)c c
a AAPC was not reported for groups of insufficient size.
b Statistically significant AAPC are in bold (p < 0.05) and 95% CI are given in parentheses.
c The difference in AAPC across the four age groups is statistically significant (p < 0.05).
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incidence. Prolonged exposure to radiofrequency signals from
mobile phones or occupational electric and magnetic fields,
which have been under investigation,34,35 are unlikely to have
contributed in a major way specifically to the increase of inci-
dence seen only in the elderly or the young. If the increase in
incidence in the young is the result of exposure to a tumouri-
genic factor in pregnancy or early childhood then the latent
period would have to be very short to produce such an effect.
Studies which have looked at maternal occupation during
pregnancy, paternal occupation during peri-conceptional per-
iod, maternal exposure to tobacco smoke, N-nitroso com-
pounds in household water during pregnancy and proximity
of home address at birth to high voltage power lines have
not found a consistent link or a dose-risk relationship.40–47
Clearly the aetiology of the majority of CNS tumours is still
unknown and these arguments will need to be revisited as
our understanding increases.
In the absence of an identifiable causative factor, is there
an alternative explanation for the continuing rise of some
CNS tumours? Some of the answer probably lies in the obser-
vation of a decrease in incidence in the last ten years of CNS
tumours characterised by lack of specificity for behaviour
(CNS tumours of unknown/borderline behaviour, Fig. 2) or
histology (e.g. unspecified CNS tumours, and gliomas not
otherwise specified, Table 1). This would suggest that
improvements in neurosurgical techniques and develop-
ments in neuropathology have enabled more specific diagno-
sis to be made leading to a shift of tumours previously
diagnosed as ‘‘not otherwise specified’’ or ‘‘unspecified’’ to
more specific histologies and registered as such. Data on
CNS tumours from the European Automated Childhood Can-
cer Information System show an increasing proportion of
microscopically verified CNS tumours over time leading to a
decrease in the ‘‘not specified’’ category.48 Included among tu-
mours that are now being increasingly recognised, are oligo-
dendroglial tumours and mixed gliomas (using 1p/19q
chromosomal loss as a diagnostic tool)49 and neuronal tu-
mours like central neurocytomas where diagnosis is assisted
by electron microscopy and immunohistochemistry.50 How-
ever, there is an increase in astrocytic tumours overall and
shift alone from astrocytoma not otherwise specified to ana-
plastic astrocytoma or glioblastoma cannot explain the
increase.
There is another interesting facet to the trends of these
groups of less specific CNS tumours. As seen in Table 1 their
incidence actually increased for the initial period of the anal-
ysis (along with most other histological sub-groups of CNS tu-
mours) before declining. This would imply that the initial
increase was a result of a factor which affected all groups. It
has been proposed elsewhere that a steep increase in the
use of CT scan imaging of the head, particularly in the elderly,
accounted for a large part of the observed increase in inci-
dence seen in the USA and Nordic countries during the
1970s and 1980s.23,25,31,51 Our observations support this, as el-
derly patients with an underlying primary CNS tumour who
present with focal neurological symptoms or after accidents
are far more likely previously to have been clinically
(mis)diagnosed as having cerebrovascular disease or transient
ischaemic attack without the benefit of neuroimaging.52 This
argument can be extrapolated to low-grade astroglial and
neuronal tumours as well. Smith et al. have attributed the in-
crease in incidence seen in low-grade glial lesions in the brain
stem in children to changes in detection and/or reporting of
childhood CNS tumours during the mid-1980s in USA.24 An-
other consequence of the widespread availability and use of
improved neuroimaging has been the diagnosis of slow grow-
ing low-grade CNS tumours at an earlier age. In our study the
median age at diagnosis for pilocytic astrocytoma decreased
from 13 years in the period 1979–1983 to 10 years from 1999
to 2003 (data not shown).
The increase in high-grade astrocytomas (anaplastic astro-
cytomas and glioblastomas) and high-grade gliomas (anaplas-
tic oligodendrogliomas) is more difficult to interpret. The
increase is not restricted to children or the elderly but has
happened across all age groups (Table 2) and so cannot be
simply attributed to increased availability of neuroimaging
or a change in attitude towards the elderly. Due to the aggres-
sive nature and poor outlook of these tumours, they are unli-
kely to be under diagnosed or picked up coincidentally. As
distinct and well-recognised malignant pathological entities,
the incidence of this group of CNS tumours is unlikely to be
affected by changes in classification or registration practices,
although advances in neurosurgery and neuropathology
would lead to increased specificity and some shift between
tumour categories.
Studies from Europe19,20 and USA53 have reported contin-
uing increase of high-grade astrocytomas and gliomas in
the 1990s and early part of the 21st century. Lo¨nn et al. re-
ported that the increase in the incidence of glioblastoma from
1993 to 1998 seen in the Nordic countries was confined to
those aged 60–79 years with no change in those aged 20–
59 years.19 On the other hand, the increase in incidence of
high-grade astrocytomas in Netherlands from 1989 to 2003
was seen in those aged 15–44 years as well as those above
65 years of age with no significant change in adults aged 45–
64 years.20 Finally, McCarthy et al., have recently reported
continuing increases in the incidence of anaplastic oligoden-
droglioma in those aged 20–64 years from USA.53 Our analysis
shows that the increase of high-grade astrocytomas and glio-
mas in the most recent period is not restricted to those aged
65–84 years (Fig. 4). All these factors make it difficult to dis-
miss the increase in incidence in high-grade astrocytomas
and other gliomas as an artefact. This is a group of tumours
for which aetiological studies may yet yield some clues to
their changing incidence.
5. Conclusion
In summary, we present the single largest study on the longi-
tudinal trends of CNS tumours derived from data obtained
from a high quality national cancer registration system. The
overall increase of incidence seen in CNS tumours in England
in 1970s and 1980s was mainly in the young and the elderly
and has now levelled off and may be decreasing. There is
however variation in these trends by histology and the inci-
dence of some histological sub-groups has continued to in-
crease until the most recent period of analysis. Much of the
initial increase can be attributed to the emergence of widely
available neuroimaging, while more recent changes in trends
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of specific sub-groups of CNS tumours is likely to be as a re-
sult of increased specificity of diagnosis leading to a shift in
registered categories. However, the trends of high-grade
astrocytomas and gliomas as well as pilocytic astrocytomas
need further observation and investigation.
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Condensed Abstract  
Malignant germ cell tumours, which display heterogeneity by histology and site, occur at 
all ages with incidence peaks in infancy and young adulthood. Regardless of site, the 
similarity in shapes of the age-incidence curves of germ cell tumours, suggests a common 
initiation of these tumours in embryonic/foetal life with variable rates of tumour 
progression as a result of local factors or events during postnatal and pubertal period. 
 
Abstract 
Background - Gonadal and extragonadal germ cell tumours (GCT) are thought to arise 
from primordial germ cells and could have similar aetiopathogenesis. Unlike testicular 
GCT, there has been limited comprehensive population-based analysis of ovarian and 
extragonadal GCT. 
Methods - All malignant GCT and benign and uncertain behaviour central nervous 
system (CNS) GCT registered in England in the age group 0-84 years from 1979-2003 
were included.  Incidence rates were calculated and adjusted to world standard 
population. 
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Results – There were 33364 GCT (92.5% testes, 3.9% ovary, 3.2% extragondal) in 
persons aged 0-84 years. CNS was the most common extragonadal site. An initial peak in 
incidence at 0-4 years of age of non-germinomas was seen at all sites except ovary. 
Second incidence peaks between ages of 10-39 years, which was more marked in males, 
were also seen at all sites. The age at this incidence peak varied by site and was 10-14 
years (CNS), 15-19 years (ovary), 25-29 years (other extragonadal sites), and 30-34 years 
(testes). A significant increase in incidence with time was seen in germinomas (testes, 
CNS) and non-germinomas (testes, ovary). 
Conclusions – These age-incidence patterns suggest a common initiation of GCT in 
embryonic/foetal life with variable rates of tumour progression as a result of subsequent 
events which may be site-specific. Future genetic studies need to consider GCT from all 
sites to enable a better understanding of their aetiology. 
 
Keywords 
Germ Cell Neoplasms; Testicular Neoplasms; Ovarian Neoplasms; Central Nervous 
System Neoplasms; Mediastinal Neoplasms; Incidence; Longitudinal Trends; England 
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Introduction 
Malignant germ cell tumours (GCT), which display heterogeneity by histology 
and site, occur at all ages with incidence peaks in infancy and young adulthood. 3.3% of 
all cancers in 0 to 14 year olds are malignant GCT while in the 15 to 24 year age group 
the proportion increases to 13.8%.1,2 Testicular tumours, most of which are GCT, are the 
most common malignancy in young men aged 15 to 44 years3 and the incidence of these 
cancers is estimated to have doubled in the last 40 years.4 In contrast to testicular GCT, 
ovarian GCT represent only 3% of all malignant ovarian tumours with ovarian carcinoma 
predominating. They are however the most common malignant ovarian tumour in females 
aged less than 20 years of age.5,6  
Whereas the epidemiology of testicular GCT has been the subject of extensive 
research, there has been limited population based analysis of ovarian GCT and none for 
extragonadal GCT. Knowledge of extragonadal GCT has been derived from retrospective 
reviews of hospital cases or those on clinical trials7-10 and such information is likely to be 
affected by hospital referral patterns and clinical trial registration practices. The secular 
trends in the incidence of GCT of the ovary, CNS and other extra-gonadal sites, in 
contrast to the well documented trends for testicular GCT, are so far largely unexplored.  
The initiation and promotion of testicular, ovarian and extragonadal GCT could 
be due to exposure to similar endogenous and/or exogenous causative factors perhaps 
acting at different sites and at different stages of life. Analysing and contrasting the 
variation in incidence patterns of GCT across different sites by age, sex and histology 
could provide a greater understanding of factors critical in tumourigenesis. In order to 
address this, we present here detailed incidence patterns and trends of gonadal and 
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extragonadal GCT for the whole of England during the period 1979 through 2003 using 
high quality national cancer registration data.  
 
Methods 
Source of Data 
Cancer registration in England is carried out by a network of eight population-
based regional registries. These regional registries collect data on cancers registered to 
residents of their areas, and submit a standard dataset on these registrations to Office for 
National Statistics (ONS) in London.11 Anonymised, national cancer registration data on 
individual patients of all ages newly diagnosed between 1979 and 2003 were obtained 
from the ONS. Information supplied included year of diagnosis, age at diagnosis, sex of 
patient, primary site, morphology and behaviour codes.  
National population estimates by single year of age, sex and calendar year were 
supplied by the Population Estimates Unit, ONS. Annual mid-year estimates of 
population in England are based on census data together with information on births, 
deaths and migration.12 
Categorisation of Tumours  
Cases of all malignant GCT (morphology codes 9060-9090 with behaviour code 
‘3’) based on the International Classification of Diseases for Oncology 1st and 2nd edition 
(ICD-O1 and ICD-O2) morphology codes were selected.13,14  In addition, GCT with the 
above morphology codes located in the central nervous system (CNS) but with benign or 
uncertain behaviour code (0 and 1 respectively) were also selected. GCT were grouped 
by histology into germinomas (morphology codes 9060-9064), non-germinomas (9071, 
 60 
 
 
9080-9084, 9090) and other & mixed GCT (9070, 9072, 9073, 9085, 9101-9102) based 
on the ICD-O1 and ICD-O2 morphology codes.  
In addition to grouping by histology, GCT were also grouped by site into 
1. Testicular (International Classification of Diseases 9th revision (ICD-9) site codes15 
186.0-187.9 and International Classification of Diseases 10th revision (ICD-10) site 
codes16 C62.0-63.9),  
2. Ovarian (ICD-9 site code 183.0 and ICD-10 site code C56.0),  
3. Extragonadal – These were further divided into four subgroups based on site 
a. CNS (ICD-9 site codes 191.0-192.9, 194.3, 194.4, 225.0-225.9, 227.3, 227.4, 
237.0, 237.1, 237.5, 237.6 and ICD-10 site codes C71.0-C72.9, C75.1-C75.3, 
D33.0-D33.9, D35.2-35.4, D43.0-43.9, D44.3-D44.5) 
b. Mediastinum & thorax (ICD-9 site codes 162.0-165.9, 171.4, 195.1 and ICD-10 
site codes C33.9-C39.9, C49.3, C76.1) 
c. Abdomen & pelvis (ICD-9 site codes 151.0-159.9, 171.5, 171.6, 179.0-185.0, 
188.0-189.9, 195.2, 195.3 and ICD-10 site codes C16.0-C26.9, C48.0-C48.8, 
C49.4, C49.5, C51.0-C58.9 [except C560], C61.9, C64.9-C68.9, C76.2, C76.3) 
d. Other specified (ICD-9 site codes 140.0-150.9, 193.0 and ICD-10 site codes 
C00.0-C15.9, C73.0) 
4. Unspecified (ICD-9 site codes 171.0-171.3, 171.8, 171.9, 172.0-173.9, 195.0, 195.4-
199.1 and ICD-10 site codes C44.0-C44.9, C49.0-C49.2, C49.6-C49.9, C76.7-C80.0) 
Statistical Methods 
Age, sex, site and histology specific incidence rates were calculated and 
expressed per million person years. All rates were adjusted to the world standard 
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population using direct methods.17 To assess the variation in the longitudinal trends with 
age, the total time period was divided into five quinquennia 1979-1983, 1984-1988, 
1989-1993, 1994-1998 and 1999-2003. Average annual percentage change (AAPC) along 
with the 95% confidence intervals were then calculated for the entire period from 1979-
2003. P-values for variability in incidence trends by age group (0-9, 10-49 and 50-84 
years), sex, site and histology were also calculated using Poisson regression. Those above 
the age of 85 were excluded because of possible under-ascertainment and often less 
specificity of diagnosis. SPSS, R and Microsoft Excel were used for analyzing the data 
and producing tables and graphs.  
 
Results 
Overall Incidence 
 During the period 1979 through 2003, 33364 GCT (31740 males and 1624 
females) were registered in England for those aged 0 to 84 years and the overall age-
adjusted incidence rate was 26.44 per million person years. GCT comprised 0.7% of all 
cancers overall and 11.2% in persons under 30 years of age. The population covered, 
equated to 1.18 billion PYs. The distribution of GCT in gonadal and extragonadal sites is 
shown in figure 1. There were 30875 testicular and 1316 ovarian GCT. The age-adjusted 
incidence rates of testicular and ovarian GCT were 48.37 and 2.34 per million person 
years respectively. 1060 of the total GCT (3.2%) were extragonadal in location and the 
age-adjusted incidence rate was 1.05 per million person years.  
Although the majority of GCT were located in the gonads in both sexes, there was 
variation in location by age (figure 2). 42% of all GCT in both male and female children 
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0 to 14 years of age were extragonadal. The proportion of extragonadal GCT was highest 
in girls aged 0 to 4 years (figure 2A) and the most common location was abdomen and 
pelvis (including sacrococcygeal). In boys the proportion of extragonadal GCT was 
highest at ages 5 to 14 years (figure 2B) and the most common location was CNS. 
Age-Specific Incidence Patterns  
 The age-specific incidence rates for gonadal and extragonadal GCT are shown in 
figure 3 and 4 respectively. In males, there was a smaller incidence peak at 0 to 4 years of 
age at most sites followed by a larger peak of incidence in adolescence and young 
adulthood in GCT at most sites. There was variation in the age when this latter peak was 
achieved - CNS (10-14 years), mediastinum & thorax (25 to 29 years), abdomen & pelvis 
(25 to 29 years) and testes (30 to 34 years). In contrast, in females the dominant peak 
incidence at 0 to 4 years at all extragonadal sites exceeded that in males with the 
maximum differential in abdomen & pelvis, but was absent in ovarian GCT. The ovarian 
GCT peak in incidence was at 15 to 19 years. This pubertal peak was also seen in CNS 
GCT at 10 to 14 years of age but was not well-defined in other extragonadal sites in 
females. 
Distribution and Incidence Patterns by Site and Histology 
 CNS was the most common location for extragonadal GCT in both males and 
females followed by mediastinum & thorax in males and abdomen & pelvis in females 
(Figure 1 and Table I). Germinoma (seminoma) was the most common histology in 
testicular GCT whilst non-germinoma was most common in ovarian and extragonadal 
GCT. This pattern was true for most extragonadal sites with the exception of the pineal 
gland where germinomas exceeded non-germinomas. 
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 Detailed age-incidence patterns for GCT by histology and each of the gonadal and 
extragonadal sites are shown in figure 5 and 6 and a summary of the observations is in 
Table II.  
Longitudinal Incidence Trends 
 For the period 1979 to 2003, there was a statistically significant increase in the 
incidence of GCT overall as well as for testicular, ovarian and CNS GCT but not in GCT 
of mediastinum & thorax and of abdomen & pelvis (table III). The overall increase was 
seen in germinomas and non-germinomas but this varied by site. There was significant 
increase in incidence of testicular seminomas and, to a lesser extent, of non-seminomas. 
In ovarian GCT the increase was exclusively from non-dysgerminomas with no change in 
dysgerminomas. In CNS GCT the increase was entirely due to an increase in the 
incidence of germinomas. Most of this increase was seen in the above tumour groups in 
the 10 to 49 year age group. There was also a significant increase in the incidence of non-
germinomas of the abdomen & pelvis in the 0 to 9 year age group.  
 
Discussion 
This analysis of 33364 cases of gonadal and extragonadal GCT across the whole 
of England from 1979 through 2003 is the first comprehensive review on incidence 
patterns and longitudinal trends of these tumours. The large difference in the incidence of 
testicular and ovarian/extragonadal GCT seen in this analysis is likely to be related to the 
lower number of susceptible germ cells surviving in non-testicular sites by the time of 
puberty. After initial multiplication by mitosis, the primordial germ cells (oogonium) in 
the ovary peak in numbers (around 7 million) at 16-20 weeks of gestation after which 
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they enter meiotic arrest (now called oocyte) and then steadily decline in numbers so that 
by birth 1-2 million oocytes are left and by puberty only 300,000.18 While the number of 
primordial germ cells in extragonadal locations is not known, like their counterparts in 
the ovary, they also enter meiotic arrest in foetal life and undergo apoptosis.19,20  In 
contrast, the mitotic proliferation of spermatogonal germ cells continues throughout adult 
reproductive life.  
 The published literature is dominated by studies on testicular GCT with limited 
population-based information on ovarian5,21,22 and CNS GCT23,24, and none on GCT 
located at other extragonadal sites. Consequently, there are no previous studies 
contrasting the incidence patterns of gonadal and extragonadal GCT. Such an analysis is 
important in gaining a better understanding of the aetiopathogenesis of these tumours 
which show considerable heterogeneity by site and histology, but are regarded as one 
disease entity.25 The heterogeneity is thought to be a reflection of the developmental 
potential of germ cells at different stages of maturation and with different imprinting 
status.25 The primordial germ cells, which form in the wall of the yolk sac during the 
fourth week of embryogenesis and migrate into the developing gonads, are considered to 
be the cell of origin of gonadal (testicular and ovarian) GCT. Extragonadal GCT are also 
thought to arise in the same primordial germ cells which have migrated aberrantly along 
the midline to the CNS, mediastinum and other para-axial sites.26 The remarkably similar 
shape of the age-incidence curves (with some variations which are further explored 
below) of these tumours regardless of site, as summarised in Table II, is consistent with a 
common cell of origin and possibly a common initiation. 
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It is probable that subsequent to the migration of primordial germ cells to the 
respective gonadal and extragonadal sites, there are further critical events during foetal 
and/or postnatal life which determine the promotion of tumourigenesis and the rate at 
which this happens. Based on some of the epidemiological observations in our analysis, it 
is likely that these events vary among the different sites where GCT will eventually 
develop. Firstly, there is variation in the age of peak incidence of GCT by site in 
adolescents and young adults. Secondly, while the peak incidences of germinoma and 
non-germinoma are seen at the same age at extragonadal sites, this is not true for 
germinomas of the gonads which peak in incidence 5 to 10 years after the non-
germinoma peak. Thirdly, the longitudinal trends of testicular, ovarian and extragonadal 
GCT are dissimilar. 
The observed differences by site in the incidence patterns and longitudinal trends 
of GCT can also provide clues to the exposures associated with GCT. The incidence of 
testicular GCT has doubled in the last 40 years and an annual increase of 3-6% is 
reported for Caucasian populations.27,28 No definitive causative factors have been found 
to explain this rise in incidence, although there is a strong birth cohort effect and 
exposure to endogenous maternal estrogens in-utero has been suggested.27-29 There is a 
paucity of epidemiological studies on prenatal and postnatal risk factors associated with 
ovarian and extragonadal GCT which address similar questions. Our analysis confirms 
the rise in incidence of testicular seminomas and non-seminomas. But, lack of a similar 
parallel increase in GCT of ovarian and extragonadal sites suggest that the hypothesized 
hormonal factors may have a lesser role in the aetiopathogenesis of GCT located at these 
sites. 
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In summary, the remarkable similarity between the shapes of age-incidence 
curves of GCT suggests a common initiation of these tumours. This is likely to happen 
early in the embryonal period prior to migration of primordial germ cells into the genital 
ridges or ectopic sites. However, the variation in peak incidence and longitudinal trends 
by site suggests that progression of tumourigenesis is influenced by events during the 
foetal and/or postnatal period which are likely to be site-specific. Future genetic and 
epidemiological studies need to consider GCT at all sites rather than be restricted to 
testicular and ovarian GCT to enable a better understanding of the biology and aetiology 
of these tumours.  
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 Figure 1  Distribution of GCT in Gonadal and Extragonadal Sites in England, 1979 
to 2003  
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Figure 2 Age Related Variation in the Proportion of Gonadal and Extragonadal 
GCT in (A) Females, and (B) Males  
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Figure 3 Age- and Sex-Specific Incidence Patterns of Gonadal GCT in England, 
1979 to 2003 
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Figure 4 Age- and Sex-Specific Incidence Patterns of Extragonadal GCT in 
England, 1979 to 2003 
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Figure 5 Age- and Histology-Specific Incidence Rate Patterns of Gonadal GCT in 
England, 1979 to 2003 (Note different scales on the Y-axis) 
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Figure 6 Age- and Histology-Specific Incidence Rate Patterns of Extragonadal 
GCT in England, 1979 to 2003  
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Table I  Distribution of Gonadal & Extragonadal GCT by Site and Histology in 
England, 1979 to 2003 
 
Germinoma 
Non-
Germinoma 
Mixed GCT 
Unspecified 
Histology 
Total 
Incidence 
rate* 
Testes 17202 9353 2556 1764 30875 48.37 
     
         
Ovary 433 836 47 0 1316 2.34 
     
         
All Non Gonadal 394 605 61 0 1060 1.05 
  Male 329 403 45 0 777 1.45 
   CNS 200 141 9 0 350 0.71 
   Pineal 168 40 4 0 212   
   Non-Pineal 32 101 5 0 138   
   Mediastinum & Thorax 99 149 12 0 260 0.43 
   Abdomen & Pelvis 29 104 21 0 154 0.28 
   Others 1 9 3 0 13 0.03 
  Female 65 202 16 0 283 0.65 
   CNS 48 86 2 0 136 0.3 
   Pineal 22 8 0 0 30   
   Non-Pineal 26 78 2 0 106   
   Mediastinum & Thorax 6 25 2 0 33 0.06 
   Abdomen & Pelvis 11 87 10 0 108 0.28 
   Others 0 4 2 0 6 0.01 
         
    
Unspecified Site 47 55 11 0 113 0.09 
*Expressed per million person years.  
GCT – Germ Cell Tumours, CNS – Central Nervous System  
 78 
 
 
  
Table II Summary of Incidence Peaks Seen in Gonadal and Extragonadal GCT 
Site Histology 0 to 4 Years Age Incidence Peak Adolescent & Young Adult Incidence Peak 
Testes 
Germinoma No Yes (peak at 35 to 39 year of age) 
Non-Germinoma Yes Yes (peak at 25 to 29 year of age) 
Ovary 
Germinoma No Yes (peak at 20 to 24 year of age) 
Non-Germinoma No Yes (peak at 15 to 19 year of age) 
Central Nervous System 
Germinoma No Yes (peak at 10 to 14 year of age and male > female) 
Non-Germinoma Yes (female > male) Yes (peak at 10 to 14 year of age and male > female) 
Mediastinum & Thorax 
Germinoma No Yes (peak at 25 to 29 year of age and male > female) 
Non-Germinoma Yes (female = male) Yes (peak at 25 to 29 year of age and male > female) 
Abdomen & Pelvis 
Germinoma No No 
Non-Germinoma Yes (female > male) Yes (peak at 25 to 29 year of age and male > female) 
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Table III Age-Adjusted Incidence Rates of GCT by Histology and Site for Successive Five Year Periods in England, 1979-2003 
    Age-Adjusted Incidence Rate in Million Person Years Average Annual Percentage Change (95% Confidence Interval)* 
    1979-1983 1984-1988 1989-1993 1994-1998 1999-2003 0 to 84 yrs 0 to 9 yrs 10 to 49 yrs 50 to 84 yrs 
Overall 19.83 24.58 28.35 31.75 34.76 2.67 (2.51,2.83) 1.05 (-0.23,2.35) 2.91 (2.73,3.08) 1.35 (0.92 1.78) 
  Germinoma 10.46 12.61 14.32 18.00 20.48 3.43 (3.21,3.65) 8.92 (4.36,13.67) 3.67 (3.43,3.91) 2.14 (1.61,2.67) 
  Non-Germinoma 8.16 9.17 8.79 10.38 8.83 0.56 (0.29,0.83) 0.2 (-1.18,1.6) 0.71 (0.42,0.99) -1.08 (-2.08,-0.07) 
Testes 36.25 45.34 52.58 58.99 65.21 2.78 (2.61,2.94) -2.66 (-4.66,-0.62) 2.95 (2.77,3.13) 1.88 (1.42,2.33) 
  Germinoma 19.92 24.10 27.35 34.36 39.46 3.47 (3.24,3.69)  3.7 (3.46,3.95) 2.32 (1.78,2.86) 
  Non-Germinoma 13.95 15.70 14.83 18.03 15.13 0.58 (0.29,0.87) -2.74 (-4.85,-0.59) 0.64 (0.34,0.95) 0.67 (-0.6,1.96) 
Ovary 1.92 2.01 2.02 2.52 2.51 1.36 (0.59,2.14) 3.07 (-0.22,6.48) 2.64 (1.75,3.55) -4.83 (-6.64,-2.98) 
  Germinoma 0.71 0.76 0.64 0.80 0.71 -0.03 (-1.35,1.31) 6.18 (-0.96,13.86) 0.5 (-0.94,1.96) -6.68 (-10.73,-2.46) 
  Non-Germinoma 1.14 1.25 1.34 1.61 1.61 1.65 (0.68,2.63) 2.06 (-1.84,6.12) 3.5 (2.32,4.69) -4.72 (-6.78,-2.62) 
Central Nervous System 0.31 0.33 0.50 0.50 0.53 2.94 (1.64,4.26) 1.77 (-1.12,4.75) 3.8 (2.25,5.38) -1.02 (-5.01,3.12) 
  Germinoma 0.11 0.09 0.27 0.29 0.35 6.88 (4.92,8.89) 6.95 (0.94,13.32) 7.31 (5.19,9.49)   
  Non-Germinoma 0.21 0.23 0.22 0.19 0.17 -1.11 (-2.91,0.71) -0.57 (-3.96,2.94) -1.76 (-4.17,0.7) 0.08 (-4.28,4.66) 
Mediastinum & Thorax 0.21 0.23 0.32 0.27 0.19 -0.15 (-1.76,1.48)   0.37 (-1.38,2.16) -5.52 (-10.29,-0.5) 
  Germinoma 0.07 0.06 0.09 0.13 0.09 2.35 (-0.42,5.2)  2.67 (-0.25,5.7)   
  Non-Germinoma 0.14 0.16 0.22 0.13 0.09 -1.66 (-3.73,0.44)  -1.11 (-3.38,1.2) -9.38 (-16.09,-2.14) 
Abdomen & Pelvis 0.19 0.28 0.22 0.26 0.26 0.49 (-1.22,2.24) 5.87 (2.64,9.19) -1.72 (-4.11,0.73) -3.4 (-7.53,0.9) 
  Germinoma 0.02 0.04 0.03 0.04 0.05 1.92 (-2.48,6.54)  0.47 (-4.87,6.13)   
  Non-Germinoma 0.15 0.21 0.16 0.21 0.17 -0.19 (-2.19,1.85) 4.88 (1.65,8.23) -3.91 (-6.92,-0.8) -4.91 (-10.41,0.93) 
 * Average Annual Percentage Change was not reported for groups of insufficient size 
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Condensed Abstract 
Incidence patterns of osteosarcoma and Ewing sarcoma during adolescence points 
towards a link with puberty. The variation in these patterns with site suggests pubertal 
bone growth to be a key factor in osteosarcoma while different biological pathways, 
which may be unrelated to growth, could also be relevant for Ewing sarcoma. 
 
Abstract 
Background – Nearly 6% of malignant tumours in teenagers and young adults (TYA) 
aged 15 to 24 years are bone tumours, although their contribution to cancer-related 
mortality is disproportionately higher in this age group. Studies suggest a link between 
osteosarcoma and Ewing sarcoma and puberty although the biological pathways have not 
yet been fully elucidated.  
Methods - Using the national cancer registration data for England, we have analysed 
incidence patterns and analysed variation with age, sex, morphology and site. 
Results - During the period 1979 through 2003, 1185 bone tumours (12.9% of all bone 
tumours) were registered in TYA. Nearly 85% of these were osteosarcoma and Ewing 
sarcoma both of which peak in adolescence. The peak incidence of osteosarcoma of the 
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long bones of the lower limb more than six times larger than that at any other site. In 
contrast, peak incidence of Ewing sarcomas located in the central axis exceeded those in 
the long bones of the lower limb. Less than 10% of bone tumours in TYA were 
chondrosarcomas and the incidence was highest for central axis chondrosarcomas 
followed by those in the long bones of the lower limb.  
Conclusions – These patterns suggest that puberty plays a role in the development of 
osteosarcoma and Ewing sarcoma but not chondrosarcoma. Variation in these patterns 
with site suggests pubertal bone growth to be a key factor in osteosarcoma while different 
biological pathways which may be unrelated to bone growth could also be relevant for 
Ewing sarcoma. 
 
Keywords 
Bone Neoplasms; Osteosarcoma; Ewing Sarcoma; Chondrosarcoma; Incidence; 
Longitudinal Trends; Adolescents; Young Adults; England 
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Introduction 
 In England, only 0.2% of all primary cancers (excluding non-melanoma skin 
cancers) arise in bone.1 However, the proportion varies with age and is 3.8% in children 
aged 0 to 14 years of age and 5.7% in teenagers and young adults (TYA) aged 15 to 24 
years.1-3 Bone tumours contribute disproportionately to cancer-related mortality in TYA 
and are third only to leukaemias and central nervous system tumours.4  
Overall, osteosarcoma is the most common primary malignant tumour of the bone 
(35%) followed by chondrosarcoma (25%) and Ewing sarcoma (16%).5 Other rare 
tumour types each comprise less than 10%. Osteosarcoma and Ewing sarcoma have a 
peak in incidence in adolescence while chondrosarcoma is seen mainly at an older age. 
Clinical studies show that long bones of the lower limb and pelvic bones are the most 
common site of occurrence of these tumours.6 There is however little information on the 
variation in site distribution of these tumours by age. The published literature is similarly 
deficient in population-based data on the variation in age-incidence patterns of these 
tumours by site.7  
We present here detailed incidence patterns and trends for osteosarcomas, Ewing 
sarcomas, chondrosarcomas and other tumours of the bone across all ages for the whole 
of England during the period 1979 through 2003 using high quality national cancer 
registration data. Elucidating the variation of age-incidence patterns of these tumours 
with site will assist in understanding the possible aetiological relationship between 
critical periods of growth and age of onset for each of these tumours and at different site 
groups. Such information will be valuable in the context of the suggested link between 
growth and bone tumours.8,9   
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Methods 
Source of Data 
Anonymised, national cancer registration data for England on individual patients 
of all ages newly diagnosed between 1979 and 2003 were obtained from the Office for 
National Statistics (ONS). Information supplied included year of diagnosis, age at 
diagnosis, sex of patient, primary site code, morphology code and behaviour code.  
National population estimates by single year of age, sex and calendar year were 
supplied by the Population Estimates Unit, ONS. Annual mid-year estimates of 
population in England are based on census data together with information on births, 
deaths and migration.10 
Categorisation of Tumours  
Malignant bone tumours were selected from the dataset. These were grouped by 
histology based on the International Classification of Diseases for Oncology 1st and 2nd 
edition (ICD-O1 and ICD-O2) morphology codes11,12 into osteosarcomas (morphology 
codes 9180-9190), Ewing sarcoma (9260, 9362, 9470-9473), chondrosarcomas (9220-
9240) and others. Extra-skeletal Ewing sarcoma cases were also included.3 This is in 
recognition of the presence of the common EWS/Fli-l fusion gene in these tumours and 
difficulties in ascertaining whether some tumours are arising in bone and invading soft 
tissue or vice versa.3,13 
For analysis by site, two major groups were defined:  
 87 
 
1. Bone (International Classification of Diseases 9th revision (ICD-9) site codes14 
170.0-170.9 and International Classification of Diseases 10th revision (ICD-10) site 
codes15 C40.0-C41.9). These  were further sub-classified into six site sub-groups: 
a. Long bones of the lower limb (ICD-9 site codes 170.7 and ICD-10 site codes 
C40.2) 
b. Scapula and long bones of the upper limb (ICD-9 site code 170.4 and ICD-10 site 
code C40.0) 
c. Short bones of the upper and lower limb (ICD-9 site code 170.5, 170.8 and ICD-
10 site code C40.1, C40.3) 
d. Bones of cranium and face including mandible (ICD-9 site code 170.0, 170.1 and 
ICD-10 site code C41.0, C41.1) 
e. Bones of central axis including vertebral column, sternum, clavicle, pelvic bones, 
sacrum and coccyx (ICD-9 site code 170.2, 170.3, 170.6 and ICD-10 site code 
C41.2-C41.4), and 
f. Unspecified site (ICD-9 site code 170.9, 195.0-195.8, 199.0-199.2 and ICD-10 
site code C40.8, C40.9, C41.8, C41.9, C76.0-76.8, C80.0) 
2. Extra-skeletal (ICD-9 site code 140.0-165.9, 171.0-194.9 and ICD-10 site code 
C00.0-C39.9, C43.0-C75.9) 
Statistical Methods 
Age, sex, site and histology-specific incidence rates were calculated and 
expressed per million person years. All rates were adjusted to the world standard 
population using direct methods.1 SPSS and Microsoft Excel were used for analyzing the 
data and producing tables and graphs. 
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Results 
 During the period 1979 through 2003, 9146 bone tumours were registered in 
England in persons aged 0 to 84 years and the overall age-adjusted incidence rate was 
7.19 per million person years. The population covered, equated to 1.18 billion person 
years. Osteosarcoma was the most common primary malignant tumour of the bone with 
3124 cases (34.2%) followed by chondrosarcoma with 2485 cases (27.2%), Ewing 
sarcoma with 1764 cases (19.3%) and 1773 (19.4%) were other bone tumours (chordoma 
4.4%, giant cell tumour 2.0%, other specified 0.3% and unspecified 12.7%). Sex-specific 
age-adjusted incidence rates for these tumours are shown in Table I.  
18.64% of Ewing sarcomas were of extraskeletal origin while this proportion was 
much smaller for osteosarcoma (0.3%) and chondrosarcoma (4.4%). The most common 
extraskeletal sites for each of these bone tumours were: breast for osteosarcoma; 
connective tissue (mainly lower limb and pelvis), nasal cavity and larynx for 
chondrosarcoma; and connective tissue (mainly lower limb and thorax) for Ewing 
sarcoma.  
There was variation in the distribution of bone tumours by age (Figure 1). Ewing 
sarcoma was most common in those aged 0 to 9 years while osteosarcoma was the 
predominant bone tumour at ages 10 to 29 years. Chondrosarcoma was the most common 
bone tumour at ages of 30 years and above. 1535 bone tumours (16.3% of all bone 
tumours) were seen in children aged 0 to 14 years and the relative proportion of 
osteosarcoma, Ewing sarcoma and chondrosarcoma was 46.0%, 44.3% and 2.5% 
respectively. 1185 bone tumours (12.9%) were seen in TYA aged 15 to 24 years and the 
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relative proportions of osteosarcoma, Ewing sarcoma and chondrosarcoma in this age 
group were 50.7%, 33.8% and 8.0% respectively.  
Osteosarcoma and Ewing sarcoma showed distinct peaks of incidence at 10 to 14 
years of age in females and at 15 to 19 years of age in males with the incidence peak 
greater in males (Figure 2). Osteosarcoma also showed a second but smaller peak of 
incidence at older ages. The incidence of chondrosarcoma and other bone tumours 
increased steadily with age with the incidence slightly higher in males. 
Incidence Patterns by site 
 Figure 3 to 5 show age-incidence patterns of osteosarcoma, Ewing sarcoma and 
chondrosarcoma for the six site sub-groups of bone as well as those with extraskeletal 
location. Osteosarcoma at all sites (except those located in the cranial and facial bones) 
showed an initial incidence peak at 15 to 19 years of age with the peak of osteosarcoma 
of the long bones of the lower limb more than six times larger than that at any other site 
in this age group. Osteosarcoma at all sites had minimum incidence at 45 to 54 years of 
age with increasing rates thereafter. In the older age groups the incidence of 
osteosarcoma at the central axis matched that of the long bones of the lower limb.  
The peak incidence of Ewing sarcoma at all sites was between 10 to 19 years of 
age, and peak incidence of Ewing sarcomas located in the central axis exceeded those in 
the long bones of the lower limb. Subsequently incidence rates declined and were very 
low after the age of 34 years and close to zero after 54 years of age. The incidence of 
chondrosarcoma at all sites did not show an adolescent peak, but steadily increased with 
age. The incidence was highest for central axis chondrosarcomas followed by those in the 
long bones of the lower limb.  
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Longitudinal incidence trends 
 For the period 1979 to 2003, the incidence of osteosarcoma and chondrosarcoma 
was stable (Figure 6). The incidence of Ewing sarcoma was stable until the mid-1990s 
before rising sharply and remaining stable at a higher rate over the most recent period of 
analysis. The increase in incidence of Ewing sarcoma located in extraskeletal sites was 
responsible for the overall increase in incidence (Figure 7). The incidence of Ewing 
sarcoma of bone remained stable throughout the period.  
 
Discussion 
 This analysis of 9146 primary malignant bone tumours across the whole of 
England from 1979 through 2003 is to date the single largest reported population-based 
study of these tumours. Overall eight out of ten primary malignant bone tumours are 
osteosarcomas, chondrosarcoma or Ewing sarcomas, and the relative frequency of these 
tumours seen in our study is similar to that reported in previous smaller population- and 
hospital-based series.6,7,16  
 Longitudinal trends over the 25 year period of analysis show a stable incidence of 
Ewing sarcoma of the bone, osteosarcoma and chondrosarcoma. The step increase in 
incidence of Ewing sarcoma at extraskeletal sites is likely to be related to improved 
diagnosis. Advances in diagnostics, including identification of the t(11;22) chromosomal 
translocation and characterisation of EWS-FLI1 gene fusions17,18 leading to their more 
accurate categorization could be responsible for this increase.13 
 The peak of incidence of osteosarcoma and Ewing sarcoma in adolescence, which 
is larger and later in adolescent males than females, points to a link with puberty. Despite 
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this similarity, marked variations by primary site between the two tumours may provide 
clues to the critical pathways in tumourigenesis. The adolescent incidence peak of Ewing 
sarcoma of bone is seen at all sites but the incidence peak of tumours of the central axis 
exceeds that in long bones of the lower limb. This pattern broadly correlates with the 
structure of the adult human skeleton, which by weight at 29 to 39 years of age, is made 
up of bones of the central axis (29%), long bones of the lower limb (25%), skull and 
facial bones (21%), long bones of the upper limb (15%), and short bones of the upper and 
lower limbs (9%).19 Although such data, which are obtained from studies on skeletal 
samples either prepared in anatomy laboratories or derived from cemeteries, are not 
available for children or adolescents, we know from the ratio of sitting height and leg 
length that children and adolescents will have a larger proportion of bones of the central 
axis, skull and face in comparison to long bones of the lower limb.20  
In contrast to Ewing sarcoma, tumours of the long bones of upper and lower limb 
are markedly over-represented in the adolescent peak of osteosarcoma. These are the 
bones which have the greatest increase in length during the pubertal growth spurt as a 
result of growth of cartilage at the epiphyseal plate, as well as endochondral ossification 
of this cartilage. These observations suggest that bone growth during puberty may be one 
key step in the evolution of an osteosarcoma cell. Further indirect evidence of the 
importance of bone growth is provided from a reported association of greater height at 
diagnosis among patients with osteosarcoma which is stronger and more consistent in 
comparison to Ewing sarcoma.8,9,21-24 
 While the link between pubertal growth and osteosarcoma onset has biological 
plausibility, its basis has still not been determined. Pubertal growth mediators, 
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particularly IGF-125,26 and sex steroids27,28 are candidates of interest but their role may be 
in the promotion rather than initiation of tumourigenesis. Our current level of knowledge 
is also insufficient to comment on the significance of antenatal and childhood extrinsic 
and intrinsic exposures and growth patterns on the development of these bone tumours. 
Evolution of a malignant cell is a multi-step process and preceding pre-malignant 
changes might occur during other periods of rapid growth, e.g. in foetal life, during 
infancy and/or during the mid-childhood growth spurt.  
The adolescent incidence peak of Ewing sarcoma remains unexplained. Unlike 
osteosarcoma, bone growth during puberty would be a less likely major mechanism. If 
one considers the primitive tissue of origin of this tumour and the nearly zero incidence 
in older adults, it has similarities with the embryonal tumours2 of childhood although the 
incidence peak in Ewing sarcoma is later than for them. The striking racial variation in 
the distribution of this tumour29, and reported associations with congenital hernias22, rib 
anomalies30, low birth weight31 and parental occupation in agriculture during the peri-
conception period32 suggest a stronger prenatal component to the aetiology of Ewing’s 
sarcoma.  
Less than 10% of bone tumours in TYA at ages 15 to 24 years in our analysis 
were chondrosarcoma. Of the 146 chondrosarcomas in this age group, 31.5% were in 
long bones of the lower limb and 28.8% in bones of the central axis. This is different to 
the overall distribution of chondrosarcomas which are most common in bones of the 
central axis. This age-related difference could be due to chance (because of relatively 
small number of cases) or from misclassification of chondroblastic osteosarcoma, which 
have peak incidence in adolescence and can be difficult to distinguish from 
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chondrosarcoma.33 However, if this age-related difference is true, the role of genetic 
susceptibility in tumours in this age group must be considered as TYA are not likely to 
have had the same length of lifestyle-related exposures compared to older people. 
Patients who develop chondrosarcoma secondary to enchondromas (seen in syndromes 
like Ollier disease and Maffucci syndrome) are generally younger than those with 
primary chondrosarcoma.34 Clinical series of chondrosarcomas in children and young 
people have not shown a particularly high proportion of chondrosarcomas secondary to 
these syndromes.35,36Additionally, a range of cytogenetic changes have been seen in 
chondrosarcoma but there is no description of high-penetrance mutations in those with 
chondrosarcomas at a younger age.34  
 In summary, incidence patterns of osteosarcoma and Ewing sarcoma during 
adolescence point towards a link with puberty. The variation in these patterns with site 
suggests pubertal bone growth to be a key factor in osteosarcoma while different 
biological pathways which may be unrelated to growth could be relevant for Ewing 
sarcoma. Chondrosarcoma is relatively infrequent in TYA and it is yet not established 
whether chondrosarcomas in this age group are epidemiologically and genetically 
different from those which develop in older adults.  
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Table I  Overall, Sex- and Site-Specific Incidence Rates (in Million Person Years) for Osteosarcoma, Ewing Sarcoma and 
Chondrosarcoma at Ages 0 to 84 Years in England, 1979 to 2003 
              TUMOUR 
SITE 
Osteosarcoma Ewing Sarcoma Chondrosarcoma 
Total Number 
Age-Adjusted Incidence 
Total Number 
Age-Adjusted Incidence 
Total Number 
Age-Adjusted Incidence 
Total Male Female Total Male Female Total Male Female 
Overall 3124 2.65 3.06 2.26 1764 1.84 2.06 1.61 2485 1.56 1.86 1.27 
Bone 3083 2.62 3.03 2.24 1352 1.44 1.65 1.22 2316 1.45 1.73 1.17 
Skull & Face 179 0.12 0.14 0.11 41 0.04 0.07 0.02 192 0.13 0.12 0.15 
Central Axis 487 0.31 0.33 0.3 505 0.53 0.58 0.48 833 0.52 0.66 0.37 
Short Bones 85 0.07 0.09 0.05 61 0.07 0.07 0.06 234 0.14 0.16 0.11 
Long Bones Upper Limb 354 0.3 0.35 0.25 163 0.18 0.21 0.15 266 0.17 0.21 0.13 
Long Bones Lower Limb 1745 1.66 1.93 1.39 413 0.44 0.52 0.37 531 0.34 0.4 0.28 
Unspecified 263 0.18 0.21 0.15 257 0.26 0.29 0.23 319 0.19 0.23 0.17 
Extraskeletal 11 0.01 0.01 0.01 324 0.31 0.32 0.3 110 0.07 0.09 0.06 
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Figure 1 Age Related Variation in the Proportion of Osteosarcoma, Ewing Sarcoma and 
Chondrosacoma 
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Figure 2 Age-Specific Incidence Rate Patterns of Osteosarcoma, Ewing Sarcoma and 
Chondrosacoma in Males and Females in England, 1979 to 2003 
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Figure 3 Age- and Site-Specific Incidence Rate Patterns of Osteosarcoma in England, 1979 
to 2003 
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Figure 4 Age- and Site-Specific Incidence Rate Patterns of Ewing Sarcoma in England, 
1979 to 2003 
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Figure 5 Age- and Site-Specific Incidence Rate Patterns of Chondrosarcoma in England, 
1979 to 2003 
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Figure 6 Trends in Age-Standardised Incidence Rates of Osteosarcoma, Ewing Sarcoma 
and Chondrosacoma in England, 1979 to 2003 
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Figure 7 Trends in Age-Standardised Incidence Rates of Ewing Sarcomas of Bone and 
Extraskeletal Sites in England, 1979 to 2003 
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Abstract 
Objective - Some evidence exists that patients with osteosarcoma and Ewing sarcoma are 
taller than the general population. However, previous studies are under-powered, lack 
comprehensive data and show inconsistencies. 
Methods - Random-effects meta-analyses were undertaken on identified studies linking 
osteosarcoma and Ewing sarcoma with height at diagnosis. Outcomes in individual 
studies were reported as standard deviation (SD) scores or percentages of study 
population with height at diagnosis above the median of the reference population. A 
separate meta-analysis for each outcome and tumour type was performed. 
Results – 14 studies examined the height of patients with osteosarcoma or Ewing 
sarcoma. Meta-analyses on SD scores found patients with osteosarcoma were 0.260 SD 
(95%CI: 0.088-0.432) taller than the reference population (five studies). A meta-analysis 
on percentages found 62% (95%CI: 57%-67%) of patients were estimated to have a 
height above the median (six studies).Patients with Ewing sarcoma were 0.096 SD 
(95%CI 0.004-0.188) taller (four studies). Only one available Ewing sarcoma study 
reported percentages and a meta-analysis was not possible. 
Conclusion - The average height of patients with osteosarcoma was significantly above 
the average height of the reference population. The association of greater height with 
Ewing sarcoma was also significant but much weaker.  
 
Keywords 
Osteosarcoma, Ewing Sarcoma, Growth, Body Height, Meta-analysis 
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Introduction 
Osteosarcoma and Ewing sarcoma are the two most common malignant bone 
tumours in children, teenagers and young adults aged 0 to 24 years.1,2  Relatively little is 
known about the aetiology of these tumours. Less than 10% of all osteosarcoma cases can 
be attributed to well-recognised risk factors including ionising radiation, chemotherapy, 
cancer predisposition syndromes, Paget’s disease and fibrous dysplasia. Even less is 
known about the causation of Ewing sarcoma although associations have been seen with 
parental occupation related to agriculture and with congenital hernias.3 The biological 
basis of these associations remains to be explained. 
 An interesting link seems to exist between growth, particularly in adolescence, 
and both osteosarcoma and Ewing sarcoma. In 1953 Johnson suggested that a particular 
bone tumour of a given cell type usually arose in the field where the homologous cells 
were most active and so osteosarcoma arose in the metaphysis which had abundant 
osteoclasts whereas round cell tumours (Ewing sarcoma) develop in the bone-free 
marrow cavity of the mid-shaft (diaphysis).4 Further studies on human and canine 
osteosarcoma suggested a link between growth and occurrence of these tumours.5-8 Price 
observed that there was an overall preponderance of osteosarcoma in males, with the 
mean age of occurrence later than in females.5 There was also a predilection of 
osteosarcoma for long bones of the lower limb with the mean age of occurrence later than 
osteosarcoma in the upper arm. In dogs, where osteosarcoma is 40 to 50 times more 
common than in humans,6 an increasing risk of osteosarcoma had been seen with 
increasing weight and increasing height of the dog which was present even after adjusting 
for the breed size.7,8 Exploring this link further, Fraumeni in 1967 showed that human 
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males and females with osteosarcoma (and Ewing sarcoma to a lesser degree) were 
significantly taller at diagnosis than controls.9 Subsequently several other studies have 
yielded conflicting results.10-12  
The aim of this study is to explore the strength of association between height at 
diagnosis and onset of osteosarcoma and Ewing sarcoma. Specific objectives are to 
identify relevant studies and to perform a meta-analysis where feasible. By these means 
we aim to identify areas for future research. 
 
Materials and Methods 
A comprehensive literature search of Medline (1950 to 2009) was undertaken 
with no language restriction. Search strategy included combining keywords 
“osteosarcoma”, “Ewing sarcoma”, “bone neoplasms”, “epidemiology”, “risk factors”, 
“aetiology” and “genetics”. There was further emphasis on the literature exploring links 
between growth and development of osteosarcoma and Ewing sarcoma by combining 
keywords “growth”, “height”, “length”, “stature”, and “puberty”. Reference lists of 
relevant studies were also searched for additional studies.  
Identified relevant studies were critically appraised and data on outcomes relating 
to an association with height at diagnosis were extracted. Three categories of outcome 
data were identified: 
1. Mean standard deviation score (SDS) of height at diagnosis in the study population, 
2. Percentage of study population with height at diagnosis above the median, 
3. Other (e.g. mean height of study population and of control population) 
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Random-effects meta-analyses were undertaken using the Restricted Maximum 
Likelihood method (REML)13 if there were adequate number of studies with outcomes 
reported in the first two categories specified above. Results were displayed by using 
forest plots.14 Each study is represented by a block (the area of the block indicates the 
weight assigned to that study) at the point estimate of grouped effect with a horizontal 
line (depicting 95% confidence intervals) extending either side of the block. The overall 
estimate from the meta-analysis and its confidence intervals are put at the bottom, 
represented as a diamond. The centre of the diamond represents the pooled point 
estimate, and its horizontal tips represent the 95% confidence intervals. 
The presence of heterogeneity was assessed by p-value of Cochran’s Q on the 
basis of inverse variance weights and its magnitude estimated using I2.15 The between 
study variance, tau2, was also calculated as an estimate of the degree of heterogeneity.16 
The number of studies included in our meta-analyses failed to reach the threshold used in 
standard methods for assessing publication bias17. 
 
Results 
A total of 14 relevant studies were identified (Table I). Of these six included 
patients with osteosarcoma and Ewing sarcoma, six studies with osteosarcoma only, and 
two studies with Ewing sarcoma only. For ten of these studies, it was feasible to extract 
the data required for inclusion in a meta-analysis. For the other four, the results have been 
summarised in Table II. 
Meta-analysis for Osteosarcoma 
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Five studies reported their results using mean SDS for height at diagnosis in 
osteosarcoma study populations and were included in the first meta-analysis (Figure 1). 
In this analysis, patients with osteosarcoma were estimated to be 0.260 standard 
deviations (95%CI: 0.088 to 0.432) taller than the reference population (heterogeneity 
I2=83%, tau2=0.03). Six studies used the second category of outcome data (percentage of 
study population with height at diagnosis below/above the median) to report results on 
osteosarcoma which were included in the second meta-analysis (Figure 2). 62% (95%CI: 
57% to 67%) of patients with osteosarcoma were estimated to have a height above the 
median for the reference population (heterogeneity I2= 39%, tau2=0.006). Longhi et al12 
reported outcomes for both the above categories and so these were included in each of the 
meta-analyses. 
Meta-analysis for Ewing sarcoma 
Four studies on Ewing sarcoma study populations reported results under the first 
category of outcome data (mean SDS of height at diagnosis in the study population). 
These were included in the third meta-analysis (Figure 3). Patients with Ewing sarcoma 
were estimated to be 0.096 standard deviations (95%CI 0.004 to 0.188) taller than the 
reference population (heterogeneity I2=0%, tau2=0). Since the REML estimated tau2 to be 
zero, the method was reduced to a fixed-effects approach. Therefore, we conducted a 
sensitivity analysis with the widely used DerSimonian-Laird (DL) method18 and 
estimated patients to be 0.112 standard deviations taller than the reference population. 
However, the effect was not significant (95%CI -0.029 to 0.252). Heterogeneity with the 
DL method was not estimated to be negligible: I2=43%, tau2=0.009. 
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 There was only one study9 for the second category of outcome data (percentage of 
study population with height at diagnosis below/above the median) which showed that 
61% of the patients with Ewing sarcoma were taller than the median. 
Discussion 
The epidemiological observation of peak incidence of osteosarcoma and Ewing 
sarcoma at 15 to 19 years of age in males and 10 to 14 years of age in females, along with 
the suggested link of tall stature with these tumours would imply that growth, and in 
particular pubertal growth, plays a critical role in tumourigenesis. Since Fraumeni’s 
initial report,9 several other studies, which have subsequently looked at the association, 
have yielded conflicting results.10-12,19-28 This is partly because of methodological 
limitations including small study samples, sub-optimal data collection methods (parental 
recall of height at diagnosis on telephone interviews) and lack of uniformity in reporting 
results. This meta-analysis is an opportunity to settle controversies arising from 
conflicting results. 
We found that the average height of patients with osteosarcoma was significantly 
above the average height of the reference population on meta-analysis using either of the 
outcome data categories. In all ten studies, the point estimate of effect is in favour of 
greater height, and in seven out of the ten studies, the 95% confidence intervals imply 
statistical significance, which suggests the presence of a strong and consistent 
association. Moreover, the magnitude of the estimated effect from the meta-analysis of 
percentage of study population with height at diagnosis above the median SD scores 
(62%) is similar to the magnitude of the estimated effect from the meta-analysis of SD 
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scores (0.26 SD which would equate to 60% study population having height at diagnosis 
above the median).  
Although the average height of patients with Ewing sarcoma was also found to be 
significantly above that of the reference population, the magnitude of the estimated effect 
was smaller.  However, the finding was not verified by our sensitivity analysis with the 
DL method.18 Although the effect estimate was similar in size, it was found not to be 
significant at the 95% level. Both methods (REML & DL) provide very wide confidence 
intervals for the effect estimate which reflect the small numbers of patients in the 
included studies. Finally, three other published studies (Table II) do not show a 
significant association of height at diagnosis with Ewing sarcoma, highlighting the 
inconsistent and weak association. 
These observations lead to two key questions. What does having a greater height 
at diagnosis than the reference population signify? And why is this association much 
stronger with osteosarcoma in comparison to Ewing sarcoma? During adolescence (when 
the incidence of these tumours peak), the height is a function of childhood growth and 
pubertal growth spurt. Is the above-average height in osteosarcoma patients due to taller 
children with normal pubertal growth spurt, or to children of average height but with a 
faster/greater pubertal growth spurt, or to a combination of the two? Rapid bone growth 
during adolescence may create a vulnerable period when cells are more likely to become 
transformed into overt malignancy. However, evolution of a malignant cell is a multi-step 
process and preceding pre-malignant changes might occur during other periods of rapid 
growth, e.g. in foetal life, during infancy and/or during the mid-childhood growth spurt. 
The challenge is to try to identify intrinsic (e.g.. hormonal and genetic) factors and 
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extrinsic environmental factors (e.g.. viruses, diet, physical exercise, toxic chemicals, 
radiation) which bring about changes in target cells eventually leading to cancer 
formation.  
The variation in the magnitude of association of osteosarcoma and Ewing 
sarcoma with height at diagnosis is not surprising when one considers the anatomical 
distribution of these tumours, both of which peak in adolescence. In our recent analyses 
of population-based data of 9424 primary bone tumours from England diagnosed during 
the period 1979 to 2003, we show that  Ewing sarcomas of the central axis (vertebral 
column, ribs, sternum, clavicle, pelvic bones, sacrum and coccyx) and long bones of the 
lower limb have nearly equal incidence peaks (Arora et al, in preparation). This pattern 
broadly co-relates with the structure of the adult human skeleton, which at 29 to 39 years 
of age, is made up of bones of the central axis (29%), long bones of the lower limb 
(25%), skull and facial bones (21%), long bones of the upper limb (15%), and short bones 
of the upper and lower limbs (9%).29  
In contrast, peak incidence of osteosarcoma of long bones of the lower limb, 
which is a metaphyseal tumour, is six times more than that at any other site. These are the 
bones which have the greatest increase in length during the pubertal growth spurt as a 
result of growth of cartilage at the epiphyseal plate, as well as endochondral ossification 
of this cartilage. Further support for this argument is provided by the observation of 
Cotterill et al11 that those patients with femoral osteosarcoma were not only significantly 
taller at diagnosis than the reference population but also taller than those with non-femur 
osteosarcoma. Such an observation was not made with Ewing sarcoma. 
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In summary, clinical observations and epidemiological incidence patterns of 
osteosarcoma in humans and animals suggest a link with growth particularly to onset of 
osteosarcoma. Our meta-analyses provide further support for this link. The lack of a 
similar convincing association of height at diagnosis with Ewing sarcoma, which also 
peaks in adolescence, suggests that different biological pathways involving puberty 
which may be unrelated to growth could be relevant. 
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Figure 1 Forest Plot of Osteosarcoma Studies with Outcome Data Category of 
Mean Standard Deviation Score of Height at Diagnosis in the Study Population 
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Figure 2 Forest Plot of Osteosarcoma Studies with Outcome Data Category of 
Percentage of Study Population with Height at Diagnosis Above the 50th Percentile  
Using the Freeman-Tukey arcsin method, reported study percentages were transformed to effects and meta-analysed. The overall 
effect was back-transformed to percentage and is displayed along with the original study percentages in the plot
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Figure 3 Forest Plot of Ewing sarcoma Studies with Outcome Data Category of 
Mean Standard Deviation Score of Height at Diagnosis in the Study Population 
 
Table 1 Summary of Studies Looking at Link between Height at Diagnosis and Osteosarcoma or Ewing Sarcoma 
Study ID Number of Cases Age Range Source of Cases & Controls Outcome Data Type 
Brostrom 198019 
Sweden 
19 - Osteosarcoma < 25 years Cases from Swedish cancer registry. 
No controls. 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – Swedish 
childhood growth standards) 
Buckley 199820 
USA & Canada 
152 - Osteosarcoma 
153 - Ewing Sarcoma 
< 21 years Cases registered on Children’s Cancer Group, database.  
Controls identified by random digit telephone dialling matched 
by age and race. 
Mean height of cases and controls 
Cotterill 200411 
UK 
364 - Osteosarcoma 
356 - Ewing Sarcoma 
< 40 years Cases on national bone tumour studies. 
No controls.  
Mean SDS of height at diagnosis (Reference population 
– UK national childhood growth standards) 
Fraumeni 19679  
USA 
85 - Osteosarcoma 
82 - Ewing Sarcoma 
< 18 years Cases at Children’s Hospital Medical Centre at Boston.  
Controls were children <18 years with primary cancer other 
than osseous cancer in same centre during same period. 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – Control 
population in study) 
Gelberg199721 
USA 
91 - Osteosarcoma < 25 years New York State cancer registry (excluding New York city). 
Controls were randomly selected from live birth records from 
the same area and were matched for sex and year of birth. 
P-value for trend of height for cases and controls 
Glasser 199122 
USA 
68 - Osteosarcoma 
54 - Ewing Sarcoma 
< 15 years Cases at Memorial Sloan-Kettering Cancer Centre at New York.  
No controls. 
Mean SDS of height at diagnosis (Reference population 
– USA childhood growth standards from NCHS) 
Holly 199223 
USA 
43 - Ewing Sarcoma < 31 years Cases from San Francisco Bay Area cancer registry. 
Controls identified by random digit telephone dialling matched 
by sex and age. 
P-value for mean height for cases and controls 
Longhi 200512 
Italy 
567 - Osteosarcoma Female < 16 
years, Male 
< 18 years 
Cases at Istituti Ortopedici Rizzoli at Bologna. 
No controls. 
Mean SDS of height at diagnosis, AND 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – Italian childhood 
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growth standards) 
Operskalski 198724 
USA 
60 - Osteosarcoma < 25 years Cases from Los Angeles County cancer registry.  
2 controls from friends/neighbours whose biological mothers 
spoke English matched by sex, race and birth year (+ 3 years). 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – USA childhood 
growth standards from NCHS) 
Pendergrass 198425 
USA 
291 - Ewing Sarcoma < 18 years Cases on Intergroup sarcoma study. 
No controls. 
Mean difference and P-value for mean height for cases 
and reference population (Reference population – USA 
childhood growth standards from NCHS) 
Pui 198710 
USA 
150 - Osteosarcoma 
113 - Ewing Sarcoma 
< 18 years Cases at St. Jude Children’s Research Hospital. 
No Controls. 
Mean SDS of height at diagnosis (Reference population 
– USA childhood growth standards from NCHS) 
Ruza 200326 
Spain 
58 - Osteosarcoma 
36 - Ewing Sarcoma 
< 18 years Cases at University Clinic of Navara at Pamplona. 
No controls. 
Mean SDS of height at diagnosis (Reference population 
– Spanish childhood growth standards) 
Scranton 197527 
USA 
35 - Osteosarcoma < 18 years Cases at Children’s Hospital & Presbyterian-University Hospital 
at Pittsburgh. 
No controls. 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – USA childhood 
growth standards) 
Troisi 200628 
USA 
156 - Osteosarcoma < 40 years Cases at orthopaedic departments in 10 USA medical centres. 
Controls were patients in same department with benign bone 
tumours or non-neoplastic conditions who were matched by age, 
sex, hospital and postal code 
Percentage with height at diagnosis below/above the 
50th percentile (Reference population – USA childhood 
growth standards from NCHS) 
SDS – Standard deviation scores, NCHS – National Centre for Health Statistics 
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Table II Summary Results of the Studies not Included in the Meta-Analysis 
Study ID Tumour Type Findings Comments 
Buckley 199820 
Osteosarcoma 
152 cases, 152 controls. Mean height of cases at diagnosis and controls was not significantly 
different in males (p=0.43) or females (p=0.73) 
Data collected by parental interview of cases 
and controls via telephone and thus dependant 
on parental recall. 
Ewing Sarcoma 
153 cases, 153 controls. Mean height of cases at diagnosis and controls was not significantly 
different in males (p=0.87) or females (p=0.96) 
Gelberg199721 Osteosarcoma 
91 cases, 106 controls. A significant association of osteosarcoma with increasing height one 
year before diagnosis was observed (p=0.01) when data collected from all sources was 
included. The association showed borderline significance when heights obtained only from 
records were included (p=0.08). 
Data collected on height one year prior to 
diagnosis from school records, medical 
records, and parental (or subject’s if > 18 
years age)  interview 
Holly 199223 Ewing Sarcoma 
43 cases, 193 controls. Mean height of cases at diagnosis and controls was not significantly 
different in males (p=0.24) or females (p=0.81) 
Data collected by parental interview of cases 
and controls in person or on telephone. 
Pendergrass 198425 Ewing Sarcoma 
• 291 cases, no controls. No significant difference among male cases and reference population in 
mean heights (p=0.69) or distribution by percentile groups (p=0.12). Female cases had a lower 
mean height of borderline significance (p=0.06) and distribution by percentile group (p=0.08).   
• Data collected from the Intergroup Ewing’s 
Sarcoma study records 
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7. Summary discussion of papers 1 to 6 
  Adult-onset cancer arises as a result of serial successive alterations to specific 
genes mainly in somatic cells, but may be also seen in germline cells leading to 
inherited or familial cancers. This multi-step process of sequential alterations in 
several different genes happens over time and is responsible for the well-recognised 
pattern of increasing incidence of cancer overall with age. The transformation of a 
normal cell into a malignant cell is usually a consequence of prolonged exposure to 
endogenous and exogenous carcinogens modified by individual susceptibility to 
cancer resulting from genetic polymorphisms or significant germline mutations. 
Worldwide 20% of cancers are considered to be associated with infection whilst 
environmental exposure to tobacco accounts for 30% of cancers in the developed 
world [1]. 
 Unlike cancer in adults, children with cancer have not lived long enough to 
sustain long periods of exposure to exogenous agents and very little is known about the 
aetiology in this age group. Overall only about 5% of all childhood cancers can be 
attributed to cancer predisposition syndromes [17]. For many diagnostic groups, the 
occurrence of the highest incidence at an early age, the primitive cell type of origin and 
the association with congenital malformations strongly suggest that many childhood 
cancers originate in utero [12,17,49]. Exposures during conception, embryonal or foetal 
life may initiate genetic changes and increase the susceptibility of later overt cancer 
during childhood. 
 Little is known about the aetiology of cancer in teenagers and young adults 
(TYA). As this age group bridges the period between childhood and adulthood, it is 
logical to consider that congenital factors as well as environmental exposures preceding 
development of cancer might play a role. Genetic susceptibility is likely to play a 
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greater role in TYA cancers compared to older adults following carcinogenic exposures 
due to the short period available for exposure. 
 The objective of this thesis was to gain a better understanding of the aetiology 
of cancer in TYA by describing in detail the incidence patterns. To achieve this, I used 
different strategies and focussed on some specific cancers. Epidemiological description 
of the distribution of cancer and the identification of groups of individuals at different 
risk for development of cancer (as done in this thesis by geographical areas, age 
groups, primary sites and time periods) provides basic information that is required to 
test hypotheses concerning the causes of cancer in this age.  
 Based on my observations, cancers in TYA can be divided into three main 
groups. Firstly, there are cancers such as pilocytic astrocytoma and medulloblastoma, 
which have a peak incidence in early childhood and the TYA cases represent the tail 
end of the age distribution. There is some evidence to suggest that this tail results from 
underlying genetic variations with the tumours. Medulloblastoma diagnosed in older 
children, adolescents and young adults may be more frequently associated with the 
germline mutations of APC gene, while pilocytic astrocytoma in persons older than 15 
years has significantly more gain of whole chromosomes in contrast to younger 
children [50,51]. 
 Secondly, for high grade gliomas, chondrosarcomas and epithelial cancers of 
lung, breast, colo-rectum, ovary and oral cavity TYA cases represent the very 
beginning of the large peaks of incidence seen in the 6th, 7th & 8th decades of life. 
Again, there is evidence to suggest that TYA with these cancers may have a 
predisposing genotype. In individuals with germ-line TP53 mutations, high grade 
gliomas tend to arise at much earlier ages [52,53]. A high proportion of predisposing 
mutations in BRCA1, BRCA2 and TP53 is seen in early-onset breast cancer patients 
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[15], and of MSH2 and MLH1 in early-onset colo-rectal cancer patients [16]. A range 
of cytogenetic changes have been seen in chondrosarcoma, but there is no description 
of high-penetrance mutations in those with chondrosarcomas at a younger age [54] 
although they are seen in patients with germline TP53 mutations (JM Birch, personal 
communication). Similarly, the spectrum of genetic changes in young people with oral 
cancer is not different from that of older adults, although there is a paucity of studies 
focussed at younger cohorts [55]. 
 While genetic predisposition is clearly relevant, necessary environmental 
exposures remain essential in the evolution of the cancer. The contrasting analysis of 
TYA cancers in England and India shows that cancers which are known to have a high 
incidence in older adults in the respective countries (epithelial cancers of lung, breast, 
colo-rectum and ovary in England and of oral cavity in India) are also higher in 
incidence in the younger age groups. Inherited differences between populations could 
play a role but this is not likely to be significant since frequency of high-penetrance 
mutations for some of the above cancers reported in Indian patients is similar to that 
reported in Europe and USA [56,57]. Future migrant studies looking at incidence of 
cancer in TYA in different ethnic groups in England will help in further understanding. 
 The final group of TYA cancers are those which peak in incidence in this age 
group. This includes osteosarcoma, Ewing sarcoma and germ cell tumours and hence 
the focus on them in this thesis. The incidence patterns of bone sarcomas suggest that 
puberty plays a role in the development of osteosarcoma and Ewing sarcoma but not 
chondrosarcoma. Variation in these patterns with site suggests pubertal bone growth 
to be a key factor in osteosarcoma while different biological pathways which may be 
unrelated to bone growth could also be relevant for Ewing sarcoma. Further evidence 
for this is provided by my meta-analysis which shows that the average height of 
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patients with osteosarcoma is significantly above the average height of the reference 
population while there is a lack of a similar convincing association in Ewing sarcoma. 
GCT are a heterogeneous group of tumours. Irrespective of site, GCT show a 
peak in incidence between ages of 10 to 39 years and show similar genetic mutations 
[58-60]. This suggests a common initiation of these tumours likely to be during 
embryonal or foetal periods or early childhood. However, the variation in peak 
incidence by site (10 to 14 years in CNS, 15 to 19 years in ovarian, 25 to 29 in 
mediastinum & thorax and abdomen & pelvis, and 30 to 34 years in testicular GCT) 
suggests that progression of tumourigenesis is affected by the local macro- and micro-
environment and events during the postnatal and pubertal period. 
The work done in this thesis follows on from the initial descriptions of cancer in 
TYA over the last decade [8,10,61]. Based on the epidemiological observations made 
here, several hypotheses have been generated:- 
1. Endogenous (hormones, growth factors) and exogenous (environmental exposures, 
diet) factors play a significant role in the initiation and/or promotion of cancer in 
TYA. 
2. These factors may exert their effect in the prenatal and/or postnatal period. 
3. For some TYA cancers, particularly those which represent the tail end of childhood 
cancers or those which have peak incidence in TYA, the initiation of 
tumourigenesis may be in embryonal and foetal life. 
4. Puberty is an important period in the evolution of some TYA cancers. The 
pathogenesis may be a result of hormonal exposures and rapid cell growth (e.g 
pubertal growth spurt).   
5. Genetic susceptibility could also play a role in TYA who develop adult-onset 
cancers. 
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6. The proportion of TYA cancers attributed to cancer predisposition syndromes is 
likely to be small. 
Future research in TYA cancers can address some of these questions by:-   
1. Contrasting incidence patterns of TYA cancers among different ethnic groups in 
England as has been done for children and older adults [62,63]. This will help to 
further elucidate the importance of environmental factors over genetic factors in the 
aetiology of specific cancers in this age group. 
2. Undertaking multi-centre and multi-national studies into the aetiology and 
molecular epidemiology of TYA cancers by collecting clinical information and 
biological samples for genetic analysis similar to past and current studies in 
childhood cancer [64,65]. A pilot interview-based study on bone tumours in 
children and young people is currently underway in England, details of which are in 
the Appendix. This will be the forerunner of a major multi-centre case-control 
study. 
3. Focussing on growth during foetal life, infancy and childhood in addition to 
pubertal growth along with other internal and external factors possibly linked to 
causation of osteosarcoma and Ewing sarcoma. 
 
In summary, I have explored the epidemiology of cancer in TYA using some 
of the established methodologies which have previously been used in advancing our 
knowledge of childhood and older adult cancers. The observations made in this thesis 
have allowed formulation of several hypotheses regarding aetiology of cancer in this 
age group which can be tested by further research.  
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Purpose of the Investigation 
 
We aim to ascertain and recruit a population-based sample of patients diagnosed up to 24 years of 
age with osteosarcoma and Ewing sarcoma; interview families, collect DNA samples and abstract 
relevant medical records; in order to determine the feasibility of setting up a multi-centre, 
international case-control study of aetiology. Specific aims of the pilot study are to: 
1. Assess the proportion of regional cases treated at the specialist paediatric (age 0-14 years) 
and teenage and young adult (age 15-24 years, TYAs) oncology units in Manchester and 
Leeds. 
2. Assess the recruitment, interview and DNA sample collection rates for cases, their mothers 
and fathers. 
3. Identify and resolve any difficulties in liaising with clinic staff in the above specialist and 
other units in approaching and recruiting families. 
4. Assess and develop further the interview questionnaires including identifying questions 
which present respondents with most difficulties. 
5. Assess the consent rates to view and subsequent availability of obstetric, neonatal and child 
health records relating to index cases in relation to age of index (0-4,5-9,10-14,15-19,20-
24). Also assess the quality and completeness of the records. 
6. Assess the accuracy of information reported at interview compared with that abstracted 
from medical records. 
7. Quantify the frequency of exposures of interest in the study population to assist with final 
questionnaire design and power calculations for the subsequent main study. 
8. Optimize biological sample collection processing and storage methodologies. 
9. Analyse patterns of growth including adult heights in parents, birthweights and heights in 
childhood and adolescence in index cases compared with population data and standard 
growth charts. 
10. Analyse familial cancer patterns in the interviewed sample in relation to other factors of 
interest (congenital anomalies, known genetic and other chronic conditions). Select 
families for future analyses of candidate genes as appropriate. 
 
Background 
Cancer statistics for England are published annually by the Office for National Statistics (ONS) 
London (1). The diagnostic classification applied to these figures is based on the International 
Classification of Diseases (ICD) which groups cancers by primary site (2). This is satisfactory in 
general since 80% of all cancers are carcinomas. Carcinomas are rare in young people and 
presentation of statistics by primary site gives a misleading picture of cancers in the young. 
Patterns of cancer incidence can provide insights into possible aetiological factors but to be 
effective, descriptive studies must employ a diagnostic classification that relates to the cells and 
tissues of origin of the respective cancers. We have developed such a scheme and applied this to 
national data (3). The Birch classification scheme has attracted international support and has 
become the accepted vehicle for cancer incidence studies in TYAs (4). 
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We have conducted preliminary analyses of national cancer data, by morphological type across 
all age groups (0-79 years) to identify cancer types which show peaks of incidence in the young. 
Of particular interest were the age-incidence curves for individual types of bone tumours. Such 
information is not retrievable from standard incidence data since all bone tumours are presented 
together. Osteosarcoma (OS) and Ewing sarcoma (ES) account for over 90% of all bone tumours 
in 0-24 year olds. The median age of diagnosis for OS and ES across all ages is 22 years and 17 
years respectively. In both OS and ES the main peak of incidence occurs earlier in females than 
males. 
Much is known about aetiology of common cancers in adults (5). Carcinoma of the lung is 
mainly due to tobacco smoke. Breast carcinoma is linked to hormonal and reproductive factors but 
is also influenced by diet and lifestyle. Colorectal carcinoma is associated with a diet rich in fat, 
refined carbohydrates and animal protein and a lifestyle involving low physical activity. For these 
cancers, clinical onset follows a prolonged period of chronic exposure. It is clear  in children and 
TYAs, there has been no opportunity for such chronic exposures. Therefore the mechanisms and 
the risk factors themselves may differ in their nature or their proportional contribution to cancer in 
these young people. It is likely that genetic susceptibility may play a greater role in this age range 
than for cancers in older people (6). 
Embryonal malignancies in young children have a prenatal origin. It is likely that all events 
required for their onset occur before birth. It is possible that while one or more events leading to 
OS and ES occur prenatally, events which precipitate the onset of disease occur post-natally during 
childhood and/or adolescence. These events may occur endogenously due to chance, or could be 
mediated through environmental exposures e.g. viruses, toxic chemicals, leading to transformation 
in a pre-malignant clone of cells which has a pre-natal origin. Factors affecting growth and 
development including diet, physical exercise and serious illness may also influence the onset of 
OS and ES in older children and TYAs. 
Clinical studies show that the earlier peak of onset of OS in girls, corresponds to their more 
advanced skeletal age and earlier adolescent growth spurt, whereas the increased risk of OS among 
boys may result from the larger bone volume formed during a longer growth period (7). OS has a 
predilection for the metaphyseal portions of the most rapidly growing bones in adolescents; the 
distal femur, proximal tibia and proximal humerus (8). Tumours of the humerus tend to occur at a 
younger age than do tumours of the femur and tibia, corresponding to the earlier growth spurt of 
the humerus (7). Thus, the tumour appears to occur most frequently at sites when the greatest 
increase in length and size of bone occurs. While ES of bone also shows an incidence peak in 
adolescence, which occurs earlier in girls than boys, the primary site distribution is less well-
defined in terms of sites of maximal growth and tumours of the vertebral column, ribs, sternum, 
clavicle, pelvis, sacrum and coccyx are more common. Some evidence exists that adolescent 
patients with OS and ES are taller than the general population (9,10) and OS patients may be 
heavier at birth (11). However, these studies were under-powered and/or lacked comprehensive 
data and there were inconsistencies. A small pilot study of OS reported case-control differences in 
IGF2 receptor haplotype which may have functional significance (12). 
Descriptive studies including time trends, geographical variations in incidence, clustering and 
ecological studies can provide pointers to possible aetiological factors. Studies of childhood bone 
tumours show stable incidence over time for OS (13,14). For ES the Manchester Children’s 
Tumour Registry (MCTR), which operates a system of special diagnostic review, found stable 
incidence (13) but there was a slight increase in national data (14) almost certainly due to 
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increased recognition of ES with  improved diagnosis. Space-time clustering among cases of 
specific disease is associated with an infectious aetiology. There was no evidence of space-time 
clustering among cases of OS based on MCTR data but weak evidence of this in a national dataset 
(15). There is little international variation in incidence of OS in children, but ES is virtually absent 
from black populations (16).This observation most likely has a genetic basis. In English national 
data on TYAs stable incidence over time has been found for both OS and ES (17). There were no 
significant variations in incidence by socioeconomic deprivation and geographical region (18). 
These small variations in incidence suggest that environmental factors play a minor role in 
aetiology or exposures have been uniformly distributed over time and geographically. However, 
this does not exclude the possibility of the involvement of environmental exposures in the onset of 
bone tumours in young people. Children and adolescents, at the stage of maximum growth, may be 
more susceptible to such exposures than older adults. The possibility that environmental agents 
may target different organs and tissues in the growing child and adolescent, compared with mature 
adults, should be considered. The role of genetic factors in modifying risks may be greater than in 
older adults (6) and studies of aetiology should incorporate molecular analyses of polymorphisms 
in genes controlling growth factors, immune response and metabolism. In addition, it is well 
known that a minority of bone sarcomas occur in association with certain cancer predisposition 
syndromes, including Li-Fraumeni syndrome (LFS) and retinoblastoma (19,20), but the 
proportions of cases attributable to these mutations is uncertain, particularly in TYAs. 
Determination of the frequency of such high penetrance mutations is important, since the presence 
of germline mutations has profound implications for future clinical management, including genetic 
counselling. 
In conclusion, although little is known about aetiology, the striking age-incidence patterns of OS 
and ES, the known genetic susceptibility in rare cases and the largely stable incidence patterns, 
allow a set of hypotheses to be formulated. Bone tumours rank 6th and 4th for mortality (14,21) in 
relation to other cancers, in children and TYAs respectively (14,21) and represent one of the most 
important causes of death in the young. It is imperative that we make the effort to identify and 
tackle causes of OS and ES leading to prevention. However, one of the biggest challenges is the 
rarity of these diseases. In order to achieve sufficient statistical power, a multi-centre international 
study is required. A necessary first step is a pilot study to establish feasibility.  
Objectives of the study 
The objectives of the full-scale study are to understand the aetiology of bone sarcomas focusing 
on genetic susceptibility, growth and development throughout childhood and adolescence as well 
as aspects of molecular epidemiology including epigenetic profiles, DNA repair capacity and 
mutation patterns. The main objectives of the pilot study are to gather sufficient information on 
young people with OS and ES to enable a protocol for the full-scale study to be developed and to 
formulate a testable set of hypotheses. The following draft set of hypotheses have been formulated: 
1. Factors associated with postnatal patterns of growth influence risk of developing OS and 
ES. 
2. An initiating event (or events) occurs earlier in childhood creating a pre-malignant clone 
(or clones) in the target tissue(s). The mid-childhood growth spurt will be a particularly 
vulnerable period. 
3. The rapid growth during the adolescent growth spurt increases the chance of malignant 
transformation. 
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4. Risk factors for OS and ES which influence growth may be endogenous or exogenous 
5. Endogenous factors include growth factors/hormones acting pre-natally and post-natally 
and genetic variation in these. 
6. Exogenous factors include nutrition, physical exercise, illnesses during childhood and 
environmental exposures that may interact with growth, especially bone growth (including 
bone-seeking elements, mitogenic substances, ionizing radiation). Susceptibility to these 
factors may be under genetic control. 
7. There will be overlap between causal factors in each of the tumour types, but the timing, 
route, combination and intensity of exposures coupled with individual genetic make-up will 
determine outcome. 
8. In a small proportion of cases, the tumours will arise in association with highly penetrant 
mutations to cancer-associated genes. 
 
Plan of Investigation 
Professor Birch and Professor McKinney will be responsible for organising the study in 
Manchester  and Leeds respectively, in collaboration with the lead clinicians Professor Eden and 
Professor Lewis. A part-time research nurse will be based in each centre.  
Case Recruitment 
Cases of histologically confirmed OS and ES in persons aged 0-24 years diagnosed during the  
period, July 2009 to August 2011, resident in the North West (NW) and Yorkshire and the Humber 
(YH) Strategic Health Authority areas will be eligible. Virtually all incident cases in children aged 
0-14 will be treated in the regional paediatric oncology units in Leeds and Manchester. It is 
expected that most cases in 15-24 year olds will be treated in the respective Teenage Cancer Trusts 
units, but adult oncology units in Leeds and Manchester may treat some of the older patients and 
these will also be monitored. During this 2 year period we predict there will be about 30 cases in 
YH (Leeds) and 40 cases in NW. We would expect to recruit at least 75% of incident cases 
(minimum 50 patients) through the main oncology centres in Leeds and Manchester. 
We will liaise with relevant clinic staff to identify and obtain permission to approach patients 
and/or their parents from the clinician in charge. Initial approach will be to the patients themselves 
or their parents depending on age. Informed consent will be needed from TYA patients to 
approach their parents. Invitation letters and information sheets will be mailed or handed to 
patients and/or parents in the hospital. Following consent clinical details of participating cases will 
be extracted from oncology records and a copy of the pathology report obtained. 
Interview procedure 
Following written informed consent, research nurses will conduct face to face interviews, using 
structured proformas with study subjects in their homes or the hospital, depending on preference. 
Separate interviews will be conducted with cases, their mothers and fathers as appropriate. The 
proformas will focus on mother’s pregnancy with the index case, birth (including birthweight) and 
neonatal care, factors in infancy and early childhood including, nutrition, illnesses, growth and 
development, factors in later childhood and adolescence including illnesses and their treatment, 
physical activity, social habits (including smoking), growth and development, family histories of 
cancer, congenital anomalies and other genetically determined conditions, parental health, 
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including adult heights, parental smoking. Information collected from the face to face interview 
will be used to assess exposure prevalence. 
The investigators have extensive experience of conducting interview-based studies and have 
previously achieved recruitment rates of over 90%. This rate  should be achieved in the pilot for 
cases in the main oncology centres. Completeness of ascertainment and recruitment will be cross-
checked with respective cancer registries. 
Collection of biological specimens 
Molecular genetic analysis will be an important component of the full study. In preparation, in 
the pilot we shall collect blood and saliva samples from cases and their parents to assess 
compliance rates. Methodologies and procedures for biological sample collection will be set up 
and optimised. Case blood samples will be obtained by arrangement with oncology staff to avoid 
additional procedures. The research nurses will be responsible for biosample collection from 
parents (blood or saliva) and saliva samples from cases (if no blood sample is possible). 
Biosamples will be stored in Manchester for future analysis. Samples will be labelled with study 
numbers including a code to indicate whether the sample is from a case, mother or father. No ID 
information will be included to allow future anonymised molecular analyses. It will be possible to 
link back to the epidemiological and clinical data via the study number but the data and laboratory 
results will be stored separately. Data and results will be linked only for statistical analysis in a 
temporary file (Data Management). 
Abstraction of medical records 
An important aspect of this pilot will be location and abstraction of relevant medical records 
including, mothers’ obstetric records (gestation, birthweight, congenital anomalies, neonatal 
problems/care) and child health records (developmental milestones, growth, general health) using 
standard proformas. For some health authorities, the latter are computerised.  Informed consent to 
access and abstract records will be obtained at interview. 
Future Analysis of Biosamples 
The power of the study will be too low for calculation of familial cancer risks, but families 
showing clustering of cancers consistent with predisposition syndromes will be selected for future 
analysis of candidate genes. We expect to collect samples from 50 families and would anticipate 
selection of about 10 families.  Analyses of these genes and low-penetrance genes/polymorphisms 
will be conducted as part of  the full-scale study and biosamples from the pilot will be incorporated 
into these. These analyses will be subject to separate ethical approval as part of the main study. 
Data Management 
Data will be coded in both centres but input, cleaned and edited centrally in Manchester. The 
data stored in Manchester will be split in three files to allow anonymisation as well as linkage. The 
following scheme will be applied. 
1. File 1 (Admin File) − A password controlled computer file containing identifying and 
demographic details of cases will be created. This file will include variables such as dates 
of birth, addresses, NHS number, hospital number and “logging” of progress with 
interviews, records abstractions and biological samples. 
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2. File 2 (QUESTIONNAIRE File) − All the questionnaire data will be held in a separate 
password controlled file with no identifying information but with individuals allocated a 
study number. Data abstracted from medical records will also be held in File 2. 
3. File 3 (LABORATORY File) − Each specimen from the same individual will be labelled 
with the study number, plus a specimen number (to allow for more than one specimen from              
the same person) and stored within the University of Manchester. Subsequently, and in 
accordance with local standard operating procedures and in compliance with the 
requirements of the Human Tissue Act, specimens may be dispatched to collaborating 
laboratories for analysis in separately funded studies with specific ethical approval. The 
laboratory receiving the samples will be given details of the specimen, the age and sex of 
the patient. Specimen details and laboratory results will be held on a third password 
controlled restricted access computer file. No identifying details  will be held in this file.  
 
At the time of analysis, files 1, 2 and 3 will be linked to create a temporary file to combine the 
clinical and epidemiological data and subsequently the laboratory results. This file will use the 
study number and relevant reference dates but no other identifiers. On completion of the analysis, 
this file will be deleted.  All data will be stored on an air gap (stand alone) network. Offices have 
keypad locks and entry to the department is by swipe card. All members of staff sign a 
confidentiality agreement as part of their contract. 
Time Table 
Jan 2009–June 2009 Prepare study materials including leaflets, consent forms and questionnaire 
   Apply for MREC approval 
   Obtain NHS trust research governance approval 
   Recruit staff and obtain NHS honorary contracts for study staff 
   Establish collaborative links with treatment centres 
   Establish laboratory procedures  
 
July 2009-Sept 2011  Ascertain, approach and interview 50 cases 
   Collect and process samples 
   Abstract data from health records 
   Collect and computerise data 
    
Oct 2011–Feb 2012 Complete data collection and computerisation 
Clean, verify and edit the data 
   Evaluate participation rates 
   Assess exposure frequencies 
   Write reports 
   Prepare protocol and grant applications for full study
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Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Information Leaflet for Children (under 12 years) 
 
What is the background to this study? 
A new large study of the causes of bone tumours in children, teenagers and young adults 
is being planned. Scientists from different countries will work together on this large 
study.  Before the large study can begin, we need to do a small study called a pilot study. 
Our pilot study is being done before the main project to collect important information, for 
example about your health, to help with the main project. 
 
Why do you need to do a pilot study? 
In the pilot study we shall try out some ways of doing the research which we hope to use 
in the large study. The pilot study will tell us if these work and whether we need to 
change anything. 
 
Who is doing the research? 
The pilot study is being carried out by teams of scientists, nurses and doctors from 
Manchester and Leeds. 
 
Why have you chosen me? 
We have chosen you because we know that you have had the kind of tumour we are 
interested in.   
 
What will you do in the research ? 
We shall be asking your parents if they would like to take part in the study by answering 
a lot of questions. A research nurse who is part of our team will arrange to meet with 
your parents to do this. We are also giving an information sheet to your parents, so you 
might want to talk to them about the study. 
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What sort of questions will they be asked? 
 Your parents will be asked to give some information about your early life which 
includes: illnesses and injuries, what happened when you were a baby, the sorts of sports 
you play, other things you like to do and also some general information about your 
family. We will also ask your mother about when she was expecting you. They do not 
have to answer all the questions if they, or you, do not want them to. 
 
Will you be doing anything else ? 
We should like a small blood sample or a saliva (spit) sample from you and your parents. 
We also want to look at your medical notes to find out more about how much you grew 
when you were younger and any illnesses or injuries you may have had. 
 
Why do you need a blood or saliva sample from me? 
You can take part in the study without giving blood or a saliva (spit) sample. If you are 
willing your doctor or nurse at the hospital will take a small sample (about 2 teaspoons) 
from you at the same time as a sample is being taken as part of your treatment, so there 
won’t be any extra needles.  
 
Instead of giving us a blood sample, you could give a saliva sample by spitting into a 
special little pot. The nurse will show you how to do this. The samples will be used in 
tests done in a laboratory, which we hope will tell us if some people are more likely to 
develop bone tumours than others. The samples will be kept at the University of 
Manchester so that they can be used for these tests in the future. 
 
Will I find out the results on my blood or saliva sample? 
No. Results on samples will not be given to those taking part in the study or their families 
and will not be passed on to their doctors or anybody else.  
 
Who will be able to look at the information in the study ? 
Only a small number of people working on the project all of whom know they must keep 
the information about you secret. 
 
Can I see my information ? 
Yes. You have a right to see all the information about you which we collected for the 
study. 
 
What will happen if I do not want to take part in the research? 
Nothing. If you do not want to take part, or if you do not want your parents to answer the 
questions, this will not affect your treatment in any way and nobody will mind.  
 
Do I have to take part in the study? 
We will try to make sure that you and your parents are happy to take part in the study. If 
you want to take part we shall need the consent of your parents. If after reading this 
information sheet, thinking it over for a few days and talking to your parents, you decide 
not to join the study that is OK. 
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What happens next ? 
One of our research nurses will contact your parents soon if they are willing, to arrange to 
meet them to ask them the questions for our research. 
 
How can I find out more about the study? 
For advice or information about the study contact: 
Professor Jill Birch 
Cancer Research UK Research Group,  
School of Cancer & Imaging Sciences 
The Medical School, Stopford Building, Room 1.900 
University of Manchester, Oxford Road 
Manchester M13 9PL 
TEL: 0161-275-5404 
FAX: 0161-275-5348 
EMAIL: jillian.birch@manchester.ac.uk 
 
OR 
Dr Richard G.Feltbower 
Centre for Epidemiology & Biostatistics 
Paediatric Epidemiology Group, Room 8.49J, Level 8 
Worsley Building, University of Leeds 
Clarendon Way, Leeds LS2 9JT 
TEL/FAX: 0113 343 4841/4877 
EMAIL: r.g.feltbower@leeds.ac.uk 
OR 
Talk to a member of your clinical team at your hospital or clinic 
 
How can I find out more about bone tumours in children, teenagers and young 
adults? 
The following organizations provide information: 
 
Bone Cancer Research Trust  Children’s Cancer & Leukaemia Group  
Suite 1d, Gledhow Mount Mansion,  University of Leicester, 3rd floor, 
Roxholme Grove, Leeds, LS7 4JJ  Hearts of Oak House, 9 Princess Road West 
Tel: 0113 262 1852    Leicester LE1 6TH 
Email: info@bone cancerresearch.org.uk Tel: 0116 249 4460 Email:info@cclg.org.uk 
WEBPAGE: www.bonecancerresearch.org.uk  WEBPAGE: www.cclg.org.uk 
 
Teenage Cancer Trust   Cancer Research UK 
3rd Floor, 93 Newman Street,   PO Box 123, Lincoln’s Inn Fields 
London, W1T 3EZ    London WC2A 3PX 
Tel: 020 7612 0370    Tel: 020 7242 0200 
Email: tct@teenagecancertrust.org.  WEBPAGE: www.cancerresearchuk.org 
WEBPAGE: www.teenagecancertrust.org 
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Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Information Leaflet for Young People (12-15 years) 
 
What is the study about ? 
A new large-scale study of the causes of bone tumours in children, teenagers and young 
adults is being planned. We hope that people from all over Europe will take part in the 
large-scale study. We shall be studying such things as nutrition, growth and development 
throughout childhood and adolescence, sport and exercise, viruses and other 
environmental exposures. Information collected from different centres will be combined 
and this will allow for powerful analyses of possible causes of these tumours. Before this 
large-scale study can go ahead, a smaller study called a pilot study is being done to 
collect information which will help with the design of the main project. 
 
What is the aim of the pilot study? 
In the pilot study we shall be trying out a questionnaire to look at the sort of answers 
given and whether there are any questions which people taking part find difficult to 
answer. We should also like to look at whether medical records that would be useful in 
the study are still available. It is also important to see how many people agree to take 
part. All these things will help us plan the main study so that it is a success. 
 
Who is doing the pilot study ? 
The pilot study is being carried out by teams of scientists, nurses and hospital doctors 
from Manchester and Leeds. 
 
Why have you chosen me? 
We have chosen you because we know that you have had the kind of tumour we are 
studying. 
 
What will I have to do ? 
We should like to arrange to carry out an interview with your parents which generally 
takes about 1 hour. A research nurse will arrange a time and place for the interview, so 
you do not have to do anything. We are also giving an information sheet to your parents, 
so you might want to talk to them about the study. 
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What sort of questions will you ask my parents ? 
At the interview your parents will be asked about your health including: illnesses and 
injuries, where you have lived and any sports or other activities you have taken part in 
and also some general information about health in your family. We will also ask your 
mother about when she was expecting you. They do not have to answer all of the 
questions if they, or you do not want them to. 
 
Do you need any other information ? 
With your permission, we should like to extract details from your oncology records about 
the particular type of bone tumour which you developed. We should also like access to 
your general health records so that we can extract information about your growth and 
development during your childhood, including height and weight at different ages and 
your developmental milestones. In addition, we shall be asking your mother if we can 
extract information from her medical records about her pregnancy, your birth and health 
soon after birth, including results of scans and other tests before you were born, your 
birth weight, size and your general health shortly after you were born. 
 
Does the study involve anything else ? 
If you agree, we would like a small blood sample from you or a sample of saliva (spit).  
We would also like to look at health records for information on growth and previous 
illnesses.  
 
Why do you need a blood or saliva sample from me? 
You can take part in the study without giving blood or a saliva sample but if you agree, a  
blood sample (5-20ml of blood or 1-4 teaspoons) will be collected at the same time as a 
sample is being taken as part of your treatment. If this is not possible, you could give a 
saliva sample. All you have to do is to spit into a small pot. We should also like a blood 
or saliva sample from your parents which would be collected by the research nurse. The 
blood and saliva samples will be used to extract genetic material to look for differences 
which may affect the chances of developing bone tumours.  
 
What will happen to the samples ? 
The material will be stored at the University of Manchester and will be used for future 
analysis. The blood/saliva samples will be considered as being gifted to the University 
and you will have no rights over any commercial developments arising from their use in 
research. 
 
Will I find out the results on my or my parents blood or saliva sample? 
No. Results on samples given for research are not passed on to those who took part in the 
research, nor to their families, to their doctors or anybody else.  
 
Who will look at the information ? 
A very small number of staff directly working on the project will look at the information. 
Other staff working for the NHS and/or the University may also need to look at part of 
the information to make sure that the research is being carried out properly and to check 
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that all the information is kept secure. All staff know that the information must be kept 
confidential.  
 
Can I look at the information ? 
Yes. You have a right to see all the information about you collected by us at interview 
and from your medical records.  
 
What will happen if I do not want to take part in the research? 
Nothing. This research is entirely voluntary and this will NOT affect your medical care in 
any way. 
 
How do I know if your work is ethical? 
All our research is carried out with the approval of medical research ethics committees. 
The members of these committees include doctors, health professionals and other 
ordinary people. 
 
Do I have to take part in the study? 
We always try to make sure that you and your parents are happy to take part in the study. 
If after reading this information sheet, thinking it over for a few days and discussing it 
with your parents, you decide not to join the study that is OK. 
 
What happens next ? 
If you and your parents are happy to take part, one of our research nurses will contact 
your parents to arrange an interview. 
 
How can I find out more about the study? 
For advice or information relating to the study contact: 
Professor Jill Birch 
Cancer Research UK Research Group,  
School of Cancer & Imaging Sciences 
The Medical School, Stopford Building, Room 1.900 
University of Manchester, Oxford Road 
Manchester M13 9PL 
TEL: 0161-275-5404 
FAX: 0161-275-5348 
EMAIL: jillian.birch@manchester.ac.uk 
 
OR 
 
Dr R.G.Feltbower 
Centre for Epidemiology & Biostatistics 
Paediatric Epidemiology Group, Room 8.49J, Level 8 
Worsley Building, University of Leeds 
Clarendon Way, Leeds LS2 9JT 
TEL/FAX: 0113 343 4841/4877 
EMAIL: r.g.feltbower@leeds.ac.uk 
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OR 
Talk to a member of your clinical team at your hospital or clinic 
 
If you have a concern about any aspect of this study, you should ask to speak to 
researchers who will do their best to answer your questions. If they are unable to resolve 
your concern, or you wish to make a complaint regarding the study, please contact a 
University Research Practice and Governance Co-ordinator on 0161 275 7583 or 0161 
275 8093 or by email to research-governance@manchester.ac.uk 
 
How can I find out more about bone tumours in children, teenagers and young 
adults? 
The following organizations provide information: 
Bone Cancer Research Trust  Children’s Cancer & Leukaemia Grp 
Suite 1d, Gledhow Mount Mansion  University of Leicester, 3rd floor, 
Roxholme Grove, Leeds, LS7 4JJ  Hearts of Oak House, 9 Princess Road West 
Tel: 0113 262 1852    Leicester LE1 6TH 
Email: info@bonecancerresearch.org.uk Tel: 0116 249 4460 Email:info@cclg.org.uk  
WEBPAGE:www.bonecancerresearch.org.uk  WEBPAGE: www.cclg.org.uk    
 
Teenage Cancer Trust   Cancer Research UK 
3rd Floor, 93 Newman Street,   PO Box 123, Lincoln’s Inn Fields 
London, W1T 3EZ    London WC2A 3PX 
Tel: 020 7612 0370    Tel: 020 7242 0200 
Email: tct@teenagecancertrust.org.  WEBPAGE: www.cancerresearchuk.org  
WEBPAGE: www.teenagecancertrust.org 
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Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Information Leaflet for Patients over 16 years 
 
What is the study about ? 
A new large-scale multi-centre study of the causes of bone tumours in children, teenagers 
and young adults is being planned. We shall be studying such things as nutrition, growth 
and development throughout childhood and adolescence, sport and exercise, viruses and 
other environmental exposures. Information collected from different centres will be 
combined and this will allow for powerful analyses of possible causes of these tumours. 
Prior to this large study, our smaller pilot study is being undertaken to collect essential 
information, for example about your health, to help with the design of the larger project. 
 
What is the aim of the pilot study? 
In the pilot study we shall be trying out a questionnaire to look at the range of answers 
given and whether there are any questions which people find difficult to answer. We 
would also like to look at whether medical records that would be useful in the study are 
still available. In addition, it’s important to know what proportion of families agree to 
take part. All of these things will help us design a successful full-scale study.  
 
Who is doing the research? 
The pilot study is being carried out by teams of scientists, nurses and hospital doctors  
from Manchester and Leeds. 
 
Why have you contacted me? 
We have contacted you because we are inviting you to take part in this study. The reason 
for choosing you is that you recently developed a type of bone tumour which we are 
studying.  
 
What does the study involve ? 
If you agree to take part, we shall arrange to carry out an interview which generally takes  
about 1 hour. The research nurse who will carry out the interview will arrange a time and 
place which is convenient for you. In addition, with your permission, we should also like 
to interview your parents.  
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If I agree what sort of questions will I be asked? 
At the interview you will be asked about your health including: illnesses and injuries, 
your occupations and where you have lived and any sports or other activities you have 
taken part in. We shall also ask about your early life and your development during 
adolescence. We should like to ask your parents similar questions and also ask your 
mother about the time before you were born when she was expecting you. You can 
choose not to answer any of the questions. 
 
Do you need any other information ? 
With your permission, we should like to extract details from your oncology records about 
the particular type of bone tumour which you developed. We should also like access to 
your general health records so that we can extract information about your growth and 
development during your childhood, including height and weight at different ages and 
your developmental milestones. In addition, we shall be asking your mother if we can 
extract information from her medical records about her pregnancy, your birth and health 
soon after birth, including results of scans and other tests before you were born, your 
birth weight, size and your general health shortly after you were born. 
 
Does the study involve anything else ? 
If you agree, we would like a small blood sample or a sample of saliva (spit) from you. 
The blood samples will be taken by your doctor at the same time as a routine sample is 
taken. 
 
Why do you need a blood or saliva sample from me? 
You can take part in the study without giving a blood or saliva sample but if you agree, 
the research nurse or hospital clinic staff will take the samples. Between 5-20ml (1-4 
teaspoons) of blood will be taken for the research. Alternatively, you could give a saliva 
sample by spitting into a small pot. The blood and saliva samples will be used to extract 
genetic material to look for variations in genes which may affect the likelihood of 
developing bone tumours.  
 
What will happen to the samples ? 
The material will be stored at the University of Manchester and will be used for future 
analysis. The blood/saliva samples will be considered as being gifted to the University 
and you will have no rights over any commercial developments arising from their use in 
research. 
 
Will I find out the results on my blood or saliva sample? 
No. Results on samples donated for research will not be given to participants and their 
families and will not be passed on to their doctors or anybody else. The tests that will be 
carried out are not medical tests and the results will only be used for research. So, taking 
part in the study should not have any adverse effects on you (including employment 
status or ability to get insurance). 
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Who will have access to the data information ? 
Only a very restricted number of staff directly working on the project will have access to 
information collected in the study. NHS and/or University staff responsible for auditing 
research conduct and data security will also have limited access for this purpose. All staff 
are trained in confidentiality procedures.  
 
Can I have access to the information ? 
Yes. You have a right to see all the information collected at interview and extracted from 
medical records which concerns you and held by us. 
 
What will happen if I do not want to take part in the research? 
Nothing. This research is entirely voluntary and this will NOT affect your  medical care 
in any way. 
 
How do I know if your work is ethical ? 
All our research is carried out with the approval of medical research ethics committees. 
The members of these committees include doctors, health professionals and lay people. 
 
 
What should I do now? 
Please return the reply slip in the envelope provided. If you are willing, one of our 
research nurses will contact you to arrange an interview. 
 
How can I find out more about the study? 
For advice or information relating to the study contact: 
Professor Jill Birch 
Cancer Research UK  Research Group 
School of Cancer & Imaging Sciences 
The Medical School, Stopford Building, Room 1.900 
University of Manchester, Oxford Road, Manchester M13 9PL 
TEL: 0161-275-5404 
FAX: 0161-275-5348 
EMAIL: jillian.birch@manchester.ac.uk 
OR 
Dr Richard Feltbower 
Centre for Epidemiology & Biostatistics 
Paediatric Epidemiology Group, Room 8.49J, Level 8 
Worsley Building, University of Leeds 
Clarendon Way, Leeds LS2 9JT 
TEL/FAX: 0113 343 4841/4877 
EMAIL: r.g.feltbower@leeds.ac.uk 
OR 
Talk to a member of your clinical team at your hospital or clinic 
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If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. If they are unable to resolve 
your concern, or you wish to make a complaint regarding the study, please contact a 
University Research Practice and Governance Co-ordinator on 0161 275 7583 or 0161 
275 8093 or by email to research-governance@manchester.ac.uk 
 
How can I find out more about bone tumours in children, teenagers and young 
adults? 
The following organizations provide information 
 
Bone Cancer Research Trust  Children’s Cancer & Leukaemia Group 
Suite 1d, Gledhow Mount Mansion  University of Leicester, 3rd floor, Hearts of 
Roxholme Grove, Leeds, LS7 4JJ  Oak House, 9 Princess Road West, 
Tel: 0113 262 1852    Leicester LE1 6TH 
Email: info@bonecancerresearch.org.uk Tel: 0116 249 4460 
WEBPAGE:www.bonecancerresearch.org.uk Email:info@cclg.org.uk  
        WEBPAGE: www.cclg.org.uk 
    
Teenage Cancer Trust   Cancer Research UK 
3rd Floor, 93 Newman Street,   PO Box 123, Lincoln’s Inn Fields 
London, W1T 3EZ    London WC2A 3PX 
Tel: 020 7612 0370    Tel: 020 7242 0200 
Email: tct@teenagecancertrust.org.  WEBPAGE: www.cancerresearchuk.org 
WEBPAGE: www.teenagecancertrust.org 
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Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Information Leaflet for Parents & Guardians 
 
 
What is this study about ? 
A new large multi-centre study of causes of bone tumours in children, teenagers and 
young adults is being planned. We shall be studying such things as nutrition, growth and 
development during childhood and adolescence, sport and exercise, viruses and other 
environmental exposures. Information collected from different centres will be combined 
and this will allow for powerful analyses of possible causes of these tumours. Prior to this 
large study, our smaller pilot study is being undertaken to collect essential information, 
for example about your child’s health, to help with the design of the larger project. 
 
What is the aim of the pilot study? 
In the pilot study, we shall be trying out a questionnaire to look at the range of answers 
given and whether there are any questions which people find difficult to answer. We 
would also like to look at whether medical records that would be useful in the study are 
still available. In addition, it’s important to know what proportion of families agree to 
take part. All of these things will help us design a successful full-scale study. 
 
Who is doing the research? 
The pilot study is being carried out by teams of scientists, nurses and hospital doctors 
from Manchester and Leeds. 
 
Why have you contacted me? 
We have contacted you because we are inviting you to take part in this study. The reason 
for choosing you is that you have a son or daughter who developed a type of bone tumour 
which we are studying.  
 
What does the study involve? 
If you agree to take part, we shall arrange to carry out an interview which generally takes  
about 1 hour. The research nurse who will carry out the interview will arrange a time and 
place which is convenient for you.  
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If I agree what sort of questions will I be asked? 
At the interview you will be asked about your son’s/daughter’s and your family’s health 
including: illnesses and injuries, your occupations and where you have lived and any 
sports or other activities your son/daughter has taken part in. We shall also ask about your 
son’s/daughter’s growth and development including adolescence. For mothers, we shall 
ask about the pregnancy with your child who developed the bone tumour and other 
pregnancies (if any). You can choose not to answer any of the questions. 
 
Do you need any other information ? 
With your permission we should like to have access to certain medical records. These 
include your child’s oncology records so that we can extract details about the particular 
type of bone tumour which they developed. We should also like access to your child’s 
general health records so that we can extract information about their growth and 
development, including height and weight at different ages and their developmental 
milestones. For mother’s, we should like to extract information from their obstetric 
records including results of scans of the baby before birth, results of mother’s blood tests 
and details of any problems during pregnancy e.g. high blood pressure. We should also 
like to record the baby’s birth weight, size, general condition and any problems shortly 
after birth. 
 
Does the study involve anything else ? 
If you agree, we would like a small blood sample or saliva (spit) sample from you and 
your son/daughter. The blood sample from your son/daughter will be taken by their 
doctor at the same time as a routine sample is taken. 
 
Why do you need a blood or saliva sample from me and my son/daughter ? 
You can take part in the study without giving blood or a saliva sample but if you agree, 
the research nurse or hospital clinic staff will take the samples. Between 5 and 20ml (1-4 
teaspoons) of blood will be taken for the research. Alternatively, you and/or your 
son/daughter could give a saliva sample by spitting into a small pot. For young children, 
saliva samples are collected by placing tiny sponges in the child’s mouth between the 
gums and the inner cheek.  The sponges are gently moved around for about half a minute 
to soak up as much saliva as possible.  The blood and saliva samples will be used to 
extract genetic material to look for variations in genes which may affect the likelihood of 
developing bone tumours.  
 
What will happen to the samples ? 
The material will be stored at the University of Manchester and will be used for future 
analysis. The blood/saliva samples will be considered as being gifted to the University 
and you will have no rights over any commercial developments arising from their use in 
research. 
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Will I find out the results on my or my son’s/daughter’s blood or saliva sample? 
No. Results on samples donated for research will not be given to participants nor to their 
families and will not be passed on to their doctors or anybody else. The tests that will be 
carried out are not medical tests and the results will only be used for research. So, taking 
part in the study should not have any adverse effects on you or your son/daughter 
(including employment status or ability to get insurance). 
 
Who will have access to the information ? 
Only a very restricted number of staff directly working on the project will have access to 
information collected in the study. NHS and/or University staff responsible for auditing 
research conduct and data security, will also have limited access for this purpose. All 
staff are trained in confidentiality procedures. 
 
Can I have access to the information ? 
Yes. You have a right to see all the information collected at interview and extracted from 
medical records which concerns you and held by us. 
 
What will happen if I do not want to take part in the research? 
Nothing. This research is entirely voluntary and this will NOT affect your or your 
son’s/daughter’s medical care in any way. 
 
How do we know if your work is ethical? 
All our research is carried out with the approval of medical research ethics committees. 
The members of these committees include doctors, health professionals and lay people. 
 
What should I do now? 
Please return the reply slip in the envelope provided. If you are willing, one of our 
research nurses will contact you to arrange an interview. 
 
How can I find out more about the study? 
For advice or information relating to the study contact: 
Professor Jillian M. Birch 
Cancer Research UK Research Group, 
School of Cancer & Imaging Sciences 
The Medical School, Stopford Building, Room 1.900 
University of Manchester, Oxford Road 
Manchester M13 9PL 
TEL: 0161-275-5404 
FAX: 0161-275-5348 
EMAIL: jillian.birch@manchester.ac.uk 
OR 
Dr R.G.Feltbower 
Centre for Epidemiology & Biostatistics 
Paediatric Epidemiology Group, Room 8.49J, Level 8 
Worsley Building, University of Leeds 
Clarendon Way, Leeds LS2 9JT 
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TEL/FAX: 0113 343 4841/4877 
EMAIL: r.g.feltbower@leeds.ac.uk 
 
OR: Talk to a member of your clinical team at your hospital or clinic. 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. If they are unable to resolve 
your concern, or you wish to make a complaint regarding the study, please contact a 
University Research Practice and Governance Co-ordinator on 0161 275 7583 or 0161 
275 8093 or by email to research-governance@manchester.ac.uk 
 
How can I find out more about bone tumours in children, teenagers and young 
adults? 
The following organizations provide information 
Bone Cancer Research Trust  Children’s Cancer & Leukaemia Group  
Suite 1d, Gledhow Mount Mansion  University of Leicester, 3rd floor, Hearts of  
Roxholme Grove, Leeds, LS7 4JJ  Oak House, 9 Princess Road West, 
TEL: 0113 262 1852    Leicester LE1 6TH 
EMAIL: info@bonecancerresearch.org.uk Tel: 0116 249 4460.Email:info@cclg.org.uk 
WEBPAGE: www.bonecancerresearch.org.uk  WEBPAGE: www.cclg.org.uk 
 
Teenage Cancer Trust   Cancer Research UK 
3rd Floor, 93 Newman Street,   PO Box 123, Lincoln’s Inn Fields 
London, W1T 3EZ    London WC2A 3PX 
TEL: 020 7612 0370    TEL: 020 7242 0200 
EMAIL: tct@teenagecancertrust.org.  WEBPAGE: www.cancerresearchuk.org 
WEBPAGE: www.teenagecancertrust.org 
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CTYAB/CFPts 12-15 
 
Version 2  Aug 09 
 
 
 
Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Consent Form for Patients aged 12-15 years 
 
Researchers: Professor Jillian Birch and Dr Richard Feltbower  
This form should be completed by patients aged 12 years to 15 years. 
You will be given a copy of the information leaflet and a copy of this form to keep. 
 
Name of Patient …………………………………  Date of Birth of Patient ……………………… 
 
Hospital/Clinic …………………………………………………………………………………….. 
 
Please read and complete the following: 
 
I have read and understood the information contained in the information leaflet  
 
I have had the opportunity to ask questions and have received satisfactory answers to my questions. 
 
I understand that participation is voluntary and I am free to withdraw my agreement at any time 
without having to give a reason and without affecting my treatment. 
 
I agree to my mother/father/guardian(s)* being interviewed for the above study and understand that the 
information they give will be for confidential use in the study and future studies of childhood teenage 
and young adult bone tumours. 
 
I agree to my medical notes, including; GP/oncology/child health/neonatal* being viewed by a member 
of the research team and to information being extracted from them. 
 
I understand that the information from my medical notes containing clinical and personal information 
(including NHS number, addresses and post codes) will be held securely and confidentially by the 
research team for use in the study and future studies of childhood, teenage and young adult bone 
tumours. 
 
I understand that relevant sections of my medical notes and data collected during the study may be 
looked at by individuals from The University of Manchester, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
I agree to give a blood/saliva sample* for use in the study and future studies into childhood, teenage 
and young adult bone tumours. 
 
 
I understand that I will not be given the results from the blood samples or saliva samples. 
Initials 
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Patient signature aged 12-15 years 
 
Signature………………………………………….. 
 
Full name (block capitals) ……………………………………….   Date ………………………. 
 
Doctor/researcher taking consent 
 
Signature ………………………………….. Full name (block capitals) …………………………. 
 
Position ……………………………………. Date …………………………. 
Please return this form to: Professor J M Birch, Cancer Research UK Research Group, 
School of Cancer & Imaging Sciences, The Medical School, Stopford Building, Room 1.900 
University of Manchester, Oxford Road, Manchester M13 9PL  
* Delete as necessary 
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CTYAB/CF par 16+ 
Version 2  Aug 09 
 
 
 
 
 
Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Consent Form for Parents/Guardians of Patients over 16 years of age. 
 
Researchers: Professor Jillian Birch and Dr Richard Feltbower 
This form should be completed by the parent/guardian of patients who are over 16 years of age. You 
will be given a copy of the information leaflet and a copy of this form to keep. 
 
Name of Patient …………………………………  Date of Birth of Patient ……………………… 
 
Hospital/Clinic/GP …………………………………………………………………………………….. 
 
Please read and complete the following:       
           
 
I have read and understood the information contained in the information leaflet  
 
I have had the opportunity to ask questions and have received satisfactory answers to my questions. 
 
I understand that participation is voluntary and I am free to withdraw my agreement at any time 
without having to give a reason and without affecting my child’s treatment. 
 
I agree to be interviewed for the above study and understand that the information I give will be for 
confidential use in the study and in future studies of childhood, adolescent and young adult bone 
tumours. 
 
I agree to my medical notes, including; GP/obstetric* being viewed by a member of the research team 
and to information being extracted from them. 
 
I understand that the information from my medical notes containing clinical and personal information 
(including NHS number, addresses and post codes) will be held securely and confidentially by the 
research team for use in the study and future studies of childhood, adolescent and young adult bone 
tumours. 
 
I understand that relevant sections of my medical notes and data collected during the study may be 
looked at by individuals from The University of Manchester, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
I agree to give a blood/saliva sample* for use in the study and future studies into childhood, teenage 
and young adult bone tumours. 
 
I understand that I will not be given the results from the blood samples or saliva samples. 
 
Initials 
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Parent/Guardian signature of child over 16 years 
 
Signature………………………………………….. 
 
Full name (block capitals) ……………………………………….   Date ………………………. 
 
Doctor/researcher taking consent 
 
Signature ………………………………….. Full name (block capitals) …………………………. 
 
Position ……………………………………. Date …………………………. 
Please return this form to: Professor J M Birch, Cancer Research UK Research Group,  
School of Cancer & Imaging Sciences, The Medical School, Stopford Building, Room 1.900, 
University of Manchester, Oxford Road, Manchester M13 9PL 
 
* Delete as necessary 
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CTYAB/CF par under 16 
Version 2  Aug 09 
 
 
 
 
 
 
Pilot Study of Childhood, Teenage & Young Adult Bone Tumours 
 
Consent Form for Parents/Guardians of Patients under 16 years of age. 
                                                    
Researchers: Professor Jillian Birch and Dr Richard Feltbower  
This form should be completed by the parent/guardian of patients who are under 16 years of age. You 
will be given a copy of the information leaflet and a copy of this form to keep. 
 
Name of Patient …………………………………  Date of Birth of Patient ……………………… 
 
Hospital/Clinic…………………………………………………………………………………….. 
 
Please read and complete the following: 
 
I have read and understood the information contained in the information leaflet  
 
I have had the opportunity to ask questions and have received satisfactory answers to my questions. 
 
I understand that participation is voluntary and I am free to withdraw my agreement at any time 
without having to give a reason and without affecting my child’s treatment. 
 
I agree to be interviewed for the above study and understand that the information I give will be for 
confidential use in the study and future studies of childhood, teenage and young adult bone tumours. 
 
I agree to my medical notes, including; GP/obstetric* being viewed by a member of the research team 
and to information being extracted from them. 
 
I agree to my child’s medical notes, including; GP/oncology/child health/neonatal* being viewed by a 
member of the research team and to information being extracted from them. 
                                                                                                                                                                           
I understand that the information from my and my child’s medical notes containing clinical and 
personal information (including NHS number, addresses and post codes) will be held securely and 
confidentially by the research team for use in the study and future studies of childhood, teenage and 
young adult bone tumours. 
 
I understand that relevant sections of my medical notes and data collected during the study may be 
looked at by individuals from The University of Manchester, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
I agree that a blood/saliva sample* may be taken from my child for use in this study and for future 
studies into child, teenage and young adult bone tumours. 
 
I agree to give a blood/saliva sample* for use in the study and future studies into child, teenage and 
young adult bone tumours. 
 
Initials 
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I understand that I will not be given the results from any of the blood samples or saliva samples.                
 
 
Parent/guardian signature of child under 16 years 
 
Signature………………………………………….. 
 
Full name (block capitals) ……………………………………….   Date ………………………. 
 
Doctor/researcher taking consent 
 
Signature ………………………………….. Full name (block capitals) …………………………. 
 
Position ……………………………………. Date …………………………. 
Please return this form to: Professor J M Birch, Cancer Research UK Research Group, 
School of Cancer & Imaging Sciences, The Medical School, Stopford Building, Room 1.900, 
University of Manchester, Oxford Road, Manchester M13 9PL 
* Delete as necessary 
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Family ID 
ID No: 
Study ID 
                                    Index Case (16 to 24 Years) Questionnaire 
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Family ID 
ID No: 
Study ID 
 
Personal Details 
 
Thank you for agreeing to help us with this study.  Most of the  
questions I am going to ask you are about your childhood 
and adolescence. 
                 
           Time Started        Hr                 Min 
                         (24 hr clock)   
Can I stress again that all your answers will be treated in the strictest confidence and the information 
will not be passed to anyone outside the study.  
 
Index Case                                    Sheet no. 
 
First Name____________________________________ Last Name_________________________________ Total Sheets  
Address 
at interview____________________________________________Date of Diagnosis 
_____________________________________________________ 
_____________________________________________________                                                                     Sex: 
 
 
Postcode    
 
Date of Birth 
 
NHS No. 
 
 
Mother (or Surrogate)                                         Parent I.D. 
 
First Name____________________________________ Last Name_________________________________Title_________                               
Current 
Address__________________________________________          All previous names______________________________ 
_________________________________________________  
_________________________________________________          Name when                                                        was born: 
Postcode    
 
 
NHS No. 
         
 
Father (or Surrogate)                                         Parent I.D. 
 
First Name____________________________________ Last Name_________________________________Title_________                                                                     
Current 
Address 
 
 
 
Postcode: 
 
NHS No. 
day month year 
day month year 
1=male 
2=female 
day month year 
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Family ID 
ID No: 
Study ID 
GP Details 
 
 
May I have (or confirm) the name and address of the GP you are currently registered with. 
 
 Name    _________________________________________________________________ 
 
               Address_________________________________________________________________ 
 
                             _________________________________________________________________ 
 
                             _________________________________________________________________ 
 
Postcode: 
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Family ID 
ID No: 
Study ID 
 
 Section I      General background    
 
 
 
May I ask you some general questions about yourself? 
 
  
 01. Would you currently describe yourself as                                                      circle  1=married/ 2=cohabiting/ 3=widowed 
                     4=separated/ 5=divorced/ 6=single? 
 
 
02. How would you describe yourself ? 
     
                                                circle 1=White/ 2=Black-Carribean / 3=Black-African/ 4=Black-‘Other’/ 5=Indian/ 6=Pakistani/ 
                                                                                               7=Bangladeshi/ 8=Chinese/ 9=any ‘other’ ethnic group. 
 
If other: 
 
How would you describe yourself ?_________________________________________________________  
 
                                   
 
03. Are you still at school?        1=yes/ 2=no 
 
04. (If appropriate) How old were you when you left school? 
 
 
 
 05. (If appropriate) Do you have any educational qualifications  such as 
 
                                                                          CSEs /’O’ Levels / ‘O’ Grades / GCSEs / or their equivalents ? 
 
      Highers / ‘A’ levels or their equivalents ? 
 
 
                                 Any higher or professional qualifications ? 
 
If yes: 
 What are these qualifications ?______________________________________________________________ _ 
 
          ______________________________________________________________ _ 
 
06. Do you own or rent your current home or do you live with your parents/siblings ?                                                   
         1=owner/  2=tenant/  3=parents/siblings/ 4=other/  9=NK 
 
 
 If other : specify___________________________________________________________________ 
 
   __________________________________________________________________ 
 
 
If tenant,  who do you rent it from?          1=council/  2=housing association/  3=private/  4=other/  9=NK 
 
 
 If other : specify___________________________________________________________________ 
 
   ___________________________________________________________________ 
 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
years 
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Family ID 
ID No: 
Study ID 
 
Section II                  Growth   
 
 
 
 
1. At what age did you enter infant school (Year 1)?       
      OR 
     When did you enter infant school (Year 1)?  
2. When you entered infant school (Year 1), compared to other  
       children in the same class, were you   1=Taller/ 2=Shorter/ 3=Average Height  
 
3. At what age did you enter junior school (Year 4)?       
      OR 
     When did you enter junior school (Year 4)?  
4. When you entered junior school (Year 4), compared to other  
       children in the same class, were you   1=Taller/ 2=Shorter/ 3=Average Height  
 
5. At what age did you enter secondary school (Year 7)?       
      OR 
     When did you enter secondary school (Year 7)?  
6. When you entered secondary school (Year 7), compared to other  
       children in the same class, were you   1=Taller/ 2=Shorter/ 3=Average Height  
 
7. At what age did you leave school?       
      OR 
     When did you leave school?   
8. When you left school, compared to other  
       children in the same class, were you   1=Taller/ 2=Shorter/ 3=Average Height  
 
9. What was  height at diagnosis 
       If not known ask Q10  
 
10. Around the time when you were diagnosed with a bone tumour, compared to other  
       children of same age, were you  1=Taller/ 2=Shorter/ 3=Average Height  
 
month year 
Years Mths 
month year 
Years Mths 
month year 
Years Mths 
month year 
Years Mths 
ft in cm 
OR 
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Family ID 
ID No: 
Study ID 
     Section III                  Puberty  
 
 
 
If Index case is FEMALE 
 
1. At what age did you notice any change in your breasts?  
  
2. At what age did you shoot up in height?     
      OR 
      At what age did you suddenly outgrow your clothes?  
      OR 
      At what age did you suddenly increase your shoe size?   
 
3. At what age did you start your periods?     
 
If the Index Case is MALE 
 
1. At what age did you shoot up in height?     
      OR 
      At what age did you suddenly outgrow your clothes?  
      OR 
      At what age did you suddenly increase your shoe size?   
 
2. At what age did you start shaving regularly > twice/week?         
       
3.   At what age did your voice change?     
 
 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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Family ID 
ID No: 
Study ID 
 
Section IV                  Sports/Exercise  
 
 
Which of the following sports or physical activities did you participate at any time prior to 
diagnosis? 
1. Swimming       1=Yes / 2=No    
2. Cycling       1=Yes / 2=No    
3. Horse Riding       1=Yes / 2=No  
4. Walking/Hiking > 2 miles     1=Yes / 2=No    
5. Running/Jogging/Cross-Country    1=Yes / 2=No   
6. Skiing/Snowboarding      1=Yes / 2=No    
7. Athletics       1=Yes / 2=No    
8. Aerobics/Dance Exercise     1=Yes / 2=No 
9.  Gymnastics       1=Yes / 2=No    
10. Martial Arts (Judo, Karate, etc.)     1=Yes / 2=No  
11. Street Sports (skate boarding, rollerblading, etc.)  1=Yes / 2=No    
12. Weight lifting or weight training    1=Yes / 2=No 
13. Football       1=Yes / 2=No 
14. Rugby        1=Yes / 2=No    
15. Cricket        1=Yes / 2=No 
16. Basketball       1=Yes / 2=No 
17. Netball        1=Yes / 2=No 
18.  Hockey       1=Yes / 2=No    
19. Tennis        1=Yes / 2=No   
20. Badminton       1=Yes / 2=No    
21. Squash        1=Yes / 2=No    
22. Others ________      1=Yes / 2=No   
23. Others ________      1=Yes / 2=No   
24. Others ________      1=Yes / 2=No  
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Family ID 
ID No: 
Study ID 
Section IV                  Sports/Exercise  
 
 
Please complete one for each sport recorded YES on previous page (attach extra sheets if necessary) 
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------- 
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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Family ID 
ID No: 
Study ID 
Section IV                  Sports/Exercise  
 
 
Please complete one for each sport recorded YES on previous page (attach extra sheets if necessary) 
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------- 
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
1. Sport/Physical Activity ___________________________________ 
2. At what age did you first start doing the sport/physical activity      
       
3. At what age did you stop doing the sport/physical activity (if applicable)    
        
4. How many times did you participate in the sport/physical activity in a typical 4 week period  
      
5. To what level did you participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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Family ID 
ID No: 
Study ID 
 
Section V      Social Habits  
 
I now have some questions about smoking 
                       
 01. Have you ever done any of the following 
 
  # Smoked at least 100 cigarettes in your life 
 
  # Smoked at least one cigar per week for 6 months or longer 
 
  # Smoked at least one pipe of tobacco per week for 6 months or longer 
 
 If yes, ask questions below; if no, go to next section 
  
                Cigarettes    Cigars           Pipe 
           Yrs      Yrs             Yrs 
 02.  How old were you when you started to smoke regularly?                                Age 
 
 03.  Do you still smoke now?       1=yes/2=no/ 9=NK 
 
 04. If no,         Yrs      Yrs             Yrs 
        How old were you when you stopped smoking?                                 Age 
 
  
 06. What about smoking prior to diagnosis? (Check all that apply until  age of diagnosis) 
           no.      no.             no. 
       On average how many did you smoke per day in the year before diagnosis 
 
           no.      no.             no. 
       On average how many did you smoke per day 2 years before diagnosis 
 
           no.      no.             no. 
       On average how many did you smoke per day 3 years before diagnosis 
 
           no.      no.             no. 
       On average how many did you smoke per day 4 years before diagnosis 
 
           no.      no.             no. 
       On average how many did you smoke per day 5 years before diagnosis 
 
           no.      no.             no. 
       On average how many did you smoke per day more than 5 years before diagnosis 
 
             
 . 
1=yes 
2=no 
9=NK 
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Family ID 
ID No: 
Study ID 
 
Section VI                  Illness history 
 
 
 
 
01. Did you ever have any of the following infections (prior to diagnosis), and if so, can you remember when? 
                                                  Date of diagnosis of tumour: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consult 
GP 
1=yes 
2=no 
9=NK 
  Month                  Year 
 
Consult 
GP 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
If ‘yes’, when If ‘yes’, when 
Measles 
Mumps 
German Measles 
Chicken Pox 
Shingles 
Whooping Cough 
Pneumonia 
Glandular Fever 
Meningitis 
Cold sores / Herpes 
 
 
  Month                  Year 
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Family ID 
ID No: 
Study ID 
Section VI                  Illness history  
 
 
 
Do you have, or have you ever had any of the following ? 
 
 
 
 
                     Diabetes  01  
 
 
                                                  Asthma  02 
 
 
                           Eczema or other chronic skin conditions e.g. psoriasis  03 
 
 
   Congenital abnormalities/syndromes   04 
                     
 
               Other neoplasms (inc.benign)  05 
                     before or since diagnosis 
 
              Hernias 06 
 
 
                Fractures  07  
 
 
     Any Bony conditions (including metallic/prosthetic implants) 08 
 
      
      Other Conditions requiring regular  09 
                    visits to clinics or hospital 
 
 
 
 
 Total illness records following 
 
1=yes 
2=no 
9=NK 
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Family ID 
ID No: 
Study ID 
 
Section VI               Illness history    
 
 
Please complete one for each illness recorded on Page 180  (attach extra sheets as necessary) 
May I have more details of these illnesses ? 
 
          illness no.  ICD-10 
 
01..Condition_____________________________________________________ 
 
               Month                    Year           Years          Months 
02. When was it first diagnosed ?                         date                   or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate).  If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
        Hospital code 
 
 
 
          illness no.  ICD-10 
 
01. Condition_____________________________________________________ 
 
               Month                     Year           Years          Months 
02. When was it first diagnosed ?                          date     or age 
 
 
          
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
      _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code 
 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
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Family ID 
ID No: 
Study ID 
Section VI    Illness history    
 
 
Please complete one for each illness recorded on Page 180 (attach extra sheets as necessary) 
May I have more details of these illnesses ? 
 
          illness no.  ICD-10 
 
01..Condition_____________________________________________________ 
              Month                    Year           Years          Months 
02. When was it first diagnosed ?                          date                   or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code: 
 
 
 
          illness no.  ICD-10 
 
01. Condition_______________________________________________________ 
 
               Month                     Year           Years          Months 
02. When was it first diagnosed ?                          date     or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code 
 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
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Family ID 
ID No: 
Study ID 
 
Section VII    Further information 
 
 
 
 
Is there anything else you would like to tell me about  
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
Do you have any comments on this interview? (This may help in the design of studies in the future)
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
             
                                                                                                                                                                                                                                1 = yes 
May we have permission to contact you if we need further information or to resolve any queries?                            2 = no 
                                                                                                                                                                                                                                 9 = NK 
 
 
  Home telephone or mobile number: 
                        
 
 
                                                                                                                                                                                   hours             mins 
                                                     
Thank you for your help and co-operation in this interview.   Time completed: 
 
 
 
Interview conducted by: 
 
 
Place of Interview           Home                  Clinic          Other _________________ 
 
 
Mode of Interview           Face to Face       Phone          Other _________________ 
 
 
Samples Taken           Blood  Date _________________ 
 
             Saliva  Date _________________ 
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ID No: 
Study ID Family ID Person ID 
                                     Parent’s Questionnaire 
 
 
 
 Section                                                                       Page 
 
 - Personal Details      185 
 
 - GP Details       186 
 
 I General Background     187 
 
 II Employment History     189 
 
 III General Health      191 
 
 IV Social Habits      195 
 
 V Reproductive History   (mother only)   196 
 
 VI Index Pregnancy   (mother only)   200 
 
 VII Index Case          202 
 
 VIII Family Illnesses      215 
 
 IX Family History      219 
 
 X Further information     224 
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ID No: 
Study ID Family ID Person ID 
 
Personal Details 
 
Thank you for agreeing to help us with this study.  Most of the  
questions I am going to ask you are about your life, work and 
health,  and about …………….’s childhood and adolescence.      
                 
           Time Started        Hr                 Min 
                         (24 hr clock) 
Can I stress again that all your answers will be treated in the strictest confidence and the information 
will not be passed to anyone outside the study.  
 
Index Case                                    Sheet no. 
 
First Name____________________________________ Last Name_________________________________ Total Sheets  
Address 
at interview____________________________________________Date of Diagnosis 
_____________________________________________________ 
_____________________________________________________                                                                     Sex: 
 
 
Postcode    
 
Date of Birth 
 
NHS No. 
 
 
Mother (or Surrogate)                                         Parent I.D. 
 
First Name____________________________________ Last Name_________________________________Title_________                                                                     
Current 
Address__________________________________________          All previous names______________________________ 
_________________________________________________  
_________________________________________________          Name when                                                        was born: 
Postcode    
 
 
NHS No. 
 
Father (or Surrogate)                                         Parent I.D. 
 
First Name____________________________________ Last Name_________________________________Title_________                                                         
Current 
Address 
 
 
 
Postcode: 
 
NHS No. 
day month year 
day month year 
1=male 
2=female 
day month year 
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ID No: 
Study ID Family ID Person ID 
GP Details 
 
 
May I have (or confirm) the name and address of the GP you are currently registered with. 
 
 Name    _________________________________________________________________ 
 
               Address_________________________________________________________________ 
 
                             _________________________________________________________________ 
 
                             _________________________________________________________________ 
 
Postcode: 
 
 is ……………………………………registered with the same GP?          1  = Yes 
                     2  = No 
 
 
 If   NO: 
 Name    _________________________________________________________________ 
 
 Address _________________________________________________________________ 
 
               _________________________________________________________________ 
 
               _________________________________________________________________ 
 
 Postcode: 
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ID No: 
Study ID Family ID Person ID 
 
Section I      General background    
 
 
 
 1a) So that I can make this interview as short as possible and collect the right information 
       may I ask if you are the natural mother/father of   ………………………………………...? 
 
 
 
 
 
 
1b)If no:  then ask      When did ………………………first live with you  ? 
 
 
 
 
 
If mother/father is not the biological parent limited questions to be asked: see separate instructions (Appendix A) 
 
 
2a) Has …………………….  ever lived away from you for longer than six months? 
 
If Yes  : 
 
 
 
 2b)   Why was this_____________________________________________________________     
 
 
Please could you tell me when this was? 
 
 
 
 
 
 
 
 
 
 
 2b)   Why was this_____________________________________________________________     
 
 
 Please could you tell me when this was? 
 
 
 
 
 
 
 
 
Total number of times  away
     Date 
 
       Or 
 
Child’s age 
 
month year 
years months 
1=yes 
2=no 
9=NK 
age 
month year years months 
date or 
from 
age 
month year years months 
date or 
to 
age 
month year years months 
date or 
from 
age 
month year years months 
date or 
to 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 Section I      General background    
 
 
 
May I ask you some general questions about yourself? 
 
 03. What is your date of birth ? 
 
 
 04. Would you currently describe yourself as                                                      circle  1=married/ 2=cohabiting/ 3=widowed 
                     4=separated/ 5=divorced/ 6=single? 
 
 
05. How would you describe yourself ? 
     
                                                circle 1=White/ 2=Black-Carribean / 3=Black-African/ 4=Black-‘Other’/ 5=Indian/ 6=Pakistani/ 
                                                                                               7=Bangladeshi/ 8=Chinese/ 9=any ‘other’ ethnic group. 
 
If other: 
 
How would you describe yourself ?_________________________________________________________  
 
              years                    
 
06. How old were you when you left school? 
 
 
 
 
 
 07. Do you have any educational qualifications  such as 
 
                                                                          CSEs /’O’ Levels / ‘O’ Grades / GCSEs / or their equivalents ? 
 
      Highers / ‘A’ levels or their equivalents ? 
 
 
                                 Any higher or professional qualifications ? 
 
If yes: 
 What are these qualifications ?______________________________________________________________ _ 
 
          ______________________________________________________________ _ 
 
08. Do you own or rent your current home ?                                                   1=owner/  2=tenant/  3=other/  9=NK 
 
 
 If other : specify___________________________________________________________________ 
 
   __________________________________________________________________ 
 
 
If tenant,  who do you rent it from?          1=council/  2=housing association/  3=private/  4=other/  9=NK 
 
 
 If other : specify___________________________________________________________________ 
 
   ___________________________________________________________________ 
 
month year day 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
Section II     Employment History    
 
 
 
Please go through the employment section of the pre-interview questionnaire (Appendix B), confirm 
jobs and dates recorded, and correct where necessary.  Show card listing exposures as below. 
 
Then ask the following about each job in turn. 
 
 
I would like to ask you some more details about each of your jobs 
 
Did your job as _________________ ever involve you in handling or being exposed to: 
 
Show prompt card and code answers on the pre-interview questionnaire 
 
 
 
 None 0 
 
 Solvents, degreasers or cleaning agents such as benzene, toluene or carbon tetrachloride? 1 
 
 Paints, lacquers, paint removers, turpentine products or thinners? 2 
 
 Dyes or pigments? 3 
 
 Petrol, petroleum products or paraffin? 4 
 
 Lead or compounds containing lead? 5 
 
 Fertilizers? 6 
 
  Pesticides, fungicides or herbicides? 7 
 
 Radioactive materials, X Rays or any other kind of ionizing radiation? 8 
 
 Wood dust/Sawdust (including MDF)? 9 
 
 Farm Animals/ Poultry? 10 
 
 Unknown? 11 
 
 
 
Fill in after interview 
 
Section II     Employment History    Mother/father Detail  Number of sheets 
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ID No: 
Study ID Family ID Person ID 
Section II     Employment History    Exposure Record Page: 
 
 
To be completed for any job where an exposure is reported.  Fill in after interview 
Complete record for each exposure.    Total number of job exposures  
                         
01. Do you remember the names of the materials involved? (specify) _________________ Job No. 
 
____________________________________________________________   Exp. No.  
 
 
02. Did you yourself work with _______________________________ (as above)?        1=Yes  2=No  9=NK 
 
03. Please can you describe in detail your contact with _______________________________ (as above)?                
_________________________________________________________________________________ 
       _________________________________________________________________________________ 
       _________________________________________________________________________________ 
       _________________________________________________________________________________ 
      
04. Over what period was this? Date from   to  
 
    Or Age    to 
 
 
 If exposure was to ionizing radiation: 
05. During this time were you monitored for exposure to radiation?   1=Yes  2=No  9=NK 
 
        If ye:, how  Circle 1=film badge/ 2= blood tests/ 3=film badge & blood tests/ 4=other/ 9=NK 
        If other: specify __________________________________________________________________ 
 
  
                         
01. Do you remember the names of the materials involved? (specify) _________________ Job No. 
 
____________________________________________________________   Exp. No.  
 
 
02. Did you yourself work with _______________________________ (as above)?        1=Yes  2=No  9=NK 
 
03. Please can you describe in detail your contact with _______________________________ (as above)?                
_________________________________________________________________________________ 
       _________________________________________________________________________________ 
       _________________________________________________________________________________ 
       _________________________________________________________________________________ 
      
04. Over what period was this? Date from   to  
 
    Or Age    to 
 
 
 If exposure was to ionizing radiation: 
05. During this time were you monitored for exposure to radiation?   1=Yes  2=No  9=NK 
 
        If ye:, how  Circle 1=film badge/ 2= blood tests/ 3=film badge & blood tests/ 4=other/ 9=NK 
        If other: specify __________________________________________________________________ 
  
month year month year 
years months years months 
month year month year 
years months years months 
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ID No: 
Study ID Family ID Person ID 
Section III      General health                        
 
 
 
 
1. What is your height?   
 
 
 
 If Respondent is Mother 
 
 
2. At what age did you start your periods?     
  
 If Respondent is Father 
 
 
3. At what age did you start shaving regularly > twice/week?     
 
 
4. At what age did your voice change?     
ft in cm 
OR 
Years Mths 
Years Mths 
Years Mths 
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ID No: 
Study ID Family ID Person ID 
 
Section III      General health                        Illnesses  
 
 
 
Do you or have you ever suffered from any of the following illnesses?: 
 
 
 
 
                                                                      Diabetes  1 
 
                                                         Thyroid disease  2 
 
                                               Rheumatoid  arthritis  3 
 
                                                                        Asthma  4 
 
                                                                     Epilepsy  5 
 
                                        Leukaemia or Lymphoma  6 
 
                         Other cancer or malignant tumour  7 
 
                                                           Benign tumour  8 
 
                                                     Hereditary disease  9 
 
                                            Congenital abnormality 10 
 
                                                           Chronic illness 11 
 
 
If ‘yes’ to any of above, please complete a record for each condition 
And enter the total number of illnesses below. 
 
                               Total number of illness records to follow: 
 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section III      General health                        Illnesses  
 
Please complete for each illness listed on the previous page  (attach extra sheets if necessary). 
                        Illness no.    ICD-10 
 01. Condition?________________________________________________________ 
 
 
02. What treatment did you have ?_______________________________________ _ 
 
03.  Can you remember the date this condition began ?                  date 
 
 or:         or   
 
  How old were you ?       age 
 
 
 04. Were you treated : 
                                                                                              1=as a hospital in patient/ 2=as an outpatient/  3=by your GP/ 4=other/ 9=NK 
 
  if other:   Specify______________________________________________________________ 
05. Which hospital did you attend when the treatment began  (if appropriate ) ? 
 
Name________________________________________________________________________________ 
 
Address______________________________________________________________________________ 
 
 ____________________________________________________________________________________ 
 
 
Who was the consultant ( if appropriate) ?____________________________     Hospital code  
 
  
                     Illness no.    ICD-10 
 01. Condition?________________________________________________________ 
 
 
02. What treatment did you have ?_______________________________________ _ 
 
03.  Can you remember the date this condition began ?                              date 
 
 or:         or   
 
 How old were you ?       age 
           
 04. Were you treated : 
                                                                                                  1=as a hospital in patient/ 2=as an outpatient/  3=by your GP/ 4=other/ 9=NK 
 
  if other:   Specify______________________________________________________________ 
05. Which hospital did you attend when the treatment began  (if appropriate ) ? 
 
Name________________________________________________________________________________ 
 
Address______________________________________________________________________________ 
 
 ____________________________________________________________________________________ 
 
 
Who was the consultant ( if appropriate) ?____________________________    Hospital code  
 . 
month year 
years months 
month year 
years months 
 . 
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ID No: 
Study ID Family ID Person ID 
Section III      General health                        Illnesses  
 
 
Please complete for each illness listed on the previous page  (attach extra sheets if necessary). 
                        Illness no.    ICD-10 
 01. Condition?________________________________________________________ 
 
 
02. What treatment did you have ?_______________________________________ _ 
 
03.  Can you remember the date this condition began ?                              date 
 
 or:         or   
 
  How old were you ?       age 
           
 
 04. Were you treated : 
                                                                                               1=as a hospital in patient/ 2=as an outpatient/  3=by your GP/ 4=other/ 9=NK 
 
  if other:   Specify______________________________________________________________ 
05.Which hospital did you attend when the treatment began  (if appropriate ) ? 
 
Name________________________________________________________________________________ 
 
Address______________________________________________________________________________ 
 
  ____________________________________________________________________________________ 
 
 
Who was the consultant ( if appropriate) ?____________________________   Hospital code  
 
  
                     Illness no.    ICD-10 
 01. Condition?________________________________________________________ 
 
 
02. What treatment did you have ?_______________________________________ _ 
 
03.  Can you remember the date this condition began ?                              date 
 
 or:         or   
 
 How old were you ?       age 
           
 04. Were you treated : 
                                                                                               1=as a hospital in patient/ 2=as an outpatient/  3=by your GP/ 4=other/ 9=NK 
 
  if other:   Specify______________________________________________________________ 
05.Which hospital did you attend when the treatment began  (if appropriate ) ? 
 
Name________________________________________________________________________________ 
 
Address______________________________________________________________________________ 
 
  ____________________________________________________________________________________ 
 
 
Who was the consultant ( if appropriate) ?____________________________   Hospital code 
 . 
month year 
years months 
month year 
years months 
 . 
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ID No: 
Study ID Family ID Person ID 
Section IV      Social Habits 
 I now have some questions about smoking 
 01. Have you ever done any of the following 
 
  # Smoked at least 100 cigarettes in your life 
 
  # Smoked at least one cigar per week for 6 months or longer 
 
  # Smoked at least one pipe of tobacco per week for 6 months or longer 
 
 If yes, ask questions below; if no, go to next section 
  
                Cigarettes    Cigars           Pipe 
           Yrs      Yrs             Yrs 
 02.  How old were you when you started to smoke regularly?                                Age 
 
 03.  Do you still smoke now?       1=yes/2=no/ 9=NK 
 
 04. If no,         Yrs      Yrs             Yrs 
        How old were you when you stopped smoking?                                 Age 
 
 05. What about during the one year before ________________________ was born? 
           no.      no.             no. 
       On average how many did you smoke per day? 
 
 
 06. What about during the pregnancy - On average how many did you smoke per day? 
           no.      no.             no. 
 Before you knew you were pregnant 
 
           no.      no.             no. 
 During 1st trimester (after mother knew she was pregnant) 
 
           no.      no.             no. 
 During 2nd trimester 
 
           no.      no.             no. 
 During 3rd trimester 
 
            
 07. What about after ________________________ was born? (Check all that apply until____________ age of diagnosis) 
           no.      no.             no. 
On average how many did you smoke per day when ______________ <12 mths of age 
 
           no.      no.             no. 
On average how many did you smoke per day when ______________ 1 -4 years of age 
 
           no.      no.             no. 
 On average how many did you smoke per day when ______________ 5-9 years of age 
 
           no.      no.             no. 
On average how many did you smoke per day when ______________ 10-14 years of age 
 
           no.      no.             no. 
On average how many did you smoke per day when ______________ 15-19 years of age 
 
           no.      no.             no. 
On average how many did you smoke per day when ______________  20-24 years of age 
       
 . 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
Section V                              Reproductive  History (mother only) 
 
 Now, I would like to ask a few questions about all your pregnancies, including any ectopics, miscarriages, stillbirths 
              and terminations, starting with the first.  
 
01.  Initials 
 
02.  ID of Pregnancy 
03. When did the 
        pregnancy end? 
 
04. How many weeks did  
        the pregnancy last? 
 
05. Was this a:  
 
(Miscarriage = <20 wks 
 stillbirth = 20+ wks) 
 
 
06. How was the  
      baby delivered?  
      (if appropriate) 
 
 
 
07. What sex was the  
        baby? 
 
 
08. What was the baby’s 
       birthweight? 
 
 
09. Did this baby have  
       the same father as 
         ………………….? 
 
10.Was there anything 
   wrong with the baby 
   noted during pregnancy? 
If ‘yes’ please detail p 15 
11.Was there anything 
   wrong  with the baby 
   noted shortly after birth? 
If ‘yes’ please detail p 15 
 
12. Is he/she alive and 
      well?(Do not ask for 
       index child) 
 
13 If ‘no’: date of death 
 
 
14.  Cause of death 
 
15. Place of death (town) 
 
 
P P P 
1=yes 
2=no 
9=NK 
Weeks 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6=hydatid mole 
 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6= hydatid mole 
 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6=hydatid mole 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=male 
2=female 
9=NK 
1=male 
2=female 
9=NK 
1=male 
2=female 
9=NK 
lbs oz 
Gms 
lbs oz 
Gms 
lbs oz 
Gms 
month year day month year day month year day 
month year 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
month year month year 
Weeks Weeks 
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ID No: 
Study ID Family ID Person ID 
Section V                              Reproductive  History (mother only) 
 
 Continued from page 196.  (attach extra sheets if necessary) 
  
01.  Initials 
 
02.  ID of Pregnancy 
03. When did the 
        pregnancy end? 
 
04. How many weeks did  
        the pregnancy last? 
 
05. Was this a:  
 
(Miscarriage = <20 wks 
 stillbirth = 20+ wks) 
 
 
06. How was the  
      baby delivered?  
      (if appropriate) 
 
 
 
07. What sex was the  
        baby? 
 
 
08. What was the baby’s 
       birthweight? 
 
 
09. Did this baby have  
       the same father as 
         ………………….? 
 
10. Was there anything 
   wrong with the baby 
   noted during pregnancy? 
If ‘yes’ please detail p 15 
11. Was there anything 
   wrong  with the baby 
   noted shortly after birth? 
If ‘yes’ please detail p 15 
 
12. Is he/she alive and 
      well?(Do not ask for 
       index child) 
 
13. If ‘no’: date of death 
 
 
14. Cause of death 
 
15. Place of death (town) 
 
 
 
P P P 
1=yes 
2=no 
9=NK 
Weeks 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6=hydatid mole 
 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6=hydatid mole 
 
1=live birth 
2=miscarriage 
3=still birth 
4=termination/abortion 
5=ectopic 
6=hydatid mole 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=normal 
2=assisted 
3=caesarean 
9=not known 
 
1=male 
2=female 
9=NK 
1=male 
2=female 
9=NK 
1=male 
2=female 
9=NK 
lbs oz 
Gms 
lbs oz 
Gms 
lbs oz 
Gms 
month year day month year day month year day 
month year 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
month year month year 
Weeks Weeks 
                                                                                         
 
 
___________________________________________________________________________________________________________________________________ 
 198
ID No: 
Study ID Family ID Person ID 
Section V                              Reproductive  History (mother only) 
 
FURTHER DETAILS:           (attach extra sheets if necessary) 
 
Please identify if additional details refer to Q10(during pregnancy) or Q11(shortly after birth) on Pages 196/197. 
 
 
 
 
Q10/11  Details         ICD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q10/11  Details         ICD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P Pregnancy Number 
P Pregnancy Number 
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ID No: 
Study ID Family ID Person ID 
Section V                              Reproductive  History (mother only) 
 
FURTHER DETAILS:           (attach extra sheets if necessary) 
 
Please identify if additional details refer to Q10(during pregnancy) or Q11(shortly after birth) on Pages 196/197. 
 
 
 
 
Q10/11  Details         ICD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q10/11  Details         ICD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P Pregnancy Number 
P Pregnancy Number 
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ID No: 
Study ID Family ID Person ID 
 
Section VI                                Index Pregnancy (mother only)  Illnesses  
 
 
I would like to ask you now in more detail about your pregnancy with……………………………….….. 
 
 
01.  What type of antenatal care did you have ?                1=hospital/ 2=shared/  3=G.P./   4=none/ 5=other/  9=NK 
 
if other: specify ______________________________________ 
 
02. Which GP and consultant looked after you during your pregnancy? 
 
 
GP _________________________________________         Consultant______________________________ 
 
Address______________________________________  Hospital________________________________ 
 
            _______________________________________   ________________________________ 
 
        Hospital code 
03. At any time during the pregnancy were you admitted to hospital for any reason  
      including an emergency admission 24 hours before delivery ?                                              
 
If no:  go to Page 18 
If yes: complete for each admission 
 
 
i)Why was this ?______________________________________________________________ 
 
ii) When was this (weeks since LMP) ?                 from week      to week 
 
iii)Which hospital ? __________________________________________________________________ 
 
iv)Who was the consultant ? ________________________________________ Hospital code 
 
 
 
 
i) Why was this ?_______________________________________________________________ 
 
ii) When was this (weeks since LMP) ?                 from week              to week 
 
iii) Which hospital ? __________________________________________________________________ 
 
iv)Who was the consultant ? _______________________________________   Hospital code 
 
 
 
                    Total number of admissions  
 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section VI                               Index Pregnancy (mother only)  Illnesses  
 
 
01. We are interested in illnesses which you may have had during your pregnancy with…………………………………. 
       Did you have any of the following? 
                                                                 Weeks of pregnancy since last LMP                                 Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
02. During your pregnancy did you have any other illnesses or conditions requiring visits to your doctor? 
If yes: 
 
 What was wrong?_____________________________________________________________ 
 
 When was this (weeks since LMP)?_______________________________________________     from week 
 
                        to week 
 
 What treatment did you have? ____________________________________________________  
             
 
 
What was wrong?_____________________________________________________________ 
 
 When was this (weeks since LMP)?_______________________________________________     from week 
 
                        to week 
 
 What treatment did you have? ____________________________________________________  
             
German measles 
Measles 
Shingles 
Chickenpox 
Glandular fever 
Mumps 
Pneumonia 
Influenza 
Cystitis or 
Kidney infections 
Any other infection 
(Please specify) 
From week To week To week From week 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section VII                  Index Case       Neo-natal history 
 
 
I would like to ask you about ……………………………….’s. Birth and early childhood. 
 
01. Where was ………………………….… born                                1=hospital / 2 = GP unit / 3=Home/ 4= other 
 
                  If other : specify___________________________________________________________________ 
 
 Name  (Hospital/ GP Unit )  _____________________________________ 
  
 Address(Hospital/ GP Unit ) _____________________________________ 
  
       _______________________________ Hospital code 
 
02.In total, how many days was …………………in the hospital ?                                     days 
 
 
03.Was  the baby admitted to special care baby unit  (SCBU ) after birth?                                 1=yes/2=no/ 9=NK 
 If yes : 
 
Why was this? _____________________________________________________________    
 
How was he/she treated? ___________________________________________________________ 
 
 
How many days was …………………… kept in the special care baby unit  ?                                                        days 
 
 
04. Did the baby have any illness or abnormality noted at birth, or shortly after  birth                1=yes/2=no/ 9=NK 
                                       (In addition to question 11 on page 10) 
 If yes : 
 
Please describe this? ____________________________________________________________    
 
How was he/she treated? ___________________________________________________________ 
 
 
How many days old  was …………………… at  the time?                                                            days 
 
 
 
05. Was the baby kept in hospital for any reason, or given a follow-up appointment?                1=yes/2=no/ 9=NK 
 If yes : 
 
Why was this? ____________________________________________________________    
 
How was he/she treated? ___________________________________________________________ 
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Early life and Development 
 
 
01.  Was ……………………… breast fed at all?             1=yes/2=no/ 9=NK 
 
 IF NO; go to Q 4 
 
 IF YES: 
               Days         Weeks                   Months 
02. For how long (until CHILD was what age) were you giving  
       ……………………… ONLY breastmilk?? 
 
               Days        Weeks                   Months 
03.  How old was ………………. When you gave your last breastfeed       
 
 
04.   Did you ever use formula milk?       1=yes/2=no/ 9=NK  
 
 IF No: go to Q6 
 
  IF YES                Days                      Weeks
   
 05a)  How old was ………….when he/she had his /her first formula feed ? 
 
 05b)  Was this soya based ?       1=yes/2=no/ 9=NK 
               
             Years       Months 
 06. At what age did you introduce cow’s milk  ? 
 
               
              Months       Weeks 
             
07. How old was ………….. when you first introduced solid food ? 
 
               Years       Months 
 
 08.   At what age did…………………………………..…begin  sitting without support ? 
 
 09. At what age did……………..………………..………begin crawling or moving about  ? 
 
 10. At what age did……………….……………..……….begin walking   ? 
 
 
11. Did ………………………….…..attend the recommended developmental checks?             1=yes/2=no/ 9=NK 
 
12. At the development checks were there any problems  e.g. with growth or weight gain; or hearing or speech problems ? 
 
        IF YES;  please specify____________________________________________________________________ 
 
  ______________________________________________________________ 
 
  ______________________________________________________________ 
 
  _______________________________________________________________ 
 
  _______________________________________________________________  
or 
or or 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Vaccinations 
 
Ask questions 2 - 4  
Please check all the immunisations on record card and transfer details to vaccinations record on Page 205. 
 
01. Record card seen ( fill in by interviewer) 
 
02. Did ……………………...have all the recommended immunisations during the first years of life? 
 
IF NO: 
03. Which ones were missed or not given and why was this? 
 
 Name__________________________________________________________________ 
 
 Reason_________________________________________________________________ 
 
 
 Name__________________________________________________________________ 
 
 Reason_________________________________________________________________ 
 
 
 Name__________________________________________________________________ 
 
 Reason_________________________________________________________________ 
 
 
04. Did …………………..….ever have any other vaccinations, for example for a foreign holiday? 
 
 IF YES: 
 
    Which ones were they? 
   
(i)Name__________________________________________________________________ 
              Years      Months 
 (ii) How old was he/she at the time?        
 
 
 
 
(i)  Name__________________________________________________________________ 
              Years      Months 
 (ii) How old was he/she at the time?        
 
 
 
 
(ii) Name__________________________________________________________________ 
              Years      Months 
 (ii) How old was he/she at the time?        
 
 
 
 
 
 
 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section VII                  Index Case       Vaccinations 
 
 
       Details on this form were taken from: 
          1 - Mother’s record / 2 - GP record card/  3 - clinic record card/  4 - other/  9 - NK 
 
 If other : please specify_______________________________________________________________________ 
 
       Details recorded at interview               1=yes/2=no/ 9=NK 
 
 
          “Triple Vaccine” 
            Diphtheria/  HIB   Diphtheria/  Polio drops 
            Tetanus/       Tetanus  
            Whooping cough 
 
        Day    Month      Year             Day    Month   Year   Day    Month      Year       Day    Month      Year 
       Dose 1 
 
     
       Dose 2 
 
 
       Dose 3 
 
 
       Booster 
 
 
 
       Other vaccinations 
 
       Immunization                              Date given 
 
 
             Day    Month       Year    Day     Month       Year 
       Smallpox      Mantoux 
       testing for BCG 
     
       BCG      Tetanus 
       (booster) 
 
       Measles      Polio 
       (booster) 
 
       Measles/Mumps/Rubella    HIB 
       (single dose) 
        
       Rubella (alone)     Other_____________ 
         dose 1 
 
       Other_____________ 
         dose 2 
 
       Other_____________ 
         dose 3 
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Study ID Family ID Person ID 
Section VII                  Index Case       Growth   
 
 
 
 
1. What was _________________ length at birth?  
 
2. At what age did __________________enter infant school (Year 1)?       
      OR 
     When did __________________ enter infant school (Year 1)?  
3. When ___________________ entered infant school (Year 1), compared to other  
       children in the same class, was he/she   1=Taller/ 2=Shorter/ 3=Average Height  
 
4. At what age did __________________enter junior school (Year 4)?       
      OR 
     When did __________________ enter junior school (Year 4)?  
5. When ___________________ entered junior school (Year 4), compared to other  
       children in the same class, was he/she   1=Taller/ 2=Shorter/ 3=Average Height  
 
6. At what age did __________________enter secondary school (Year 7)?       
      OR 
     When did __________________ enter secondary school (Year 7)?  
7. When ___________________ entered secondary school (Year 7), compared to other  
       children in the same class, was he/she   1=Taller/ 2=Shorter/ 3=Average Height  
 
8. At what age did __________________ leave school?       
      OR 
     When did __________________ leave school?   
9. When ___________________ left school, compared to other  
       children in the same class, was he/she   1=Taller/ 2=Shorter/ 3=Average Height  
10. What was _____________________ height at diagnosis 
       If not known ask Q11  
11. Around the time when __________________ was diagnosed with a bone tumour, compared to other  
       children of same age, was he/she   1=Taller/ 2=Shorter/ 3=Average Height  
  
in cm 
OR 
month year 
Years Mths 
month year 
Years Mths 
month year 
Years Mths 
month year 
Years Mths 
ft in cm 
OR 
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Puberty  
 
 
 
If Index case is FEMALE 
 
5. At what age did ________ notice any change in her breasts?  
  
6. At what age did ________ shoot up in height?     
      OR 
      At what age did ________ suddenly outgrow her clothes?  
      OR 
      At what age did ________ suddenly increase her shoe size?   
 
7. At what age did ________ start her periods?     
 
If the Index Case is MALE 
 
1. At what age did ________ shoot up in height?     
      OR 
      At what age did ________ suddenly outgrow his clothes?  
      OR 
      At what age did ________ suddenly increase his shoe size?   
 
2. At what age did ________ start shaving regularly > twice/week?         
       
3.   At what age did ________ his voice change?     
 
 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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ID No: 
Study ID Family ID Person ID 
 
Section VII                  Index Case       Sports/Exercise  
 
 
Which of the following sports or physical activities did ___________ participate at any time 
prior to diagnosis? 
1. Swimming       1=Yes / 2=No    
2. Cycling       1=Yes / 2=No    
3. Horse Riding       1=Yes / 2=No  
4. Walking/Hiking > 2 miles     1=Yes / 2=No    
5. Running/Jogging/Cross-Country    1=Yes / 2=No   
6. Skiing/Snowboarding      1=Yes / 2=No    
7. Athletics       1=Yes / 2=No    
8. Aerobics/Dance Exercise     1=Yes / 2=No 
9.  Gymnastics       1=Yes / 2=No    
10. Martial Arts (Judo, Karate, etc.)     1=Yes / 2=No  
11. Street Sports (skate boarding, rollerblading, etc.)  1=Yes / 2=No    
12. Weight lifting or weight training    1=Yes / 2=No 
13. Football       1=Yes / 2=No 
14. Rugby        1=Yes / 2=No    
15. Cricket        1=Yes / 2=No 
16. Basketball       1=Yes / 2=No 
17. Netball        1=Yes / 2=No 
18.  Hockey       1=Yes / 2=No    
19. Tennis        1=Yes / 2=No   
20. Badminton       1=Yes / 2=No    
21. Squash        1=Yes / 2=No    
22. Others ________      1=Yes / 2=No   
23. Others ________      1=Yes / 2=No   
24. Others ________      1=Yes / 2=No   
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Sports/Exercise  
 
 
Please complete one for each sport recorded YES on previous page (attach extra sheets if necessary) 
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------- 
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International  
--------------------------------------------------------------------------------------------------------------------------------------  
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Sports/Exercise  
 
 
Please complete one for each sport recorded YES on previous page (attach extra sheets if necessary) 
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------- 
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
1. Sport/Physical Activity ___________________________________ 
2. At what age did __________ first start doing the sport/physical activity    
        
3. At what age did __________ stop doing the sport/physical activity (if applicable)   
         
4. How many times did ___________ participate in the sport/physical activity in a typical 4 week period
        
5. To what level did __________ participate in the sport 
         1=Informal/ 2=School or Local/ 3=County or Regional/ 4=National/ 5=International 
--------------------------------------------------------------------------------------------------------------------------------------  
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
Years Mths 
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ID No: 
Study ID Family ID Person ID 
 
Section VII                  Index Case       Illness history 
 
 
 
 
01. Did……………………..have any of the following infections (prior to diagnosis), and if so, can you remember 
when? 
                                                  Date of diagnosis of tumour: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consult 
GP 
1=yes 
2=no 
9=NK 
  Month                  Year 
 
Consult 
GP 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
If ‘yes’, when If ‘yes’, when 
Measles 
Mumps 
German Measles 
Chicken Pox 
Shingles 
Whooping Cough 
Pneumonia 
Glandular Fever 
Meningitis 
Cold sores / Herpes 
 
 
  Month                  Year 
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ID No: 
Study ID Family ID Person ID 
Section VII                  Index Case       Illness history  
 
 
 
Does……………….….have, or has he/she ever had any of the following ? 
 
 
 
 
                     Diabetes  01  
 
 
                                                  Asthma  02 
 
 
                           Eczema or other chronic skin conditions e.g. psoriasis  03 
 
 
   Congenital abnormalities/syndromes   04 
                     
 
               Other neoplasms (inc.benign)  05 
                     before or since diagnosis 
 
              Hernias 06 
 
 
                Fractures  07  
 
 
     Any Bony conditions (including metallic/prosthetic implants) 08 
 
      
      Other Conditions requiring regular  09 
                    visits to clinics or hospital 
 
 
 
 
 Total illness records following 
 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section VII                  Index Case       Illness history    
 
 
Please complete one for each illness recorded on Page 212  (attach extra sheets as necessary) 
May I have more details of these illnesses ? 
 
          illness no.  ICD-10 
 
01..Condition_____________________________________________________ 
 
               Month                    Year           Years          Months 
02. When was it first diagnosed ?                         date                   or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate).  If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
        Hospital code 
 
 
 
          illness no.  ICD-10 
 
01. Condition_____________________________________________________ 
 
               Month                     Year           Years          Months 
02. When was it first diagnosed ?                          date     or age 
 
 
          
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
      _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code 
 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
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ID No: 
Study ID Family ID Person ID 
Section VII    Index  Case       Illness history    
 
 
Please complete one for each illness recorded on Page 212 (attach extra sheets as necessary) 
May I have more details of these illnesses ? 
 
          illness no.  ICD-10 
 
01..Condition_____________________________________________________ 
              Month                    Year           Years          Months 
02. When was it first diagnosed ?                          date                   or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code: 
 
 
 
          illness no.  ICD-10 
 
01. Condition_______________________________________________________ 
 
               Month                     Year           Years          Months 
02. When was it first diagnosed ?                          date     or age 
 
 
 
03. How was it treated ? ________________________________________________________________ 
 
 
 
04. Was .................................. treated as a hospital inpatient, an outpatient or by the GP ? 
    (Please record as appropriate). If ‘other’, please specify: 
 
 
GP___________________________________ Address________________________________________ 
 
       _______________________________________ 
 
Consultant____________________________ Hospital_______________________________________ 
 
         Hospital code 
 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
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ID No: 
Study ID Family ID Person ID 
 
Section VIII                                     Family illnesses       
 
 MOTHER ONLY:  We are interested in certain illnesses …………………………’s brothers and sisters may have had, 
 Including half-brothers and sisters. (Refer back to obstetric history Page 196-197 and go through pregnancies) 
 
 FATHER ONLY    Do you have any children who are not members of this household? 
 
 If yes:  How many?                         
 
                                   
Initials     
Month and Year of Birth     
 
 
            (Ask for all siblings)                  Has.<sibling> ever been diagnosed with any of the following ? 
 
         Pregnancy number: /F1 
 
     1=yes,2=no,9=NK       1=yes,2=no,9=NK 1=yes,2=no,9=NK       1=yes,2=no,9=NK 
 
01. Diabetes 
 
        02.  Leukaemia or 
Lymphoma 
 
 
03.    Other cancer 
 or tumour 
 
04.    Asthma/Eczema 
 
 
05.    Congenital  
  Abnormalities 
 
06.     Chronic Illness          
            
             
07.    Any Bony  
        Condition 
  
 
 
                       Total number 
1=yes 
2=no 
9=NK 
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ID No: 
Study ID Family ID Person ID 
Section VIII                                     Family illnesses       
 
Please complete for each illness recorded above. 
May I have more details of these illnesses ? (only record details not already obtained). 
 
Preg. No. / ID           
    
                        illness no.      icd code  
 
Condition_______________________________________________________________________  
                    
Month/Year of birth     Date of death      
               
 
Cause of death_____________________________________   Place of death_________________________________________ 
                  Yrs           Mths 
  
How old was...............................................................when it was first diagnosed?       
 
 
 
Was................................................treated as a hospital inpatient, an outpatient, or by the GP? 
(Please record as appropriate). If ‘other’, please specify 
 
 
 
Further details:___________________________________________________________________________________________ 
 
__________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
day month year 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
month year 
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ID No: 
Study ID Family ID Person ID 
  
Section VIII                                     Family illnesses       
 
Please complete for each illness recorded above. 
May I have more details of these illnesses ? (only record details not already obtained). 
 
Preg. No. / ID           
    
                        illness no.      icd code  
 
Condition_______________________________________________________________________  
                    
Month/Year of birth     Date of death      
               
 
Cause of death_____________________________________   Place of death_________________________________________ 
                  Yrs           Mths 
  
How old was...............................................................when it was first diagnosed?       
 
 
 
Was................................................treated as a hospital inpatient, an outpatient, or by the GP? 
(Please record as appropriate). If ‘other’, please specify 
 
 
 
Further details:___________________________________________________________________________________________ 
 
__________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
day month year 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
month year 
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ID No: 
Study ID Family ID Person ID 
Section VIII                                     Family illnesses       
 
Please complete for each illness recorded above. 
May I have more details of these illnesses ? (only record details not already obtained). 
 
Preg. No. / ID           
    
                        illness no.      icd code  
 
Condition_______________________________________________________________________  
                    
Month/Year of birth     Date of death      
               
 
Cause of death_____________________________________   Place of death_________________________________________ 
                  Yrs           Mths 
  
How old was...............................................................when it was first diagnosed?       
 
 
 
Was................................................treated as a hospital inpatient, an outpatient, or by the GP? 
(Please record as appropriate). If ‘other’, please specify 
 
 
 
Further details:___________________________________________________________________________________________ 
 
__________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________ 
day month year 
1=inpatient 
2=outpatient 
3=GP 
4=other 
9=NK 
month year 
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ID No: 
Study ID Family ID Person ID 
 
Section IX                       Family History  - Instructions For Questionnaire 
 
 
 
 
 
 
I would now like to ask you some questions about your family. 
 
 
We are interested in both how many close relatives you have and whether they have had some 
particular illnesses. 
 
 
Firstly, please may I have some details of your own parents and your brothers and sisters and 
their children.  Also include any children and grandchildren you may have.  This gives us an idea 
of the size of your family. 
 
 
Now I should like to know whether any of your family members have ever developed tumours, 
cancer, leukaemia, or any other growths.  If so, please would you let me have some details about 
the type of condition and when it was diagnosed.  Is your (sister/brother/etc as appropriate) still 
alive?   (If not obtain date and cause of death) 
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ID No: 
Study ID Family ID Person ID 
Section IX                       Family History Summary  
 
 
 
Line 
No. 
Initials Relation to 
respondent 
Line 
No.(s) of 
Parent(s) 
Month & 
Year of birth 
Date and 
place  
of death 
Specified illness (complete separate sheet for illness details) Alive-1 
Dead-2 
NK-9 
1  Father      
        
2  Mother      
        
3  Brother/Sister      
        
  Nieces/Nephews      
        
        
        
        
        
4  Brother/Sister 
ther/Sister 
     
        
  Nieces/Nephews      
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ID No: 
Study ID Family ID Person ID 
Section IX                       Family History Summary  
 
Line 
No. 
Initials Relation to 
respondent 
Line 
No.(s) of 
Parent(s) 
Month & 
Year of birth 
Date and 
place  
of death 
Specified illness (complete separate sheet for illness details) Alive-1 
Dead-2 
NK-9 
  Brother/Sister      
        
  Nieces/Nephews      
        
        
        
        
        
  Brother/Sister      
        
  Nieces/Nephews      
        
        
        
        
        
  Brother/Sister      
        
  Nieces/Nephews      
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ID No: 
Study ID Family ID Person ID 
Section IX                       Family History  
 
 
Line 
No. 
Initials Relation to 
respondent 
Line 
No.(s) of 
Parent(s) 
Month & 
Year of birth 
Date and 
place  
of death 
Specified illness (complete separate sheet for illness details) Alive-1 
Dead-2 
NK-9 
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ID No: 
Study ID Family ID Person ID 
Section IX                       Family History Details 
 
The following 3 questions apply to any blood relatives other than your children, parents or siblings or 
their children i.e. to grandparents, aunts, uncles and first cousins under 55 years of age. 
 
01. Have any developed cancer, leukaemia or lymphoma? 
 
 
02. Are you aware of any congenital illnesses or conditions in such relatives? 
 
 
03. Are you aware of any hereditary illnesses or conditions in your family? 
 
 
If the answer to any of the above is “yes”, please complete brief summary information below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initials Relationship 1=pat 
2=mat 
Condition Age 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
1=yes 
2=no 
9=NK 
Sex 
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ID No: 
Study ID Family ID Person ID 
 
Section X    Further information 
 
 
 
Is there anything else you would like to tell me about  
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
Do you have any comments on this interview? (This may help in the design of studies in the future)
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
 
 _________________________________________________________________________________________________ 
             
                                                                                                                                                                                                                                1 = yes 
May we have permission to contact you if we need further information or to resolve any queries?                            2 = no 
                                                                                                                                                                                                                                 9 = NK 
 
 
  Home telephone or mobile number: 
                        
 
 
                                                                                                                                                                                   hours             mins 
                                                     
Thank you for your help and co-operation in this interview.   Time completed: 
 
 
 
Interview conducted by: 
 
 
Place of Interview           Home                  Clinic          Other _________________ 
 
 
Mode of Interview           Face to Face       Phone          Other _________________ 
 
 
Samples Taken           Blood  Date _________________ 
 
             Saliva  Date _________________ 
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ID No: 
Study ID Family ID Person ID 
Appendix A  INSTRUCTIONS FOR INTERVIEWING NON-BIOLOGICAL PARENTS. 
 
Pre interview questionnaires 
 
When sending out pre interview questionnaires to non-biological parents note clearly that we only require 
information dating from when they and the INDEX child commenced living together. 
 
The questionnaire. 
 
1. General background 
 
Page 4 :  Ask when the child first came to live with the family. 
Page 5    Ask this page as normal. 
 
II Employment History 
 
Only take details of jobs that parents have had since the index child came to live with the family 
 
III General health 
 
Do not ask these questions of non-biological parents, fill in with 9’s (since there is no genetic or germ cell link) 
as details are unknown for the natural parents. 
 
IV Social Habits 
 
For this question we can only really ask about the index child’s exposure to passive smoking after they came to 
live with the family. 
 
Question 1) ask as normal, “Have you ever smoked any of the following ….” 
 
Omit next question, “How old were you when you started smoking regularly?” 
 
Question 3) as normal, “Do you still smoke?” 
 
If NO to Question 3), ask question 4) as normal and then ask “Was that before index child came to live with 
you?” 
If YES to the above question, then leave smoking questions and go to next section 
 
If YES to Question 3), ask question 5), 6) and 7) as normal 
 
V Reproductive History 
 
Make a note that the natural mother is not available and leave this section. 
 
VI Index Pregnancy 
 
Make a note that the natural mother is not available and leave this section. 
 
VII Index Case - Neo-natal history 
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ID No: 
Study ID Family ID Person ID 
If child adopted as a baby the respondent may know these answers. 
 
Fill this section with 9’s if the respondent does not know 
 
VII Index Case – Early Life and Development 
 
Begin this section with question 6), “At what age did you introduce cow’s milk?” 
 
Fill in boxes with 9’s prior to question 6) in this section 
 
VII Index Case – Vaccinations, Growth, Puberty, Sports/Exercise, Illness History 
 
Again adapt this section to the situation. It is likely the respondent will have some details about the child’s 
illness history. 
 
This may also apply to the Vaccination record. 
 
VIII Family Illnesses 
 
Unless any other children in the household are actually related to the index child, it is not relevant to take 
details on this section. 
 
IX Family History 
 
This section should not be asked of non-biological parents. If the respondent knows of any medical conditions 
known to be in the natural family of the index, please take details . 
 
X Further Information. 
 
As normal. 
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ID No: 
Study ID Family ID Person ID 
 
                                                    Appendix – B Occupational History 
 
Please could you fill in as much detail as you can remember about all the jobs you have had since leaving 
school until…………………., starting with the first and including time as a student. If possible, please 
specify your job title and state exactly what you did. 
 
National Insurance Number, if known 
 
Please use continuation form if necessary 
month year 
month year 
 0   1 
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
 0  2 
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
 0  3 
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
 0  4 
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
 0  5 
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
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                                                    Appendix – B Occupational History (continued) 
 
Please use continuation form if necessary 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
month year 
month year 
  
street 
locality 
town 
county 
employer job title 
duties 
finish 
start 
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                                                       Appendix –C Residential History 
 
Please could you fill in the addresses of all houses where you have lived for longer than one year, starting 
with where you lived the year before………………………… was born, and ALL addresses 
where………………………has lived up until………………………….…. 
If you can remember ANY part of the postcode it would be most helpful. 
 
Address        Moved in  Moved out 
Postcode 
month year month year 
 0   1 
(Birth) 
street 
locality 
town 
county 
Postcode 
month year month year 
 0  2 street 
locality 
town 
county 
Postcode 
month year month year 
 0  3 street 
locality 
town 
county 
Postcode 
month year month year 
 0  4 street 
locality 
town 
county 
Postcode 
month year month year 
 0  5 street 
locality 
town 
county 
Please use continuation form if necessary 
                                                                                         
 
 
___________________________________________________________________________________________________________________________________ 
 230
ID No: 
Study ID Family ID Person ID 
                                                       Appendix –C  Residential History (continued) 
 
 
Address        Moved in  Moved out 
  
Postcode 
month year month year 
     
(Birth) 
street 
locality 
town 
county 
Postcode 
month year month year 
    
street 
locality 
town 
county 
Postcode 
month year month year 
    
street 
locality 
town 
county 
Postcode 
month year month year 
    
street 
locality 
town 
county 
Postcode 
month year month year 
    
street 
locality 
town 
county 
Please use continuation form if necessary 
